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Abstract 
         Natural products are pivotal in the development of new pharmaceutical agents as they 
may possess novel mechanisms of actions, inherent to their structural framework. Such 
intriguing metabolites are of interest to various fields of research, such as pharmacology, 
biochemistry and total synthetic chemistry. Perhaps the most compelling synthetic method 
is found with the biomimetic approach, which in addition to affording the natural product of 
interest in an efficient manner, such strategies may also offer insight into a given 
metabolite’s biosynthetic origins. This thesis will detail our investigations into the biogenic 
origins of two structural related families of natural products via a biomimetic total synthetic 
approach.  
The total synthesis of the structurally related marine natural products from Aka coralliphaga, 
has been achieved via a biogenically inspired divergent approach. This divergent strategy 
detailed siphonodictyal B as the biogenic precursor to liphagal, corallidictyals A – D and 
siphonodictyals B1 – B3. We report the successful total synthesis and stereochemical 
reassignment of siphonodictyal B, in accordance with our proposal. Additionally, the total 
synthesis of liphagal and the corallidictyals A – D was achieved directly from our confirmed 
reassigned configuration of siphonodictyal B. We propose these transformations of 
siphonodictyal B to liphagal and the corallidictyals, detailed within this work, are 
representative of biosynthetic reactions that occur within the host organism, Aka 
coralliphaga.  
Progress towards the biogenically inspired, total synthesis of virgatolide B has been made. 
Our method sought to afford virgatolide B via a hetero-Diels-Alder reaction between a  Z-
exocyclic enol ether dienophile and an o-QM, generated in situ from an analogue of 
pestaphthalide A. Synthesis of the key biogenic precursors, that would in our opinion be 
representative of those that may occur in nature, was been achieved. However, upon 
investigating various thermal and basic conditions, synthesis of virgatolide B could not be 
achieved. Despite our failed attempts at synthesising virgatolide B, we still assert that the 
virgatolides A – C are biosynthesised in nature via a divergent, [4 + 2] cycloaddition of an 
appropriate Z-exocyclic enol ether with an o-QM derived from either of the co-isolated 
pestaphthalides A or B.   
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 Natural Products and Their Influence on Modern 
Medicine 
Pharmacologically active natural products, strictly defined as secondary metabolites that are 
not essential to the functioning of primary metabolic processes (structural proteins, energy 
production, etc.), have been employed in the treatment of various ailments such as pain, 
fever and infections since recorded history.[1–3] The discovery of new natural products in the 
advancement of medicinal chemistry is essential, as demonstrated in the ten year period of 
2000 to 2010, where 50% of small molecule drugs brought to the market were either derived, 
inspired or were themselves natural products.[4] However, given a large proportion of natural 
products are used as drugs themselves, artificial access to a given metabolite is necessary to 
mitigate any detrimental impact to the host organism due to over-harvesting, as demonstrated 
by the extinction of the ancient therapeutic herb, Silphium. The disappearance of Silphium 
from the historical record around the second century BCE, serves to highlight the danger of 
unsustainable harvesting practices of naturally sourced medicines. Silphium was thought to 
be an ancient species of giant fennel, native to a small region in north Africa. The herb was 
extensively sought after by the ancient Greeks and Romans, due to its reported utility in the 
treatment of fever, pain and as a contraceptive.[5–7] Silphium quickly became absent from the 
proceeding historical record due to unsustainable harvesting practices, perpetuated by an 
ever increasing demand on the black market, in conjunction with its impossible cultivation.[6] 
The apparent extinction of Silphium demonstrates the requirement for the investigation of 
not only the specific bioactive constituents of a given natural medicine, but also to gain 
sustainable access to the desired bioactive components, either by synthetic means or 
cultivation.[6,7]  
 The Biomimetic Approach 
Today, there are an abundance of methods for gaining artificial access to natural products 
within and outside the field of organic chemistry. To this day the most common method of 
artificially accessing natural products is via a total synthetic approach, that seeks to 
synthesise the desired product by any method available to the chemist.[8,9] Traditional 
synthetic approaches generally employ the use of protecting groups, and as a consequence 
require multiple functional group manipulations, typically resulting in a large number of 
linear synthetic transformational events. However, the development of chiral catalysts in the 
past few decades has led to the development of a new expanded tool-box of reactions. Such 
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advancements have led to the regio- and stereoselectivity optimisation of standard synthetic 
protocols.[10–13] However, as the vast majority of metabolic processes in nature are mediated 
by enzymes, many of these biosynthetic reactions do not have a direct equivalent in the 
laboratory.[14,15] Enzymes can induce non-spontaneous transformations of seemingly 
unreactive substrates by lowering the energy of activation associated with said process. 
However, if a given reaction of a particular species is spontaneous, then enzymes may 
facilitate and control said spontaneous transformations, directing them to a particular end 
product to prevent formation of various inutile by-products.[14–16] Based on this premise, the 
artificial synthesis of certain natural products may be accessible to chemists through less 
traditional methods, by imitating ‘spontaneous’ reaction sequences and events that may be 
representative of that which occurs in nature.[16] This biomimetic method of approaching the 




Scheme 1.1: Sir Robert Robinson’s non-traditional method of approaching the synthesis of natural 
products, 1917. a) original dissection and retro-synthetic analysis of tropinone (1.1 – 1.7). b) one-
pot, total synthesis of tropinone (1.1).[17] 
In his original 1917 paper, Robinson envisioned that tropinone (1.1) could be accessed, first 
by dissecting the alkaloid based upon its points of symmetry, which he concluded could be 
reduced to acetone (1.4), methylamine (1.7) and succindialdehyde (1.6) (scheme 1.1). 
Robinson successfully synthesised tropinone (1.1) via a one-pot condensation of acetone 
(1.4), methylamine (1.7) and succindialdehyde (1.6). However, due to poor yields, Robinson 
substituted acetone (1.4) for acetone dicarboxylate (1.5), which afforded tropinone (1.1) in 
a respectable yield of 42%. Based on his successful one-pot synthesis of tropinone (1.1), 
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Robinson asserted that this method of deconstruction would lead to any desired natural 
product in the most efficient manner possible.  
 
Scheme 1.2: Heathcock’s biogenically inspired total synthesis of the complex Daphniphyllum 
alkaloid, methyl homosecodaphniphyllate (1.15), via a one-pot, three-step cascade sequence.[14,18] 
This alternative method of approaching the synthesis of both simple and complex natural 
products represents a lens through which to view and frame a retro-synthetic problem. The 
underlying premise is one where nature would be expected to synthesise any product via the 
path of least resistance and that such a pathway would be relatively favourable. If a 
spontaneously arising compound conferred a substantial benefit to the host organism, its 
production might then come under enzymatic control. Such an assumption would be 
expected to apply chiefly to secondary metabolites, as they are beneficial, but not crucial to 
the survival of the host organism. As summarised by Heathcock,[14] “The basic assumption 
of this approach is that nature is the quintessential process development chemist. We think 
that the molecular frameworks of most natural products arise by intrinsically favourable 
chemical pathways - favourable enough that the skeleton could have arisen by a nonenzymic 
reaction in the primitive organism.” Under this premise, any secondary metabolite should 
be accessible to the chemist by attempting to imitate the speculated reaction sequences from 
biologically relevant precursors, without the need to employ specialised enzymes. 
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 Natural Product or Artefact? – The Role of Selective 
Pressures on the Evolution of Biosynthetic Pathways 
This brief review seeks to highlight the impact of selective pressures on various biosynthetic 
pathways in nature and serves to instil context for our work in relation to the current state of 
the biomimetic total synthetic field.  
 
Scheme 1.3: Biosynthetic pathways for the related β-lactam antibiotics, penicillins (1.22: fungi 
only), cephalosporins (1.25: both fungi and bacteria) and cephamycins (1.27: bacteria only), 
diverging from IPN (1.20), highlighting the shared evolutionary ancestry between certain species of 
bacteria and fungi.[19,20] 
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As previously discussed, natural products belong to the class of secondary metabolites that 
are not crucial to the primary metabolic processes of the host, and hence, are not all 
necessarily bioactive. The degree to which a secondary metabolite’s biosynthesis is 
regulated may be inferred by the specificity of its target function, which would emerge as a 
consequence of an applied selective pressure. Therefore, we may gain insight into a given 
natural product’s biosynthetic pathway, i.e. enzymatic or spontaneous, by assessing its 
bioactivity.  
The biosynthesis of the penicillins (1.22: fungi only), cephalosporins (1.25: both fungi and 
bacteria) and cephamycins (1.27: bacteria only) are examples of antibiotic natural products that 
are tightly regulated at every biosynthetic level in nature, through a series of substrate 
specific enzymes (scheme 1.3).[19–23] The first two biosynthetic steps for the β-lactams are 
conserved and diverge from their shared biosynthetic intermediate, isopenicillin N (1.20: 
IPN) (scheme 1.3). The biosynthesis of β-lactams demonstrates how a family of related 
natural products may emerge in multiple species that do not appear to share a recent 
evolutionary ancestor, and yet share a biosynthetic intermediate (IPN: 1.20). Penicillins, 
cephalosporins, and other naturally occurring β-lactam antibiotics, are examples of natural 
products that have evolved to combat foreign, encroaching bacterial species via a target 
specific mode of action, and thereby directly serve an evolutionary purpose.[21,24–26] Thus, 
such a case demonstrates the potential capacity of a strong selective pressure in conserving 
an emergent, enzymatically regulated biosynthetic pathway.  
In contrast to the β-lactams and other highly regulated biosynthetic routes, natural products 
may be biosynthesised via more promiscuous enzymes that are tolerant of various substrates, 
and thus, would afford a wide array of secondary metabolites.[27–29] Cytochrome P450’s and 
prenylation transferase’s, such as AstPT (scheme 1.4), are examples of promiscuous 
enzymes that facilitate simple transformations of a wide range of substrates. An obvious 
advantage for nature to evolve promiscuous enzymes is to grant access to a wide variety of 
differing metabolites that may be advantageous to the host, while also preserving resources. 
If a few metabolites that had emerged from this broader spectrum approach provided a 
significant competitive advantage, nature could then further evolve dedicated substrate-
specific enzymes to govern their biosynthesis. Such a method may serve as an evolutionary 
screening for potentially beneficial natural products. 
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Scheme 1.4: Investigations into the substrate tolerance and regioselectively of the promiscuous 
prenylating enzyme, AstPT.[30] a). AstPT only accepts dimethylallyl diphosphate (DMAPP) for the 
non-selective alkylation of Asterriquinone D (1.28: AQ D). b). Investigations into the regioselective 
alkylation of various xanthones (1.31 – 1.34) with either DMAPP, geranyl diphosphate (GPP) or 
farnesyl diphosphate (FPP) (1.35 – 1.38). 
Artefactual products of isolation are indistinguishable from natural products, which have 
emerged spontaneously upon the exposure of a given biogenic precursor to environmental 
conditions. Examples of artefacts vary from unnatural epimers of natural products, such as 
the thermal isomerisation of the (-)-gallocatechins (1.39 & 1.40) upon brewing the tea of 
camellia sinensis (scheme 1.5),[31,32] to various nucleophilic & electrophilic substitutions of 
reactive functional groups, as discovered for the isolation of the alkaloid artefact desmosine 
(1.45) (scheme 1.5).[32,33] Additionally, natural products have been found to undergo 
spontaneous rearrangement upon exposure to mild environmental conditions, to afford 
artefactual complex molecular frameworks. The conversion of the natural product coatline 
B (1.46) to the previously proposed natural product Matlaline (1.52), demonstrates the 
complexity of molecular systems that can be afforded under mild environmental conditions 
(scheme 1.5).[34,35]  
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Scheme 1.5: Examples of suspected artefacts of isolation: a) epimerisation of (-)-catechins (1.39 & 
1.40) from camellia sinensis.[31,32] b) Formation of the alkaloid artefact desmosine (1.45).[32,33] c) The 
spontaneous oxidative rearrangement of coatline B (1.46).[34,35] d) Proposed formation of the artefacts 
brevianamide B – C (1.55 – 1.57) from brevianamide A (1.53), Penicillium brevi-compactum.[32,36] 
As it may not be immediately obvious which isolated metabolites are true natural products, 
and those which may be artefacts, it is necessary to not only consider the conditions required 
to generate a suspected artefactual product, but also the environment in which the host 
organism has evolved. For example, the metabolites brevianamide A – D (1.53, 1.55 – 1.57) 
were initially isolated from the fungus Penicillium brevi-compactum, however, when the 
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fungus was extracted in low light conditions, only brevianamide A (1.53) was isolated 
(scheme 1.5).[32,36] Therefore, we can infer from the outcome of the isolation conditions 
employed and speculations regarding the habitat of the host, that brevianamides B – D (1.55 
– 1.57) are most likely artefacts that formed via the photolytic cleavage of brevianamide A 
(1.53), as fungi are non-photosynthetic organisms that do not thrive under exposure to 
sunlight. For a more detailed review on artefactual products, see Champy[32], Pettus[34], and 
Capon[37]. 
 
Scheme 1.6: Isolated non-enzymatically biosynthesised natural products from the shrub 
Dracocephalum komarovi, and the mild, biomimetic photo-catalysed formation of (-)- (+)-
komarovispirone (1.65) and cyclocoulterone (1.70) from (+)-komaroviquinone (1.58), and the rapid 
formation of (-)-coulterone (1.71) under mild reductive conditions.[32,38,39] 
Natural products that may be biosynthesised through non-enzymatically mediated processes 
would be akin to artefactual products that have instead, emerged within the host cell.[32,38,40–
42] The natural products from the highland shrub Dracocephalum komarovi (1.58, 1.65, 1.70 
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& 1.71), are examples of metabolites that may have formed in nature under non-enzymatic 
pathways (scheme 1.6).[32,38,39] Recently, (+)-komarovispirone (1.65) and (-)-
cyclocoulterone (1.70) were found to form upon exposure of (+)-komaroviquinone (1.58) to 
sunlight in Et2O at 4 ˚C, which the authors argued, was representative of the cold, winter 
conditions of the shrub’s native mountainous habitat.[38] In addition, under mild reductive 
conditions, (-)-coulterone (1.71) was rapidly acquired from (+)-komaroviquinone (1.58), 
indicating that either metabolite may be the others biosynthetic precursor, afforded 
spontaneously under REDOX conditions. The metabolites (+)-komarovispirone (1.65) and 
(-)-cyclocoulterone (1.70) may not be artefactual, but rather natural products that have 
emerged within the host plant, as indicated by their biomimetic, sunlight initiated 
transformation from (+)-komaroviquinone (1.58).[38]  
 Quinone Methides as Reactive Intermediates in Nature 
 
Scheme 1.7: Various reaction pathways for ortho-(1.72),[43–45] meta-(1.74),[46–49] and para-QMs 
(1.76).[50–57] 
Quinone methides are highly reactive species that have become of great interest to chemists 
as viable substrates in a wide range of synthetic transformations. Additionally, quinone 
methide species have been proposed to act as reactive biosynthetic precursors and 
intermediates in nature (scheme 1.7).[44,45,57–60] However, the synthetic scope of QMs has 
generally been focused around ortho- (1.72) and para-QMs (1.76),[74–76,78,85–91] as meta-QMs 
(1.74) are generally difficult to generate, short lived species, with limited synthetic 
application.[46–49] Of the three isomeric species, para-QMs (1.76) are the most stable of the 
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family, with an extensive history as viable Michael acceptors, and as stable natural products 
themselves (schemes 1.7 & 1.8).[45,57,60–62] p-QM natural products, such as kendomycin 
(1.78) and celastrol (1.79), have gained attention due to their broad spectrum of bioactivities, 
which range from anti-inflammatory and anti-carcinogenic properties to novel antibiotic 
activity against drug resistant pathogenic bacteria (MSRA).[61–66] Alternatively, endogenous 
hormones, such as estrodiol (1.80) have been found to undergo auto-oxidation and 
isomerisation to the cytotoxic estrogen o-quinone 1.82 and estrogenic p-QM 1.83 
metabolites within the body (scheme 1.8). Both estrogenic o-quinone 1.82 and p-QM 1.83 
are known carcinogens, which were demonstrated to undergo nucleophilic attack from DNA, 
elucidating one of the primary carcinogenic mechanisms of action for estrogen and other 
related endogenous/exogenous hormones (scheme 1.8).[61,67–71]  
 
Scheme 1.8: Examples of pharmacologically active p-QM natural products, kendomycin (1.78) & 
celastrol (1.79).[61,62,64,72] Metabolism of estrodiol (1.80) to the cytotoxic estrogenic p-QM 
1.83.[61,69,73] 
Although stable o-QMs have rarely been isolated,[74,75] their presence has been directly 
implicated in the biosynthesis of various natural products, such as the cannabinoids from the 
psychoactive plant, cannabis sativa.[76–78] Δ9-Tetrahydrocannabinol (1.89: Δ9-THC) and 
other cannabinoids have been found to possess both pronounced psychoactive and cytotoxic 
bioactive profiles (scheme 1.9). The intriguing psychoactive, pain relieving and cytotoxic 
properties of the cannabinoids has led to growing interest into the therapeutic effects of these 
drugs and their biosynthetic origin.[76–79] Upon enzymatic formation of the biosynthetic 
intermediate cannabigerolic acid (1.86),[80] THC acid synthase was discovered to induce an 
intramolecular hetero-Diels-Alder cyclisation of the oxidatively generated o-QM 1.87 
(scheme 1.9).[78,80–83] Over time, the afforded tetrahydrocannabinolic acid (THCA) 
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spontaneously degrades to the bioactive cytotoxic/psychoactive, artefactual metabolite Δ9-
THC (1.89), which further undergoes oxidation to the less psychoactive product cannabinol 
(1.90). THC acid synthase was shown to not exhibit any catalytic activity towards 
decarboxylated substrates, highlighting the conserved nature for the biosynthesis of the 
cannabinolic acids. As all the cannabinoids are cytotoxic, they were found to be stored within 
vesicles, and are released upon cell damage as a primary chemical defence mechanism for 
the host plant.[82] The biosynthesis of Δ9-THC (1.89) and other the cannabinoids 
demonstrates the importance of o-QMs in nature as viable biosynthetic species that grants 
nature access to a wide array of varying molecular frameworks. 
 
Scheme 1.9: Biosynthetic pathway of cannabinoids (1.88 – 1.90) via an enzyme facilitated [4 + 2] 
cycloaddition of cannabigerolic acid o-QM (1.87). Geranyl-pyrophosphate-olivetolic acid 
geranyltransferase = GOT. [78,80–83]  
 Scope 
Our work is focused upon the growing advances in uncovering the biosynthetic routes of 
natural products through biogenically inspired synthetic methods, specifically centred 
around the employment of quinone methides as reactive intermediates in the synthesis of 
heterocyclic natural products. As only a few select examples will be discussed here, several 
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reviews have been published by Bray,[43] Scheidt,[45] and Spivey,[84] which detail the wide 
scope of utility of o-QMs in natural product chemistry.  
 Spontaneous, Biomimetic Cyclisation and Cascade Reactions 
Involving para- and ortho- Quinone Methide as Biogenic Intermediates 
The use of p-QMs in both total and biogenically inspired syntheses has been largely limited 
to 1,6-conjugate Michael additions, which generally allow for limited, yet controlled 
reactions. Upon their formation, p-QMs have been demonstrated to undergo spontaneous 
1,6-conjugate additions with various nucleophilic substrates, the most notable of which are 
intramolecular cyclisations to afford heterocycles. 
 
Scheme 1.10: Examples of para-QMs as reactive species that undergo spontaneous transformations; 
a) Majetich’s synthesis of (+)-grandione (1.93) and the unexpected ring closure of generated p-QM 
1.94 to give (-)-brussonol (1.95).[34,85] b) Antus’s synthesis of fragnasols A (1.100) and C (1.101) 
from dehydrodiisoeugenol (1.99) via an oxidative cascade reaction (1.96 – 1.99).[34,86] 
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Upon investigating the biogenically inspired synthesis of (+)-grandione (1.93), Majetich and 
co-workers found that oxidation of (+)-demethylsalvicanol (1.91) led to the formation of the 
ring fused heterocyclic natural product, (-)-brussonol (1.95) (scheme 1.10 – a).[85] (-)-
Brussonol (1.95) was presumed to have formed upon isomerisation of the in situ generated 
ortho-quinone 1.92 to p-QM 1.94, which underwent nucleophilic attack to afford the ring 
fused 5,6-oxa-heterocycle moiety. The formation of dehydrodiisoeugenol (1.99) and the 
subsequent synthesis of fragnasols A (1.100) & C (1.101) by Antus et al,[86] provides insight 
into the biosynthetic pathway of these simple heterocycles in nature (scheme 1.10 – b). The 
heterocyclic scaffold for the fragnasols was installed early in their synthetic route via an 
oxidative cascade reaction of isoeugenol (1.96) with p-QM 1.97 to afford 
dehydrodiisoeugenol (1.99). Analogously to Antus’s synthetic route, dehydrodiisoeugenol 
(1.99) could serve as a biosynthetic intermediate in nature, providing the heterocyclic 
scaffold for the fragnasols A (1.100) & C (1.101) early in their biosynthesis (scheme 1.10). 
Porco Jr and co-workers published two alternative, acid catalysed protocols for the 
seemingly complex dimeric natural product, griffipavixanthone (1.107), from the p-QM 
tetrahydroxyxanthone 1.102 (scheme 1.11). The first method detailed a Lewis acid catalysed 
dimerization (1.104) of isomerised xanthone 1.103 with p-QM 1.102 via a Michael addition, 
which was proposed to undergo an intramolecular cyclisation (1.104) and arylation (1.105) 
to afford the desired griffipavixanthone scaffold (1.106) (scheme 1.11 – a).[87] Porco Jr 
published an alternative method, using a chiral phosphoric acid catalyst (1.108), which was 
found to induce a dimerization via a conjugate addition of 1.103 to p-QM 1.102, followed 
by cyclisation (1.104) and arylation of the in situ p-QM dimer 1.105 to almost exclusively 
afford the syn-(+)-isomer scaffold 1.106 (scheme 1.11 – b).[88] Proceeding from the chiral 
catalytic dimerization, demethylation of syn-(+)-1.106 was found to exclusively afford the 
natural isomer, (+)-griffipavixanthone (1.107). Porco Jr’s biogenically inspired method 
provides evidence for the existence of a substrate specific p-QM xanthone 1.102 dimerizing 
enzyme, which if true, indicates that (+)-griffipavixanthone (1.107) may possess 
undiscovered target specific, bioactive properties, having emerged as a consequence of an 
unknown selective pressure. 
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Scheme 1.11: Synthesis of (+)-griffipavixanthone (1.107) from p-QM 1.102 by Porco Jr et al.  
Comparison of a one-pot, acid catalysed transformation of p-QM 1.102 to the cyclised 
tetrahydroxyxanthone 1.106 with either; a. ZnI2,
[87] or b. chrial phosphoric acid catalyst 1.108.[88] 
The vast majority of biomimetic, and total synthetic methods involving p-QMs have either 
revolved around their employment as substrates in 1,6 conjugate additions (1.109), or as end 
products themselves (schemes 1.7, 1.10 – 1.12). Recently, interest in developing and 
widening the scope of novel p-QM reactions has been expanding beyond the already well-
known 1,6-conjugate additions to both metal and non-metal catalysed [2 + 1] (1.110 & 
1.111) and [3 + 2] (1.112 – 1.114) cycloadditions (scheme 1.12).[50–57] This developing field 
of unique transformations could prove relevant to biomimetic synthesis, as we may yet 
discover that nature has evolved enzymes which can induce such cycloaddition reactions. 
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Scheme 1.12: Examples of viable reactions, highlighting the emerging diverse utility of p-QMs 
(1.76), from 1,6 nucleophilic additions to novel [2 + 1] and [3 + 2] cycloadditions.[50–57] 
o-QM species are seldom isolated as stable species, and are more widely known for their 
ability to undergo electrocyclisations, serve as dienes in cycloadditions, and as Michael 
acceptors, making them the most versatile of the three isomeric quinone methide species 
(scheme 1.13).[43,44,59,84,89] 
 
Scheme 1.13: Various methods of generating o-QMs (1.72) and examples of their synthetic utility 
available to both chemist and nature alike.[43,44,59,84,89] 
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The propensity for in situ generated o-QMs to undergo spontaneous cyclisation reactions, as 
demonstrated by the biomimetic synthesis of (-)-bruceol (1.121) and the spirooliganones ((-
)-(17S)-1.128: A & (-)-(17R)-1.129: B),[90,91] demonstrates the validity for the occurrence of 
these efficient transformations in nature (scheme 1.14). George’s biomimetic method grants 
significant insight into the possible biosynthesis of (-)-bruceol (1.121), without the necessary 
requirement of substrate specific enzymes, despite its seemingly complex carbon framework 
(scheme 1.14 - a).[90] In nature, the epoxidation event of protobruceol (1.118) may be 
catalysed by a promiscuous cytochrome P450 enzyme, analogous to the substrate 
preferences of Jacobsen’s catalyst. However, the spontaneous proceeding epoxide ring 
opening (1.119), and intramolecular cyclisation of o-QM 1.120 would not need to be 
enzymatically mediated, and rather, the stereoconfiguration of the generated epoxide (1.119) 
would dictate the stereochemical outcome of the [4 + 2] cycloaddition.[90] 
 
Scheme 1.14: a) George’s biogenically inspired synthesis of (-)-bruceol (1.121) via a one-pot 
epoxidation and a subsequent intramolecular [4 + 2] cycloaddition from an in situ generated o-QM 
1.120.[90] b) Tong’s synthesis of (-)-(17S)-spirooliganone A (1.128) and (-)-(17R)-spirooliganones B 
(1.129), with the characteristic spirocycle afforded via a hetero-Diels-Alder reaction of (-)-sabinene 
(1.123) and o-QM 1.125, generated upon an aromatic Claisen rearrangement (1.122).[91] 
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The synthesis of spirooliganones (-)-(17S)-A (1.128) and (-)-(17R)-B (1.129), by Tong et al, 
demonstrates the efficiency of the consecutive reaction sequences that give rise to complex 
molecular frameworks, highlighting the impressive reaction economy that can be achieved 
with o-QM species (scheme 1.14, b).[91] Upon heating the reactants in a sealed tube, 1.122 
was found to have undergone an aromatic Claisen rearrangement (1.122 to 1.124) to o-QM 
1.125, which subsequently led to a hetero-Diels-Alder reaction with (-)-sabinene (1.123) to 
exclusively afford the desired regioisomers 1.126 in a 1:1 diastereomeric ratio. Finally, 
spirooliganones (-)-(17S)-A (1.128) and (-)-(17R)-B (1.129) were afforded upon subjecting 
each diastereomer 1.127 (either (-)-(17S) or (-)-(17R)) to PIFA, which led to a phenolic 
oxidative dearomatisation/spirocyclisation, and a subsequent silyl deprotection afforded the 
desired natural products. Tong’s synthesis of the natural C17 spirocyclic diasteromers, 
spirooliganones (-)-(17S)-A (1.128) and (-)-(17R)-B (1.129), provides evidence for their likely 
emergence in nature, either through non-enzymatic means, or via promiscuous enzymes. 
Hsung’s biogenically inspired synthesis of clusiacyclol A (1.136), B (1.137) and 
eriobrucinol (1.138), details an impressive one-pot cascade sequence that affords the shared 
characteristic tetracyclic carbon scaffold.[92] The key cascade reaction was initiated upon 
condensation of phloroglucinol (1.130) with citral (1.131). The in situ coupled triphenol 
1.132 was found to undergo a subsequent oxa-6π-electrocyclisation (1.133) via an o-QM 
intermediate. Upon isolation of the afforded chromane 1.134, addition of TFA:CH2Cl2 led 
to the desired tetracyclic system 1.135, in good yield (scheme 1.15 – a, a.). Alternatively, 
the in situ chromane 1.134 was found to undergo a cationic [2 + 2] cycloaddition upon 
heating the reaction mixture for a total of 40 hours (scheme 1.15 – a, b.). Finally, the afforded 
tetracycle 1.135 was acylated to give the related natural products, clusiacyclols A (c. - 
1.136), B (d. - 1.137), and eriobrucinol (e. - 1.138) (scheme 1.15 – a). Hsung’s biogenically 
inspired route represents a divergent, economical method, which capitalizes upon a 
spontaneous cascade sequence (1.130 – 1.133) to generate a reactive o-QM intermediate 
(1.133). Few examples exist of o-QMs partaking in nucleophilic additions, which may be 
attributed to their highly reactive nature and propensity to react with the bases required to 
generate enolates and other nucleophilic substrates. Corey’s synthesis of ecteinascidin 
(1.144) describes a one-pot formation of the macrocyclic moiety via a base facilitated 
elimination of alcohol 1.139, to generate o-QM 1.140 in situ (scheme 1.15 – b). In the same 
pot, o-QM 1.140 underwent a nucleophilic attack (1.141) from the deprotected anionic 
sulphide moiety to install the characteristic macrocyclic system of ecteinascidin (1.142). 
Both Hsung’s and Corey’s biomimetic methods are examples of how reactive o-QM species 
may be employed to rapidly afford complex molecular frameworks via the formation of new 
19 |                                                                                                                 A. W. Markwell-Heys 
heterocyclic and macrocyclic systems alike. Such examples of ring forming transformations 
may represent an economical method for nature to generate a variety of complex natural 
products.[43,93,94] 
 
Scheme 1.15: a) Hsung’s biogenically inspired synthesis of clusiacyclol A (1.136), B (1.137) and 
eriobrucinol (1.138) via a one-pot, coupling, o-QM 1.133 formation, followed by an oxa-6π-
electrocyclisation and a successive cationic [2 + 2] cycloaddition to afford the desired tetracyclic 
scaffold.[92] b) Corey’s total synthesis of ecteinascidin (1.144) via a one-pot, in situ generated o-QM 
1.140, followed by deprotection and nucleophilic attack of the generated thiolate anion to o-QM 
1.141.[43,94] Fl = 9-fluorenyl.  
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Scheme 1.16: Feldman’s incidental cyclisation cascade reaction, involving two consecutive 
hydrogen shifts (1.146 – 1.148) via an o-QM intermediate 1.147.[95] 
Although o-QMs have found use in cycloadditions, electrocyclisations, and to lesser degree 
as Michael acceptors, their involvement in sigmatropic hydrogen and alkyl shifts is scarce 
in natural product synthesis outside of a few examples. While investigating 6π-
electrocyclisations of substituted Z-stilbene, Feldman observed the formation of two 
unexpected tricyclic compounds 1.150 and 1.153 (scheme 1.16).[95] Upon the oxidation of 
Z-stilbene 1.145, Feldman proposed that the afforded bis(ortho-quinone monoketal) 1.146 
would undergo a 6π-electrocyclisation to give a 6,6,6-fused tricyclic scaffold, characteristic 
of morphinan alkaloids (1.154 – 1.156). However, upon heating bis(ortho-quinone 
monoketal) 1.146 in benzene under reflux, the ring fused 6,7,6-tricyclic and spirocyclic 
ketones 1.150 and 1.153 were isolated. The tricyclic (1.150) and spirocyclic (1.153) 
scaffolds were hypothesised to have formed via a [1,7]-sigmatropic hydrogen shift to 
generated o-QM 1.147, which underwent a consecutive [1,5]-sigmatropic hydrogen shift. 
The postulated in situ methide 1.148 was postulated to undergo one of two competing 
electrocyclization pathways, (1.148 – 1.149) and (1.148 to 1.151 then 1.152), which would 
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afford either 6,7,6-tricyclic ketone 1.150 or spirocyclic ketone 1.153. Such transformational 
pathways may be viable biosynthetic route to complex tricyclic ring systems, and hence, 
may become a subject of focus in the near future. 
 Outlook 
This short review has sought to outline the current state and limitation of the biomimetic 
total synthetic field, while also highlighting the diverse utility of quinone methides as 
reactive intermediates in nature. Additionally, the analysis of such successful biomimetic 
synthetic methods may not just afford insight into the biosynthetic origins of such natural 
products, but also to elucidate the degree to which these processes are regulated in nature, 
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 Project Aims  
We set out to biomimetically synthesise a series of complex natural products that appeared 
to diverge from a shared biosynthetic intermediate. In addition to accessing the target natural 
products in an efficient manner, we also sought to gain insight into the biogenic origins of 
these two families of related metabolites.  
Chapter 2: details our synthetic approach towards the seemingly related marine natural 
products from Aka coralliphaga. Investigations into the biogenically inspired synthesis of 
liphagal (2.2) and the corallidictyals A – D (2.3 – 2.6) from our proposed reassignment of 
siphonodictyal B 2.91 will be discussed (scheme 1.17). Additionally, our method will detail 
the stereochemical reassignment of the siphonodictyal natural sulfonate esters, B1 – B3, 
from 2.7 – 2.9 to 2.106 – 2.108 respectively. Finally, analysis of the seemingly divergent 
biosynthetic origin of the family of meroterpenoids will be explored, in an attempt to 
elucidate the biogenic origins of these complex natural products. 
 
Scheme 1.17: Our biogenically inspired proposal for the synthesis and stereochemical reassignment 
of the related marine natural products from Aka coralliphaga. 
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Chapter 3: will detail our investigation into the synthesis of virgatolide B (3.2) via a 
biogenically inspired [4 + 2] cycloaddition pathway involving o-QM intermediate 3.59 
(scheme 1.18). Our proposed biosynthetic pathway applies to the family of virgatolides (3.1 
– 3.3), which would diverge from the proposed commonly shared biogenic precursor and 
co-isolated natural products, pestaphthalides A (3.4) and B (3.5). Our method sought to gain 
synthetic access to the intriguing 6,6-spiroketal natural product via a novel hetero-Diels-
Alder reaction between an in situ generated o-QM intermediate (3.59) and a Z-exocyclic 
enol ether (3.74). Additionally, we were intent on unveiling the biosynthetic origins of this 
family of novel spiroketal natural products. 
 
Scheme 1.18: a): Our biosynthetic proposal for virgatolides A – C (3.1 – 3.3) and b): our proposed, 
biogenically inspired synthesis of virgatolide B (3.2) via a hetero-Diels-Alder reaction of Z-exocyclic 
enol ether 3.74 and pestaphthalide A analogue 3.66.  
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 Isolation of Meroterpenoids from Aka coralliphaga 
Aka coralliphaga (previously named both Siphonodictyon coralliphagum and Aka 
coralliphagum) is a burrowing sea sponge found off the cost of the Caribbean in coral 
reefs.[96] Aka coralliphaga was found to be rich in bioactive meroterpenoids, most of which 
share conserved carbon skeletons.[96–100] Meroterpenoid natural products are secondary 
metabolites, derived from terpene subunits, that possess two fused six membered ring 
systems (figure 2.1). To date, most of the meroterpenoids isolated from Aka coralliphaga 
have been shown to exhibit a broad spectrum of bioactivity: from anti-bacterial properties 
observed in siphonodictyal B (2.1) and corallidictyals A – D (2.3 – 2.6), to PI3 kinase 
inhibitory activity found with liphagal (2.2) and corallidictyals A (2.3) & B (2.3).[96–100] 
Siphonodictyal B (2.1) was the first meroterpenoid to be discovered by Faulkner et al in 
1981,[97,98] and Andersen isolated the suspected biogenically related metabolite liphagal (2.2) 
in 2006.[99] The corallidictyals A (2.3) & B (2.3) were first isolated by Westly et al, in 
1994.[100]  Finally, Köck isolated and identified both families of the siphonodictyals B, B1 – 
B3 (2.1, 2.7 – 2.9), and the corallidictyals A – D (2.3 – 2.6) In the 2007.[96]  
 
Figure 2.1: Isolated meroterpenoid natural products from the sea sponge Aka coralliphaga.[96–100] 
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 Previous Structural Assignments and the Proposed 
Biosynthetic Origins of Siphonodictyal B & Liphagal 
 First Assignment of Siphonodictyal B by Faulkner et al 1981 
 
Scheme 2.1: Structural assignment of siphonodictyal B, isolated with siphonodictyal A from the sea 
sponge Aka coralliphaga (Siphonodictyon coralliphagum) by Faulkner et al, 1981.[97]  
Siphonodictyal A (2.15) and siphonodictyal B (2.10 or 2.1) were first isolated as a complex 
mixture of secondary metabolites from Aka coralliphagum (Siphonodictyon coralliphagum) 
by Faulkner et al in 1981 (scheme 2.1).[97] Of the two meroterpenoids, siphonodictyal B  
exhibited strong antimicrobial activity against the bacterium, Staphylococcus aureus, 
whereas siphonodictyal A (2.15) failed to demonstrate any notable growth inhibitory 
properties.[97] Structural elucidation of siphonodictyal B proved difficult, and consequently, 
Faulkner proposed two candidate structures, 2.10 or 2.1, upon analysis of trimethyoxy ether 
derivatives, 2.11 or 2.12, following methylation of the natural sample. Ozonolysis, followed 
by quenching the lysed methylated meroterpenoid under reductive conditions gave ketone 
2.13 and aryl dialdehyde 2.14, which was proposed to be acquired from either 2.11 or 2.12. 
The stereoconfiguration of the C8 methyl substituent was determined via a 1H NMR 
decoupling experiment of the unknown trimethoxy derivative (either 2.11 or 2.12). 
Irradiation of the methyl signal, at δ 0.90 ppm, caused the multiplet at δ 2.65 ppm to collapse 
into a doublet of doublets, with coupling constants of 6 and 2 Hz. Faulkner claimed the 
observed coupling constants were consistent with that of equatorial protons, projecting from 
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a saturated six-membered ring system in a chair conformation. Upon repeating the same 
decoupling experiment for ketone 2.13, the coupling constants were found to be 6 and 12 
Hz. Faulkner proposed that during ozonolysis and the reductive quenching protocol, the 
afforded ketone had isomerised exclusively to the predicted, more stable configuration 2.13 
(scheme 2.1). As aryl dialdehyde 2.14 gave no relevant information regarding the regio-
configuration of its parent compound, either 2.11 or 2.12, a series of substituted aryl 
compounds were synthesised to build a library of 1H and 13C NMR pattern peaks. The 
afforded library of NMR spectral patterns was used as reference for the assignment of the 
aromatic phenolic moiety of siphonodictyal B. Thus, Faulkner determined that structure 
2.10, by comparison with the synthesised library of substituted methylated phenols, was the 
configuration of siphonodictyal B. 
 Reassignment of Siphonodictyal B by Faulkner et al 1986 
 
Scheme 2.2: Structural reassignment of siphonodictyal B, isolated with new meroterpenoids, 
siphonodictyals C – H (2.18 – 2.23), from the sea sponge Aka coralliphagum (Siphonodictyon 
coralliphagum) by Faulkner et al, 1986. 
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In 1986, Faulkner published a second article detailing the isolation and characterisation of 
new, structurally related meroterpenoids, siphonodictyals C – H (2.18 – 2.23), from Aka 
coralliphaga (Siphonodictyon coralliphagum). Within the same article, Faulkner and 
Sullivan re-examined their previous assignment of siphonodictyal B, which at the time, was 
assigned as structure 2.10 (scheme 2.2).[98] Faulkner conceded that prediction of the aromatic 
proton signals was too crude to accurately assign the regio-configuration of the aromatic 
substituent of siphonodictyal B. With newly isolated samples, siphonodictyal B was 
dimethylated, to afford either 2.16 or 2.17. Faulkner identified two NOESY correlations of 
the C22 aldehyde proton at δ 10.9 ppm with the C21 phenolic proton at δ 11.42 ppm, and 
the aliphatic C19 methoxy protons at δ 3.99 ppm. Irradiation of the C17 aromatic proton 
signal at δ 7.01 ppm caused an increase in intensity of the C15 olefinic proton at δ 6.13 ppm, 
and the second C18 aliphatic methoxy protons at δ 3.83 ppm; highlighting the proximity if 
all three protons to one another (scheme 2.2). From these NOESY studies, Faulkner 
concluded that the structure of the dimethoxy derivative must be 2.17, and therefore, 2.1 was 
reassigned as the true structure of siphonodictyal B. 
 Isolation and Biosynthetic Proposal of Liphagal by Andersen et al  
In 2006, Andersen isolated the meroterpenoid liphagal (2.2) (figure 2.1) from the same sea 
sponge, Aka coralliphaga, that Faulkner had previously isolated the siphonodictyals from 
(scheme 2.1 and 2.2).[97–99] Andersen argued that liphagal (2.2) possessed structural 
similarities to siphonodictyal B (2.1) as indicated by NMR analysis, and consequently 
concluded that they may share a biosynthetic precursor. Andersen proposed two possible 
biosynthetic pathways for liphagal (2.2). The first route, pathway A, detailed the initial 
synthesis of siphonodictyal B (2.1) via a polyene cyclisation (2.24) and a subsequent 1,2-
hydride shift (2.25) (scheme 2.3). Upon ring opening of the theorised siphonodictyal B 
epoxide 2.26, a cationic initiated ring expansion and cyclisation cascade sequence would 
afford liphagal (2.2) in nature. Andersen’s alternative biosynthetic pathway B detailed the 
biosynthesis of the liphagal framework via preformation of a benzofuran moiety (2.34). The 
heterocyclic oxygen of the theorised benzofuran intermediate 2.34 was envisioned to 
introduce significant electron density at C’1 2.34, which could facilitate a polyene 
cyclisation to obtain liphagal (2.2). 
 
 





Scheme 2.3: Biosynthetic pathway A (top), proposed by Andersen, which details siphonodictyal B 
(2.1) as a biosynthetic precursor to liphagal (2.2). Alternative biosynthetic pathway B (bottom), 
proposed by Andersen, which details preformation of the benzofuran moiety 2.34, in the biosynthesis 
of liphagal (2.2).[99] 
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 Reported Biogenically Inspired Synthetic Methods 
for Liphagal, Siphonodictyal B & Corallidictyal D 
At the time we were preparing our proposal (2014), there were eight reported syntheses of 
liphagal (2.2), four of which were biogenically inspired.[101–104] Throughout the literature, 
the reported biogenically inspired syntheses of liphagal (2.2) were in accordance with one 
of the two biosynthetic pathways proposed by Anderson. Reported biogenically inspired 
syntheses based on Andersen’s pathway A, detailed the preformation of a siphonodictyal B 
(2.1) backbone, which served as a scaffold for the synthesis of liphagal (2.2). Our proposal 
was fundamentally inspired by Andersen’s pathway A. Alternatively, two reported total 
syntheses of liphagal (2.2), were in alignment with Andersen’s pathway B, where the key 
biogenic step detailed an acid catalysed polyene cyclisation to afford the liphagane skeleton.  
 Literature Syntheses in Agreement with Anderson’s Biosynthetic 
Pathway B 
Within the same isolation article, Andersen reported the successful biogenically inspired 
synthesis of liphagal (2.2) in accordance with pathway B (scheme 2.4).[99] Andersen’s 
biogenically inspired method served, not only to provide significant validity for pathway B’s 
legitimacy as a biosynthetic pathway occurring in nature, but also to confirm the structural 
assignment of liphagal (2.2). Andersen’s synthetic approach detailed the preformation of 
benzofuran 2.40, which would serve to facilitate a polyene cyclisation directed by the 
heterocyclic oxygen, to afford the liphagane scaffold 2.42. The key benzofuran polyene 2.40 
was acquired via a one-pot, two-step ester coupling of aryl-Wittig salt 2.36 with carboxylic 
acid 2.38, followed by a base catalysed intramolecular Wittig olefination of the in situ 
generated ester 2.39 (scheme 2.4). The key biomimetic polyene cyclisation was attempted 
upon heating 2.40 at reflux, in formic acid and cyclohexane. However, after 2 hours, only 
one six-membered ring had undergone cyclisation (2.41), and only after heating the reaction 
mixture for a further 4 weeks was the desired liphagane scaffold 2.42 afforded. Alternatively, 
cyclisation could be achieved within a reasonable time period by subjecting polyene 2.40 to 
chlorosulfonic acid in nitropropane to give 2.42. Finally, formylation, purification via 
HPLC, and demethylation of 2.43 furnished liphagal (2.2). Although Andersen’s biomimetic 
polyene cyclisation does grant validity to the proposed biosynthetic pathway B, the 
extremely slow rate of reaction under relatively mild acidic conditions (2.40 to 2.41, then 
2.42) highlights the unfavourable nature of the reaction. 
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Scheme 2.4: Andersen’s polyene cyclisation pathway B biomimetic synthesis of liphagal (2.2).[99] 
Further validity of Andersen’s liphagal (2.2) proposal came with Mehta’s biogenically 
inspired acid catalysed polyene cyclisation (scheme 2.5),[105] inspired by biosynthetic 
pathway B. Mehta’s approach mirrored Andersen’s polyene pathway, while also investigated 
a preformed cycloalkene system. Benzofuran 2.45 was coupled with either geranyl bromide 
(2.46) or cyclogeranyl bromide 2.49 to give polyene 2.48 and cycloalkene 2.51 respectively. 
Both 2.47 and 2.50 were independently methylated via a Wittig olefination and selective 
hydrogenation, employing a lead poisoned palladium/CaCO3 catalyst, to afford 2.48 and 
2.51 respectively. Geranyl benzofuranal bromide 2.48 was subjected to Andersen’s 
optimised chorosulfonic acid and 2-nitropropane conditions, which led to a polyene 
cyclisation, directed by the electron rich benzofuranal oxygen, to furnish the liphagane 
skeleton 2.42 in an unfavourable 1:2.5 epimeric ratio. Similarly, cyclogeranyl benzofuranal 
bromide 2.51 was cyclised under identical conditions, to afford 2.42 in the same 
unfavourable, 1:2.5 epimeric ratio. Finally, formylation and separation of the epimers gave 
methoxy liphagal precursor 2.43, which concluded Mehta’s formal biogenically inspired, 
pathway B synthesis of liphagal (2.2). 
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Scheme 2.5: Mehta’s pathway B inspired biomimetic formal synthesis of liphagal (2.2).[105] 
 Literature Syntheses in Agreement with Anderson’s Biosynthetic 
Pathway A 
Baldwin and George reported a pathway A biogenically inspired formal synthesis of liphagal 
(2.2), founded in generating aromatic diol 2.56, which was postulated to undergo a pinacol-
like rearrangement to afford the liphagane scaffold 2.59 (scheme 2.6).[106] Epoxy aldehyde 
2.53 was coupled with aryl bromide 2.54 via a lithiation-bromide exchange with t-BuLi, to 
yield 2.55. The afforded epoxy benzyl alcohol 2.55 was reduced, and the resulting crude diol 
was subjected to trifluoracetic acid to facilitate a Pinacol-like cascade reaction (2.56 – 2.58). 
Upon THP deprotection of 2.55, protonation of the afforded benzylic alcohol (2.56) was 
proposed to induce a ring expansion (2.57 – 2.58) via benzylic carbocation 2.57. Following 
ring expansion (2.58), the theorised ketone intermediate 2.58 was suspected to proceed to 
the liphagane scaffold 2.59 via hemiacetal formation and dehydration. Finally, formylation 
of 2.59 concluded Baldwin and George’s biogenically inspired formal synthesis of liphagal 
(2.2), highlighting the plausibility for the existence of pathway A in nature, in contrast to 
Andersen’s and Metha’s polyene cyclisation methods.  
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Scheme 2.6: Baldwin and George’s pathway A inspired biomimetic formal synthesis of liphagal 
(2.2), via a one-pot Pinacol-like rearrangement and subsequent ring expansion.[106] 
Inspired by Andersen’s proposed biosynthetic pathway A, Alvarez-Manzaneda’s biomimetic 
approach sought to initiate a one-pot, pinacol-like rearrangement, ring expansion, and 
intramolecular cyclisation to afford the liphagane skeleton 2.66 (scheme 2.7 and 2.8).[107] 
The starting point of Alvarez-Manzaneda’s route detailed coupling of epoxide 2.53 with aryl 
bromide 2.61, followed by PDC facilitated oxidation and subsequent reduction with LiAlH4 
to obtain the desired diol, as a mixture of diastereomers 2.62 and 2.63 (scheme 2.7). Both 
diastereomers 2.62 & 2.63, were separated, and individually subjected to POCl3 in pyridine, 
which led to a Pinacol-like rearrangement and ring expansion (2.64 & 2.67) to give ketones 
2.65 & 2.68 respectively. However, upon benzyl ether cleavage, via hydrogenation and 
subsequent treatment with perchloric acid, only ketone 2.65 was shown to undergo 
cyclisation to the liphagane tetracyclic skeleton 2.66. Despite investigating various acidic 
conditions, Alvarez-Manzaneda failed to cyclise ketone 2.68 to 2.66 in any appreciable 
quantity. 
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Scheme 2.7: Alvarez-Manzaneda’s pathway A inspired biomimetic synthesis of liphagal (2.2), via a 
PO3Cl facilitated Pinacol-like rearrangement and subsequent ring expansion.
[107] 
Alvarez-Manzaneda explored an alternative cyclisation route by subjecting 2.62 to a one-
pot hydrogenation, in the presence of Amberlyst A15, which initiated a cascade reaction to 
afford liphagane skeleton 2.66, via the proposed ring expanded ketone intermediate 2.71 
(scheme 2.8). While optimising the reaction conditions, phenol 2.72 was isolated upon 
increasing the hydrogen pressure, while simultaneously decreasing the relative load of 
Amberlyst A15 to 2.62. Based on the emergence of phenol 2.72, Alvarez-Manzaneda 
proposed that the intermediate preceding the ring expansion was likely to be an o-QM (2.70), 
rather than a benzylic carbocation, which could be reduced upon a reduction in catalyst 
loading, in accordance with observations (scheme 2.8). Tetracycle 2.66 was formylated to 
2.73 and demethenylated to concluded Alvarez-Manzaneda’s biogenically inspired total 
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synthesis of liphagal (2.2), providing additional validity for the occurrence of biosynthetic 
pathway A in nature.  
 
Scheme 2.8: Alvarez-Manzaneda’s pathway A inspired biomimetic synthesis of liphagal (2.2), one-
pot cascade Pinacol-like rearrangement via a proposed orthoquinone methide intermediate 
(2.70).[107] 
 Isolation and Synthesis of the Structurally Related Meroterpenoids 
from Aka coralliphaga 
Corallidictyals A (2.3) & B (2.4) were first isolated by Westly and co-workers from Aka 
coralliphagum, as an inseparable mixture in a 3:7 ratio respectively (figure 2.2).[100] Westly 
postulated that corallidictyals A (2.3) & B (2.4) were conceivably interconverting in 
solution, by ring opening of the spirocycle via the phenolic oxygen. Westly heated an 
isolated sample of 2.3 & 2.4 at 100°C in DMSO-d6, so to observe evidence for 
interconversion of corallidictyals A (2.3) & B (2.4). However, the ratio of corallidictyals A 
(2.3) & B (2.4) did not change upon heating the samples. as observed by 1H NMR analysis. 
In an attempt to generate the hypothesised phenolic anion, following a potential ring opening 
of the spirocycle moiety, NaOD was added to a sample of corallidictyals A (2.3) and B (2.4). 
However, no change in the ratio of spirocycles was observed, consistent with previous 
thermal isomerisation attempts. Thus, Westly concluded that corallidictyals A (2.3) and B 
(2.4) were in fact distinct, non-interchangeable spirocycles. Interestingly, the mixture of 
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natural products were found to be selective, mild inhibitors of protein kinase C, which has 
been identified as a broad yet viable target in treatment of malignant tumours.[100]  
 
Figure 2.2: Isolation of corallidictyals A – D (2.3 – 2.6), and siphonodictyal B (2.1) and related 
siphonodictyal B analogues, B1 (2.7), B2 (2.8), B3 (2.9), isolated from the sea sponge Aka 
coralliphagum (Siphonodictyon coralliphagum)[96,100] 
In 2007, Köck et al isolated a series of meroterpenoids from Aka coralliphagum, all of which 
showed strong structural resemblance to siphonodictyal B (2.1) (figure 2.2).[96] 
Siphonodictyal B2 (2.8) and B3 (2.9) were determined to be mono- and di-sulfate esters of 
siphonodictyal B (2.1) respectively. Siphonodictyal B1 (2.7) was found to be a mono-sulfate 
ester, akin to siphonodictyal B2 (2.8), which possessed a taurine iminium moiety in place of 
the aryl aldehyde at C22. Additionally, the previously undiscovered corallidictyals C (2.5) 
and D (2.6) were isolated, which upon NMR analysis, were revealed to be reduced analogues 
of the co-isolated corallidictyals A (2.3) and B (2.4). Köck found that the sulfated 
siphonodictyal B isomers (2.7 – 2.9) had little, to no antimicrobial activity, unlike 
siphonodictyal B (2.1). However, corallidictyals A – D (2.3 – 2.6) showed notable 
antimicrobial activity (gram -/+ bacteria, yeast and pathogenic fungi), while also displaying 
strong cytotoxic activity against L929 mouse fibroblast cell lines. The seemingly cytotoxic 
properties of corallidictyals A (2.3) & B (2.4) appears to be most likely due to the p-QM, 
aryl aldehyde and phenolic moieties. Although, the corallidictyals C (2.3) & D (2.4) lack the 
hypothetically cytotoxic p-QM moiety, they may readily undergo oxidation, which in 
tandem with the aldehyde substituent, could be the source of their cytotoxic properties. Thus, 
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the putative reactive moieties of corallidictyals and siphonodictyals may elucidate the 
meroterpenoids seemingly broad spectrum, non-selective cytotoxic mechanism of action. 
 Literature Syntheses of Siphonodictyal B and Corallidictyal D 
At the time of our proposal formulation (2014), there was one reported attempted synthesis 
of siphonodictyal B (2.1). 
 
Scheme 2.9: Attempted synthesis of siphonodictyal B (2.1) by Seifert et al.[108] 
Seifert et al were the first to report an attempted synthesis of siphonodictyal B (2.1), which 
detailed a coupling approach of a lithiated aryl bromide (2.76) with an acyl chloride (2.75) 
to obtain the desired siphonodictyal scaffold (2.77) (scheme 2.9).[108] (±)-Drimanic acid 
(2.74) served as a starting point in Seifert’s route, which could be readily converted to the 
acyl chloride 2.75 upon treatment with oxalyl chloride and a catalytic quantity of DMF. 
Upon investigating a suitable aryl bromide coupling partner, large protecting groups, such 
as benzyloxy, were found to considerably decrease the coupling yields. Therefore 2.76 was 
chosen as a suitable aryl coupling partner due to the small size of protecting groups, which 
ensured the siphonodictyal scaffold (2.77) could be afforded in good yield. The afforded 
ketone 2.77, which was subsequently reduced, and the resulting benzyl alcohol was 
eliminated to give the desired aryl alkene 2.78. ortho-Lithiation of 2.78, followed by 
quenching with DMF gave aryl aldehyde 2.79, and deprotection of the methoxy protecting 
group gave the demethylated precursor 2.80. However, despite investigating a wide variety 
of strong Lewis and Brønsted acids, the methylenedioxy protecting group proved too 
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resistant to be removed, which concluded Seifert’s attempted synthesis of siphonodictyal B 
(2.1). 
At the time of preparation of our proposal (2014), there was one reported total synthesis of 
corallidictyal D (2.6). 
 
Scheme 2.10: Novel spirocyclisation via NIS and PPh3 by Alvarez-Manzaneda et al.
[109] 
Alvarez-Manzaneda et al reported the first total synthesis of corallidictyal D (2.6) in 2013, 
via a catalytic spirocyclisation with catalytic N-iodosuccinimide and triphenylphosphine. 
The key spirocyclisation step was modeled on a simplified o-(β-cyclogeranyl) phenol 2.81 
system, to afford the spirocycle 2.82 and tetracycle 2.83 (scheme 2.10).[109] 
 
Scheme 2.11: Total synthesis of corallidictyal D (2.6) by Alvarez-Manzaneda et al.[109] 
Starting from α-ionone (2.84), hydroxy ketone 2.85 was synthesised over 5 steps, followed 
by arylation with protected ether 2.86 in the presence of the cationic resin, Amberlyst (A-
15) (scheme 2.11). The afforded coupled ketone 2.87 was subjected to Wittig olefinic 
methenylation, followed by alkene isomerisation and selective hydrogenation to furnish the 
key desired phenol 2.88. Phenol 2.88 was subjected to Alvarez-Manzaneda’s optimised 
spirocyclisation conditions with catalytic N-iodosuccinimide and triphenylphosphine to 
afford corallidictyal D skeleton 2.89, as the exclusive isomer. Alvarez-Manzaneda 
3.5                       :                    1 
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speculated that in order to achieve exclusive stereoselectivity, the mechanism must involve 
an anti-fascial, concerted attack of the endo-alkene 2.88, thereby, precluding the formation 
of a carbocation intermediate. 2.89 was subjected to ortho-lithiation and quenching with 
DMF to install the aryl aldehyde moiety. Finally, aryl aldehyde 2.90 was demethenylated 
with AlCl3, and upon addition of a methanolic solution of HCl, enantiopure corallidictyal D 
(2.6) was afforded (scheme 2.11).  
 Our Divergent Biosynthetic Proposal  
We propose that 8-epi-siphonodictyal B (2.91), which is the C8 epimer of Faulkner’s 
assignment (2.1), is the true configuration of siphonodictyal B. Additionally, we hypothesise 
that under a divergent biosynthetic pathway, our proposed reassigned configuration of 
siphonodictyal B (2.91) is the biogenic precursor to liphagal (2.2), 8-epi-siphonodictyals B1 
- B3 (2.106 – 2.108) and corallidictyals A - D (2.3 - 2.6), all of which consequently possess 
a singular biological origin in nature (scheme 2.15). The proposed biosynthetic pathway A 
to liphagal (2.2) from siphonodictyal B (2.1), as proposed by Andersen et al (scheme 2.3), 
does appear plausible with the exception of the a C8 epimerisation event.[99] Our scepticism 
towards Andersen’s proposed epimerisation event is founded in the unlikelihood that the 
shared C8 stereoconfiguration between liphagal (2.2) and the corallidictyals A - D (2.3 - 2.6) 
(which were assigned independently of one another) is purely coincidental.[96,99,100] 
Furthermore, the stereochemical assignment of siphonodictyals B1 - B3 (2.7 – 2.9) was 
based upon NMR studies and in accordance to the configuration of siphonodictyal B (2.1) 
postulated by Faulkner. Thus, the C8 stereochemical configuration of siphonodictyal B (2.1) 
and siphonodictyals B1 - B3 (2.7 – 2.9) was not re-examined by Köck (figure 2.1 or 2.2).[96] 
As no C8 epimers of siphonodictyal B (2.1), liphagal (2.2) and corallidictyals A - D (2.3 - 
2.6) have been isolated from natural samples to date, and if we assume Andersen’s pathway 
A to be valid, then the proposed epimerisation event must be catalysed by dedicated 
substrate-specific enzyme/s in order for pathway A to be plausible. The requirement of 
substrate-specific enzymes would introduce unnecessary complexity and further convolute 
a given biosynthetic pathway. Therefore, the introduction of substrate-specific enzymes 
would appear to only waste resources if the end products did not provide a specific advantage 
to the host. A divergent biosynthetic pathway would be favoured over multiple linear 
biosynthetic pathways that would give rise to liphagal (2.2) and the corallidictyals A - D (2.3 
– 2.6), as the latter route would require multiple enzymes, resulting in a more convoluted 
pathway to the meroterpenoids than appears necessary.  
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A divergent, non-enzymatically mediated biosynthetic pathway would appear to be the 
simplest explanation and would satisfy the minimalist concept defined by Occam’s razor (or 
Ockham’s razor), where upon two differing explanations, the proposal that requires the least 
necessary assumptions is presumed to be the correct one. Simply stated, if there is no 
selective pressure to create multiple pathways for say ‘X’ natural products, in preference to 
a singular pathway that can diverge to give the same number of ‘X’ natural products, then 
the likelihood of multiple biosynthetic pathways emerging is improbable. Thus, the 
introduction of epimerisation enzymes and multiple discrete biosynthetic pathways for 
seemingly related natural products appears to overly convolute the biosynthetic origins of 
this family of meroterpenoids. Faulkner’s assignment of siphonodictyal B (2.1), regarding 
the C8 methyl substituent, requires that Anderson’s proposed pathway A to liphagal (2.2) be 
unnecessarily convoluted. Therefore, a potential miss-assignment of the C8 methyl 
substituent of siphonodictyal B (2.1) by Faulkner, would appear to resolve the proposed 
obstacles acknowledged by Andersen without the introduction of specific epimerisation 
enzymes into the biosynthetic pathway to liphagal (2.2).  
 
Scheme 2.12: Our pathway A inspired biosynthetic proposal for liphagal (2.2) from our proposed 
reassigned siphonodictyal B 2.91 via an o-QM 2.93 or a p-QM 2.94. 
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In regard to the biosynthesis of liphagal (2.2), we propose that the theoretical ring expansion, 
as detailed in Andersen’s pathway A proposal (scheme 2.3), may proceed by either o-QM 
2.93 or p-QM 2.94. Both o-QM 2.93 or p-QM 2.94 may serve as more favourable 
intermediates than the proposed benzylic carbocation 2.27 following the theorised epoxide 
ring opening event (2.92) (scheme 2.12).[44,60,84,110] Conceivably, corallidictyals A – D (2.3 
– 2.6) could be accessed from siphonodictyal B 2.91 directly. Furthermore, the family of 
corallidictyals A  B (2.3 – 2.4) may also be derived in nature from corallidictyals C & D (2.5 
& 2.6) and vice versa, via REDOX reactions (scheme 2.13 and 2.14).  
 
Scheme 2.13: Our biosynthetic proposal for corallidictyals A & B (2.3 & 2.4). 
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We hypothesise that corallidictyals A & B (2.3 & 2.4) could be accessed in nature via the 
oxidation of siphondictyal B 2.91 to either ortho-quinone (2.96 or 2.97) or para-quinone 
(2.98 or 2.99) (scheme 2.13). The proposed ortho-quinone 2.96 may be envisioned to 
undergo an anionic 5-endo-trig cyclisation to afford corallidictyals A & B (2.3 & 2.4). 
However, anionic 5-endo-trig cyclisations are disfavoured according to Baldwin’s rules, and 
hence, if such a route to corallidictyals A & B (2.3 & 2.4) does occur, it may proceed if no 
other alternative reaction pathway is available.[111,112] Although Baldwin’s rules are stated to 
apply beyond radical and nucleophilic ring closures to both homolytic and cationic 
processes, exceptions to these conjugate cationic 5-endo-trig cyclisations have been 
extensively reported throughout the literature.[11,113–115] Therefore, Baldwin’s rules do not 
appear to apply in their entirety to cationic species, which Baldwin does acknowledge, 
leaving us to speculate that a 5-endo-trig spirocyclisation of the protonated oxygenic moiety 
of quinone 2.97, may in fact be a viable mechanism for the biosynthesis of corallidictyals A 
& B (2.3 & 2.4) in nature.  
 
Scheme 2.14: Our biosynthetic proposal for corallidictyals A – B (2.3 – 2.6). 
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Plausible alternative oxidative pathways to corallidictyals A & B (2.3 & 2.4) may proceed 
via a para-quinone intermediate (2.98 or 2.99), where a concerted electrocyclization (2.98) 
or a step-wise cyclisation akin to a Nazarov reaction may occur (2.99 to 2.101) (scheme 
2.13).[116,117] Corallidictyals C & D (2.5 & 2.6) may be acquired directly from siphondictyal 
B 2.91 by either a Brønsted or Lewis acid mediated cyclisation via trapping of tertiary 
carbocation 2.104 by the phenolic oxygen (scheme 2.14). Finally, we propose that under 
mild REDOX conditions, such as those found within cells, corallidictyals A & B (2.3 & 2.4) 
may be reversibly oxidised to corallidictyals C & D (2.5 & 2.6) and back to 2.3 & 2.4 under 
reductive conditions. 
 Retro-Synthetic Analysis  
As we have proposed that the true stereoconfiguration of siphonodictyal B is 2.91 and not 
2.1, our proposal must also involve the reassignment of siphonodictyals B1 - B3 2.7 – 2.9 to 
2.106 – 2.108 in accordance with our hypothesis (scheme 2.15). Biosynthesis of 8-epi-
siphonodictyals B1 - B3 (2.106 – 2.108), as through the lens of our proposal, can be 
envisioned by a selective sulfonation at C21, resulting in siphonodictyal B2 2.107, while an 
additional sulfonation at C18 would yield siphonodictyal B3 2.108. As siphonodictyal B1 
2.106 possesses an imine sulfonic acid moiety at C22, its biosynthesis in nature may proceed 
via an imine condensation of siphonodictyal B2 2.107 with 2-aminoethanesulfonic acid, a 
ubiquitous biological substrate known colloquially as ‘taurine’ (scheme 2.15).  
We set out to synthesise our proposed reassigned C8 epimeric configuration of 
siphonodictyal B 2.91 and upon its acquisition, to compare the characterisation data to that 
of the natural sample isolated by Faulkner (scheme 2.15).[97,98] Upon the anticipated 
successful synthesis and reassignment of siphonodictyal B 2.91, we sought to investigate our 
divergent biogenically inspired hypothesis, by synthesising liphagal (2.2), corallidictyals A 
– D (2.3 – 2.6) and siphonodictyals B1 – B3 (2.106 – 2.108) from siphonodictyal B 2.91 
(scheme 2.15). Retrosynthetic analysis of siphonodictyal B 2.91 led us to envision direct 
access through a sequential elimination, formylation and global deprotection, from benzyl 
alcohol 2.109. The most direct route to benzyl alcohol 2.109 appeared to be through an aryl 
lithiated coupling of aryl bromide 2.110 with aldehyde 2.112, where aryl bromide 2.110 
could be accessed from 2,3-dihydroxybenzaldehyde 2.111, and aldehyde 2.112 could be 
synthesised from (+)-sclareolide 2.52 (scheme 2.15). 
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Scheme 2.15: Retrosynthetic analysis of our proposed reassignment of siphonodictyal B 2.91, and 
the naturally derived analogues, siphonodictyal B1 – B3 (2.106 – 2.108), under our divergent 
synthetic proposal for meroterpenoids from Aka coralliphagum. 
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 Pursuit of Siphonodictyal B 
Our priority was to synthesis the siphonodictyal B epimer 2.91 in accordance with our 
proposal (scheme 2.15), by way of a convergent approach; we sought to synthesise and 
couple the globally protected aryl bromide 2.110 with aldehyde 2.112 via a bromide-lithium 
exchange to obtain benzyl alcohol 2.109. 
 Synthesis of Aryl Bromide 2.116 
We set out to synthesise an aryl bromide that could be globally deprotected, so as to minimise 
functional group manipulations. Any protecting group chosen would need to be resistant to 
a variety of harsh conditions, while also labile enough to be removed under relatively mild 
conditions, as the foreseen conjugated alkene moiety of siphonodictyal B 2.91 was expected 
to be sensitive to strong acidic conditions. Benzyl ether protecting groups were not chosen 
as they were predicted to have been too difficult to remove under hydrogenating conditions 
in the presence of the conjugated alkenyl moiety. Additionally, benzyl ether protecting 
groups had previously introduced issues during bromide-lithium couplings as observed by 
Seifert in the attempted to synthesise siphonodictyal B (2.1), most likely due to unfavourable 
steric interactions.[108] For these reasons, iso-propoxy ether protecting groups were chosen 
as they are more labile in comparison to methoxy ethers, while still possessing a good degree 
of stability under a large array of harsh conditions.[106]  
2,3-dihydroxybenzaldehyde (2.111) was chosen as our starting point in the synthesis of aryl 
bromide coupling partner 2.116 (scheme 2.16). Di-protection of 2.111 with 2-
bromopropane, in the presence of tetrabutylammonium iodide, gave di-iso-propoxy ether 
benzaldehyde 2.113, and was of sufficient purity to be used without further purification 
following an extensive workup.[118] Oxidation of protected aldehyde 2.113 to phenol 2.114 
was achieved following an acidic Dakin oxidation procedure,[118,119] again, of sufficient 
purity without the need for a formal purification procedure. Next, protection of phenol 2.114 
was achieved with 2-bromopropane and TBAI in DMF to afford the globally protected aryl 
tris-iso-propoxy ether 2.115 in a yield of 89% over 3 steps from 2,3-dihydroxybenzaldehyde 
(2.111). Finally, treatment of tris-iso-propoxy ether 2.115 with NBS in THF at -78 ˚C, 
followed by warming to room temperature gave the desired protected aryl bromide 2.116 as 
a single regioisomer.[120] With the desired aryl bromide 2.116 in hand, we turned our 
attention to synthesising the aldehyde coupling precursor 2.112. 
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Scheme 2.16: Synthesis of aryl bromide 2.116.[118–120] 
 Synthesis of Aldehyde 2.112 
Our synthetic route to aldehyde 2.112 was based upon a methodology paper by Barrero and 
Alvarez-Manzaneda et al, which investigated the conversion of 1,2-diols to carbonyl 
compounds under Mitsunobu conditions (scheme 2.17).[121] Specifically, what caught our 
attention was the conversion of a 1,2-diol sesquiterpene 2.117 to our desired aldehyde 2.112. 
Access to the necessary diol 2.117 was foreseen via a reduction of a literature epoxide, 
following a series of well-established literature procedures.[106,122–124] 
 
Scheme 2.17: Preparation of carbonyls from 1,2-diols via Mitsunobu conditions, by Barrero et al.[121] 
(+)-Sclareolide 2.52 represented the starting point in our pursuit of aldehyde 2.112, as an 
enantiopure, relatively cheap and accessible starting material (scheme 2.18). Following a 
modified three-step protocol to diol 2.120, discovered by Kuchkova and refined by 
Sudhakarrao, treatment of (+)-sclareolide 2.52 with MeLi gave ketone 2.118 via alkylation 
of the lactone moiety.[122,123] 2.118 was subsequently oxidised under Baeyer-Villiger 
conditions to yield the acetate 2.119 and then subjected to basic hydrolysis to afford diol 
2.120 in a yield of 73% over 3 steps.[122,123] In order to eliminate the tertiary alcohol to obtain 
the quaternary alkene 2.123, oxidation of the primary alcohol of 2.120 to aldehyde 2.121 
was required to direct the proceeding elimination, which was achieved under Swern 
oxidative conditions. The newly formed aldehyde moiety of 2.121 was found to direct the 
subsequent BF3.OEt2 mediated elimination, to the conjugated alkenyl-aldehyde 2.122. 
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Finally, 2.122 was reduced to alcohol 2.123, in preparation of the Sharpless epoxidation 
(scheme 2.18).[124] 
 
Scheme 2.18: Synthesis of aldehyde coupling precursor 2.112.[122–124] 
In pursuit of 1,2-diol 2.117, Sharpless stereoselective epoxidation with the chiral unnatural 
ligand, D-(-)-diethyl tartrate, gave the desired epoxide 2.124 (scheme 2.19).[125,126] The 
stereoconfiguration of epoxide 2.124 was verified by comparison of the obtained 
spectroscopic data with that of the reported literature spectra,  without any notable formation 
of the undesired stereoisomer. Finally, reduction with LiAlH4 in THF while heating afforded 
1,2-diol 2.117 in good yield, allowing us to proceed in the investigation of Barrero’s 
Mitsunobu-like facilitated rearrangement of diol 2.117 to the desired aldehyde 2.112.  
Upon treatment of 1,2-diol 2.117 with diethyl azodicarboxylate (DEAD) and PPh3, under 
standard Mitsunobu’s conditions, the desired aldehyde was isolated as a pair of 
stereoisomers 2.112-a:b, and not as a single diastereomer as reported by Barrero et al 
(scheme 2.19).[121] Following the hypothesised formation of intermediate 2.125, the 
proposed spontaneous rearrangement of 2.126 may have afforded enol ether 2.127. The 
proposed in situ enol ether 2.127 could then undergo tautomerization to the more stable 
aldehyde 2.112, thereby rationalising the observed loss of stereochemical information 
inherent to diol 2.117. The loss of stereochemical information was not regarded an issue, as 
the anticipated coupling of aldehyde 2.112-a:b with aryl bromide 2.116 and subsequent 
elimination would afford the desired siphonodictyal B 2.91 carbon skeleton, as envisioned. 
However, increasing the reaction scale to obtain synthetically useful quantities of aldehyde 
epimers 2.112-a:b proved unexpectantly difficult, as multiple tedious workups were 
required due to the formation of an insoluble gum-like by-product, which resulted in 
unacceptable product loss. As unresolvable difficulties encountered from Barrero’s 
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Mitsunobu diol rearrangement resulted in the failure to obtain synthetically useful quantities 
of aldehyde 2.112-a:b, we set out to synthesise aldehyde 2.112 via an alternative route. 
 
Scheme 2.19: Synthesis of aldehyde epimers 2.112-a:b via Mitsunobu conditions.[121,125,126]  
 Katoh’s Biogenically Inspired Synthesis of Liphagal – Synthesis of 
Aldehyde 2.112 
 
Scheme 2.20: Biogenic inspired total synthesis of liphagal (2.2) by Katoh et al.[127] 
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During the synthesis of our target coupling precursor aldehyde 2.112, Katoh et al published 
a total synthesis of liphagal, which was claimed to be biogenically inspired by Andersen’s 
biosynthetic pathway A proposal (scheme 2.20).[99,127] Katoh’s route was akin to our own 
proposal for the biogenic synthesis of liphagal (2.2) from siphonodictyal B (2.1). However, 
the route did not involve the total synthesis of siphonodictyal B (2.1) itself, and instead, 
involved the epoxidation of a protected substrate that possessed the siphonodictyal B 
scaffold 2.130, to afford epoxide 2.131 as a racemic mixture of diastereomers. On isolation 
of epoxide 2.131 (1:1 – dr), Katoh subjected the mixture 2.131 (1:1 – dr) to TFA in CH2Cl2, 
which led to an acid catalysed, biogenically inspired ring expansion (2.132) to obtain ketone 
2.133. Subsequent acetate hydrolysis of ketone 2.133 led to a spontaneous intramolecular 
cyclisation to afford the benzofuran moiety, furnishing liphagane skeleton 2.83. Finally, 
formylation and deprotection of the methylene protecting group concluded Katoh’s 
stereoselective total synthesis of liphagal (2.2). 
Of particular interest to us was Katoh’s route to obtain aldehyde 2.112 (scheme 2.21); as our 
previously explored pathway to 2.112-a:b proved unnecessarily convoluted due to issues 
regarding reaction scaling of the Misunobu-like diol rearrangement. Additionally, our route 
detailed a longer linear sequence to obtain aldehyde 2.112 from (+)-sclereolide (2.52) (8 
steps). Comparatively, Katoh’s synthetic route appeared simpler, with fewer synthetic steps 
(6 steps from (+)-sclereolide 2.52) and appeared to be scalable. Additionally, Katoh’s 
method granted access to alcohol epimer 2.135,[127] which could be oxidised to aldehyde 
2.136, and serve as a coupling precursor in the synthesis of siphonodictyal B (2.1), in 
accordance with Faulkner’s assignment.[97,98]  
 
Scheme 2.21: Synthesis of aldehyde coupling precursor 2.112, by Katoh et al[127] 
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 Alternative Synthetic Route to Aldehydes 2.112 and 2.136 
With significant difficulties inherent to our synthetic route to aldehyde 2.112 via Barrero’s 
Mitsunobu-like rearrangement of diol 2.117,[121] we sought to mirror Katoh’s synthetic route 
to aldehyde 2.112.[127] Thus, as Katoh’s synthesis would grant access to both alcohol 2.135, 
was of interest to us as 2.135 could be oxidised to aldehyde 2.136, potentially granting access 
to siphonodictyal B (2.1), in accordance with Faulkner’s assignment.[97,98] Thus, synthesising 
both C8 epimers of siphonodictyal B, 2.1 and 2.91, would allow us to either confirm our 
hypothesis, or resolve any ambiguity in regards to the natural products stereoconfiguration. 
Upon mirroring Katoh’s published protocol, synthesis of endo-alkenyl-alcohol 2.137 via an 
acid catalysed elimination of diol 2.120 was found to be scalable without any considerable 
loss of yield (table 2.1),[127] and could be achieved in relatively good purity without the need 
for a formal purification protocol. Following the synthesis of the endo-alkenyl-alcohol 
2.137, hydrogenation conditions were investigated in order to gain access to both alcohol 
epimers, 2.134 and 2.135. Investigation into suitable catalysts commenced with 10 % 
palladium on carbon (Pd/C) in MeOH. However, despite trialling varying solvents, both 
alcohols (2.134 and 2.135) were obtained in unusually low yields (entries 1 and 2, table 2.1). 
Upon trailing hydrogenation conditions with 10% Pd/C, a relatively non-polar mixture of 
by-products was observed to form as the major product. 1H NMR and 13C NMR analysis of 
the isolated unknown polar by-product revealed the presence of multiple alkane signals and 
a single alkenyl proton. Based on the limited data available, it appeared that the primary 
alcohol of 2.137 had undergone reduction, despite the mild conditions (room temperature 
and H2 supplied via a breathable bladder). All hydrogenation conditions with 10% Pd/C 
consistently afforded the partially hydrogenated, inseparable mixture of unfunctionalized 
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Table 2.1: Acid catalysed elimination, and screening of hydrogenation conditions for the synthesis 
of alcohols 2.134 and 2.135.[127] 
Entry Catalyst (mol %)   Conditions Outcome 
1 10wt % Pd/C (10) MeOH, 0 °C, 6 h 2.134 (9%), 2.135 (14%) 
complex mixture 
2 10wt % Pd/C (10) CH2Cl2, 0 °C, 8 h 2.134 (7%), 2.135 (12%) 
complex mixture 
3 Crabtrees catalyst (1.0) CH2Cl2, 0 °C, 24 h slow/incomplete reaction 
4 Crabtrees catalyst (1.0) CH2Cl2, -10 °C, 8 h 2.134 (64%), 2.135 (4%) 
5 Wilkinson’s catalyst (5.0) CH2Cl2, rt, 24 h 2.134 (89%), 2.135 (7%) 
 
Changing from the previously employed 10 % Pd/C to Crabtree’s catalyst, Katoh’s reported 
yields could not be replicated. Additionally, despite mirroring the same reaction preparative 
method, where the solvent was degassed with argon, sonicated and evacuated to remove all 
traces of O2, the reduction of alcohol 2.137 could not be pushed to completion (entry 3, table 
2.1).[127] Upon analysis of the literature, Crabtree’s catalyst has been shown to undergo 
spontaneous self-dimerization at room temperature,[128,129]  and is reported to be particularly 
sensitive to acidic impurities. With this in mind, alkenyl-alcohol 2.137 was purified prior to 
the attempted catalytic reduction at reduced temperatures, in an attempt to remove any 
potential contaminating p-TsOH. Additionally, the gradual periodical addition of Crabtree’s 
catalyst every two hours has been suggested to help mitigate inactivation of the iridium 
catalyst via dimerization. However, despite these additional precautions, the complete 
reduction of alcohol 2.137 could not be achieved (entries 3 and 4, table 2.1). Finally, our 
investigation of hydrogenating catalysts led us to the more robust Wilkinson’s catalyst, 
which successfully reduced the crude alkenyl-alcohol 2.137 at room temperature to afford 
both alcohols, 2.134 and 2.135 (entry 5, table 2.1), in comparable selectivity and yield with 
Katoh’s Crabtree’s reduction (scheme 2.21). With both alcohols 2.134 and 2.135 at hand, 
oxidation to the desired aldehydes 2.112 and 2.136 was realised following Katoh’s Swern 
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conditions (scheme 2.22).[127] With a simple, yet robust synthetic route, granting access to 
both aldehydes 2.112 and 2.136, we set out to synthesise both C8 epimers of siphonodictyal 
B (2.1 and 2.91). 
 
Scheme 2.22: Swern oxidation of alcohols 2.134 and 2.135 to the desired aldehydes 2.112 and 2.136, 
respectively.[127] 
  Synthesis of Siphonodictyal B 2.91, in Accordance with Our 
Proposed C8 Reassignment 
With access to both aldehydes 2.112 and 2.136, we set out to synthesise siphonodictyal B 
2.91 in accordance with our proposed C8 epimeric reassignment. Synthetic access to 
siphonodictyal B (2.91), as depicted in our retrosynthetic analysis (scheme 2.15), was 
envisioned through coupling of aldehyde 2.112 with aryl bromide 2.116 via halogen-lithium 
exchange.[130] 2.116 was subjected to a cooled solution of t-BuLi in THF, followed by 
addition of 2.112 to afford benzyl alcohol 2.138, as a single stereoisomer (scheme 2.23). The 
absolute stereo-configuration of 2.138 at the hydroxy benzyl moiety was not determined.  
Elimination of benzyl alcohol 2.138, by treatment with p-TsOH in toluene gave alkene 
2.139, albeit in a lower yield than anticipated due to the unexpected formation of polar by-
product 2.140. The identity of 2.140 was found to be a p-QM as indicated upon comparison 
to the fortuitously afforded o-QM isomer 2.143, following the attempted synthesis of an 
analogous model system for liphagal (2.2) by a member of our group (scheme 2.23 – b). 
NOESY and HMBC NMR correlations elucidated the identity of both isomers, which was 
confirmed upon the subsequent reduction of both quinone methide isomers, 2.140 and 2.143, 
to their corresponding phenols, 2.141 and 2.145 respectively (scheme 2.23).  
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Scheme 2.23: a). Coupling of aryl bromide 2.116 with aldehyde 2.112 and a subsequent elimination 
of benzyl alcohol 2.138 to afford alkene 2.139, alongside undesired p-QM 2.140. b) Kuan’s and 
George’s synthesis of o-QM  2.143. c) proposed mechanistic rationale for the competing elimination 
pathways of benzyl alcohol 2.138, affording alkene 2.139 and p-QM 2.140. 
The formation of o-QM 2.143, as observed for Kuan’s system (scheme 2.23 – b), was not 
observed under any explored acid catalysed elimination conditions for our tri-iso-proxy ether 
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system 2.138. p-QM 2.140 was found to be stable under elevated thermal conditions and was 
observed to slowly decompose at a sustained temperature of 140 °C, in toluene within a 
sealed tube. Additionally, p-QM 2.140 appeared inert to strong non-nucleophilic acids (TFA, 
p-TsOH), and bases (NaH, NEt3) as a solution of refluxing toluene. Therefore, p-QM 2.140 
was determined to not be interchangeable with alkene 2.139, nor could it undergo 
rehydration to afford a benzyl alcohol. Various elimination conditions were investigated in 
an attempt to minimise the formation of the undesired p-QM by-product 2.140 (table 2.2). 
Trialling elimination conditions of 2.138 with p-TsOH at room temperature marginally 
decreased the formation of alkene 2.139, and consequently, led to an increase in the yield of 
p-QM 2.140 (entry 2, table 2.2). Despite reducing the molar equivalents of p-TsOH and 
reducing the temperature protocol, the generation of the undesired p-QM 2.140 could not be 
mitigated (entry 3, table 2.2). Employing the milder acid, pyridinium p-toluenesulfonate, 
under thermal conditions significantly reduced the formation of 2.140 and afforded alkene 
2.139 in an acceptable yield of 52%, while additionally affording starting benzyl alcohol 
2.138 (entry 4, table 2.2). Finally, generation of p-QM 2.140 was almost entirely negated 
upon elimination of 2.138 via phosphoryl chloride in pyridine,[131,132] which gave alkene 
2.139 and recovered benzyl alcohol 2.138 in acceptable yields (entry 5, table 2.2). 
We suspect that the observed formation of the undesired p-QM 2.140 from benzyl alcohol 
2.138, may be due to the equatorially projecting C8-methyl substituent potentially restricting 
free rotation of the benzylic carbocation moiety of 2.138-b. If such a restriction of rotation 
occurred, then the necessary alignment of the C9-H with the empty p-orbital of the benzylic 
carbocation (2.138-b) may have been considerably less favourable, impeding the desired 
formation of alkene 2.139 (scheme 2.23-c). Thus, in the presence of a strong acid, the 
formation of p-QM 2.140 from benzylic carbocation 2.138-b appeared to be comparatively 
favourable as the desired C9-H elimination pathway (2.138-b to 2.138-c). The formation of 
2.140 was drastically reduced upon changing from more acidic conditions, to employing 
phosphorus oxychloride in pyridine, which seemingly validated our rationale regarding the 
effect of strong acids on the formation of p-QM 2.140 (entry 5, table 2.2). Additionally, as 
the p-QM 2.140 could not be isomerised back to the desired alkene 2.139 under any acidic, 
basic or thermal conditions, we similarly suspect, that the C8-Me substituent inhibited free 
rotation of the p-QM moiety, preventing the necessary alignment of the C9-H with the 
antibonding π* system of 2.140 (scheme 2.23-c). In regards to the attempted hydration of p-
QM 2.140,  if the C8- and C13-Me substituents did in fact introduce notable steric occupancy 
around both the p-orbital of benzylic carbocation 2.138-b and the methide antibonding π* 
system of p-QM 2.140, then hydration of p-QM 2.140 via the nucleophilic attack of 
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hydroxide would prove unsurprisingly difficult. Lastly, the reduction of p-QM 2.140 with 
NaBH4 to afford phenol 2.141, appears to contradict our previous assertion regarding the 
C8- and C13-Me substituents shielding the methide moiety of 2.140 from nucleophilic 
attack. Although it has been observed that NaBH4 is able to reduce organometallic species 
via a single electron transfer mechanism,[133–135] no such electron transfer mechanisms have 
been observed for organic systems, and rather, NaBH4 acts as a source of nucleophilic 
hydride.[136–139] Therefore, although somewhat unfavourable, we would rationalise that 
NaBH4 could approach the methide moiety of 2.140 on the opposite face to the C13-Me 
substituent in order to minimise unfavourable steric shielding effects surrounding the 
methide moiety (scheme 2.23-c). Such a backside attack would be expected to suffer steric 
congestion, which appears to be reflected in the modest yields obtained for the reduction of 
both QMs 2.140 and 2.143. 
 
Table 2.2: Screening elimination conditions for alkene 2.139 from benzyl alcohol 2.138. 
Entry Catalyst/Reagent (mol eq) Conditions Alkene (2.139) p-QM (2.140) 
1 p-TsOH (0.1) PhMe, 80 °C, 15 min 41% 46% 
2 p-TsOH (1) PhMe, rt, 3 h 36% 57% 
3 p-TsOH (0.1) PhMe, rt, 5 h 38% 52% 
4 PPTS (0.1) PhMe, 80 °C, 30 min 53% (82% brsm) 12% 
5 POCl3 (1.5) Pyridine, 80 °C, 1 h 54% (90% brsm) 6% 
 
Following elimination of benzyl alcohol 2.138, ortho-directed lithiation and subsequent 
formylation of alkene 2.139 was attempted via addition of two equivalents of n-BuLi and 
tetramethylethylenediamine (TMEDA) (scheme 2.24).[140] Upon purification, following 
quenching of the ortho-lithiated mixture with DMF, the majority of the isolated product was 
found to be starting alkene 2.139, and only minor quantities of the desired aryl aldehyde 
2.146 was acquired (scheme 2.24). We suspect that the iso-propoxy protecting groups of 
alkene 2.139 may have introduced significant steric hindrance at C20, preventing an ortho-
directed lithiation event from proceeding. As the yields of the desired aryl aldehyde 2.146 
were unacceptably poor under the protocol explored, we chose to investigate an alternative 
formylation method.  
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Scheme 2.24: Attempted formylation of alkene 2.139 via an ortho-directed lithiation with n-BuLi 
(2.0 equivalents) and TMEDA. 
The first alternative formylation protocol considered was a Rieche formylation.[140] The one-
pot, Lewis acid mediated protocol could potentially install the desired aryl aldehyde moiety 
and remove the iso-propoxy protecting groups via addition of dichloromethyl methyl ether 
(Cl2CHOCH3) and BCl3, to potentially afford siphonodictyal B 2.91, in accordance with our 
proposed reassigned configuration. However, despite attempting to tweak temperature 
protocols and Lewis acid addition rates/concentrations, the formation of the desired 
formylated/deprotected product 2.91 was not observed, and only 2.147 was isolated upon 
quenching the reaction mixture (scheme 2.25). 
 
Scheme 2.25: Failed one-pot, deprotection and formylation of alkene 2.139, affording nor-formyl 
siphonodictyal B 2.147. 
With the Rieche formylation failing to afford siphonodictyal B 2.91, an ortho-directed 
lithium mediated formylation was revisited (table 2.3). By increasing the molar equivalents 
of n-BuLi to five, while maintaining the equivalents of TMEDA at two, alkene 2.139 was 
successfully formylated to afford the desired aryl aldehyde 2.146 in good yield based upon 
recovered starting material 2.139. Additional molar equivalents of n-BuLi, upwards of eight, 
led to decomposition of the starting material and resulted in the isolation of an undesired 
mixture of products, which appeared to have undergone a second formylation at C17. Upon 
addition of DMF to the reaction mixture, quenching the mixture within five minutes was 
required and could not be heated above 0 ˚C, otherwise decomposition would ensue. 2.146 
could be accessed in synthetically useful quantities by recycling recovered starting alkene 
2.139 through several ortho-directed lithiation mediated formylations.  
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Table 2.3: Formylation of alkene 2.139 (via 5 equivalents of n-BuLi), followed by deprotection of 
aryl aldehyde 2.146 to afford siphonodictyal B 2.91. Below: Comparison of Köck’s reported 1H & 
13C NMR spectra with our acquired data.[96] 
Assignment Köck  
1H NMR 




This work, 13C 
NMR, 125 MHz 
C-1 1.78, 1.40 1.79-1.27 (overlapped m) 39.1 39.1 
C-2 1.63, 1.49 1.79-1.27 (overlapped m) 19.0 19.0 
C-3 1.38, 1.16 1.79-1.27 (overlapped m) 41.9 41.9 
C-4 - - 33.0 33.0 
C-5 1.30 1.79-1.27 (overlapped m) 49.0 49.1 
C-6 1.71, 1.49 1.79-1.27 (overlapped m) 19.4 19.4 
C-7 1.72, 1.34 1.79-1.27 (overlapped m) 31.2 31.2 
C-8 2.62 2.62 (m) 31.7 31.8 
C-9 - - 157.0 157.0 
C-10 - - 40.3 40.4 
C-11 0.89 0.88 (s) 21.4 21.5 
C-12 0.86 0.85 (s) 33.6 33.6 
C-13 0.89 0.87 (d, J = 7.0 Hz) 21.9 21.9 
C-14 1.12 1.12 (s) 22.9 22.9 
C-15 6.04 6.03 (s) 113.4 113.4 
C-16 - - 116.6 116.6 
C-17 6.85 6.84 (s) 126.2 126.2 
C-18 10.03 (OH) 10.03 (s) 136.1 136.1 
C-19 9.00 (OH) 9.02 (s) 147.8 147.8 
C-20 - - 110.2 110.2 
C-21 10.90 (OH) 10.91 (s) 151.2 151.3 
C-22 10.26 10.25 (s) 194.8 194.8 
All spectra run in DMSO-d6 
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Finally, our proposed reassigned configuration of siphonodictyal B, 2.91, was acquired upon 
addition of BCl3 to a cooled solution of aldehyde 2.146 in CH2Cl2 (table 2.3). The Lewis 
acid mediated deprotection was quenched after 20 minutes, in order to mitigate the formation 
of seemingly decomposed by-products. Upon purification, 2.91 was observed to rapidly 
decompose on contact with SiO2, and consequently, was rapidly flushed through SiO2 via 
flash column chromatography immediately upon quenching the reaction mixture. NMR 
analysis and comparison of our sample 2.91 matched perfectly with Köck’s reported spectral 
data (table 2.3). However, Faulkner had only reported a few select 1H NMR spectral peaks, 
none of which matched with our acquired proton spectra for 2.91. Therefore, we set out to 
synthesise (2.1), in accordance with Faulkner’s assignment to confirm our hypothesised 
reassigned configuration of siphonodictyal B. 
 Total Synthesis of Siphonodictyal B 2.1, In Accordance with 
Faulkner’s Configuration 
With synthesis of our proposed reassigned configuration of siphonodictyal B 2.91 complete, 
we set out to synthesise siphonodictyal B (2.1) in accordance with Faulkner’s assignment to 
determine the true configuration of the natural product. Following our previously explored 
lithium-halogen exchange coupling conditions, aryl bromide 2.116 was subjected to t-BuLi 
in THF, followed by addition of aldehyde 2.136, which afforded benzyl alcohol 2.148 in 
good yield as a mixture of epimers (scheme 2.26-a). Investigation into elimination conditions 
for benzyl alcohol 2.148 commenced with the previously explored elimination conditions 
with p-TsOH in toluene. Interestingly, alkene 2.149 was isolated as the major product and 
despite mirroring the same elimination conditions that afforded both alkene 2.139 and p-QM 
2.140 from benzyl alcohol 2.138, formation of the anticipated equivalent p-QM was not 
observed. As we had previously asserted, the formation of p-QM 2.140 via acid catalysed 
elimination of benzyl alcohol 2.138 was most likely due to the C8-Me substituent projecting 
equatorially, which could consequently restrict the necessary free rotation of the generated 
benzylic cation (2.138-b) required for the elimination of C9-H (scheme 2.23-c & 2.26-b). 
This rationale appears to be supported by the clean elimination of benzyl alcohol 2.148 to 
the desired alkene 3.149 (scheme 2.26). Thus, from the comparison of these reaction 
outcomes, it is incontestable that the configuration of the C8-Me substituent is the most 
prominent factor in determining the elimination pathway of these meroterpenoid benzyl 
alcohols (2.138 and 2.148). 
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Scheme 2.26: a) Coupling of aryl bromide 2.116 with aldehyde 2.136, and subsequent elimination 
of benzyl alcohol 2.148 to give alkene 2.149. b) proposed comparison for the elimination mechanistic 
pathways of benzyl alcohol 2.138-a and 2.148-a. 
With access to alkene 2.149, we set out to install the aldehyde moiety under the same 
previously optimised ortho-directed lithiation conditions investigated for the synthesis of 
siphonodictyal B 2.91 (table 2.3). Formylation of alkene 2.149, with five and two molar 
equivalents of n-BuLi and TMEDA respectively, gave aldehyde 2.150 in reasonable 
consistent yields (scheme 2.27). As was performed previously, the recovered starting alkene 
2.149 was cycled through multiple formylation reactions to acquire synthetically useful 
quantities of aldehyde 2.150. Finally, aryl aldehyde 2.150 was deprotected via the same 
previously explored BCl3 conditions for the synthesis of siphonodictyal B 2.91, which was 
quenched after 20 minutes to afford siphonodictyal B (2.1), in accordance with Faulkner’s 
assigned configuration (scheme 2.27). As observed for the isolation of 2.91 (table 2.3), 
Faulkner’s siphonodictyal B (2.1) was found to readily decompose on contact with SiO2, and 
hence, was rapidly flushed through SiO2 via flash column chromatography to minimise any 
loss of product (scheme 2.27). NMR analysis confirmed the expected structure of 
siphonodictyal B (2.1). However, both the 1H and 13C NMR of our synthesised sample of 
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2.1 did not match the spectral data reported by Köck, nor did Faulkner’s select few 1H NMR 
natural sample peaks match any peaks of our synthesised sample (2.1).  
 
Scheme 2.27: ortho-Lithiation, formylation of alkene 2.149 (via 5 equivalents of n-BuLi), followed 
by Lewis acid mediated deprotection of aryl aldehyde 2.150, afforded Faulkner’s assigned 
configuration of siphonodictyal B (2.1). 
 Elucidation of the True Configuration of Siphonodictyal B 
In Faulkner’s original isolation paper, the isolated sample of siphonodictyal B was subjected 
to methylation experiments, and the resulting methyl ether product 2.12 was further 
characterised by NMR studies. Thus, in an effort to elucidate the true structural and 
stereoconfiguration of Faulkner’s isolated natural sample, we set out to synthesise both 
trimethoxy ether derivatives of our synthetically acquired siphonodictyal B epimers, 2.91 
and 2.1. Both synthetic siphonodictyal B epimer samples, 2.91 and 2.1, were methylated 
under identical conditions with MeI, to afford 2.151 and 2.12 respectively (table 2.4). 
Comparison of the 1H and 13C NMR data revealed that methylated siphonodictyal B 
derivative 2.151 perfectly matched that of Faulkner’s methylated sample. Thus, from these 
methylation experiments, we are confident in concluding that the true configuration of 
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Table 2.4: Methylation of both siphonodictyal B epimers 2.1 and 2.91, affording 2.151 and 2.12. 
Below: Comparison of Faulkner’s reported 1H NMR spectra of 2.12 with our afforded epimers 2.151 
and 2.12. 
Assignment Faulkner 2.12 
 
This work, 2.91  
(500 MHz) 
This work, 2.12  
(500 MHz) 
H-1 not reported 1.86 – 1.24 (m, 2H) 1.83 – 1.42  (m, 2H) 
H-2 not reported 1.86 – 1.24 (m, 2H) 1.83 – 1.42  (m, 2H) 
H-3 not reported 1.86 – 1.24 (m, 2H) 1.27 – 1.25 (m, 1H),  
1.83 – 1.42  (m, 1H) 
H-5 not reported 1.86 – 1.24 (m, 1H) 0.99 (d, J = 11.0 Hz, 1H) 
H-6 not reported 1.86 – 1.24 (m, 2H) 1.83 – 1.42  (m, 2H) 
H-7 not reported 1.86 – 1.24 (m, 2H) 1.83 – 1.42 (m, 2H) 
H-8 2.65 (m, 1 H) 2.66 (m, 1H) 2.96 (quintet, J = 6.7 Hz, 1H) 
H-11 0.91 (s, 3 H) 0.91 (s, 3H) 0.92 (s, 3H) 
H-12 0.89 (s, 3 H) 0.89 (s, 3H) 0.90 (s, 3H) 
H-13 0.90 (d, 3 H, J = 7 Hz) 0.90 (d, J = 6.5 Hz, 3H) 1.28 (d, J = 7.5 Hz, 3H) 
H-14 1.19 (s, 3 H) 1.19 (s, 3H) 1.23 (s, 3H) 
H-15 6.21 (s, 1 H) 6.21 (s, 1H) 6.21 (s, 1H) 
H-17 6.91 (s, 1 H) 6.91 (s, 1H) 6.95 (s, 1H) 
H-22 10.40 (s, 1 H) 10.40 (s, 1H) 10.43 (s, 1H) 
H-23 3.91 (s, 3 H) 3.91 (s, 3H) 3.93 (s, 3H) 
H-24 3.85 (s, 3 H) 3.85 (s, 3H) 3.86 (s, 3H) 
H-25 3.72 (s, 3 H) 3.72 (s, 3H) 3.74 (s, 3H) 
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 Biogenically Inspired Synthesis of Liphagal from 
Siphonodictyal B  
With access to siphonodictyal B (2.91), we set out to synthesise liphagal (2.2) via our 
pathway A inspired proposal (scheme 2.12). We sought to directly synthesise liphagal (2.2) 
from siphonodictyal B (2.91) via a one-pot, epoxidation and subsequent acid catalysed 
transformation. In our opinion, a successful one-pot transformation would provide 
significant evidence towards our biosynthetic proposal, being that, we believe 
siphonodictyal B (2.91) is indeed the biogenic precursor to liphagal (2.2), and the other 
structurally related meroterpenoids (2.3 – 2.6, 2.106 – 2.108) (scheme 2.15).  
 
Scheme 2.28: Attempted one-pot biogenic transformation of siphonodictyal B (2.91) to liphagal 
(2.2). 
The starting point of our investigation into the synthesis of liphagal (2.2) commenced with 
a two-step protocol investigated for a model system by a member of our group. 
Siphonodictyal B (2.91) was subjected to a mixture of m-CPBA and NaHCO3 in CH2Cl2 at 
0 ˚C (scheme 2.28). The epoxidation procedure was monitored by TLC, which revealed the 
formation of a minor faint polar spot. However, upon addition of TFA to the epoxidized 
reaction mixture, no new developing products were observed by TLC analysis, which was 
confirmed upon purification of the reaction mixture. An isolated minor fraction revealed 
trace spectral peaks that corresponded to liphagal (2.2), as elucidated by 1H NMR analysis 
of the complex mixture. Efforts to isolate the anticipated in situ siphonodictyal epoxide 2.92 
were fruitless, as the crude mixture appeared to readily degrade upon contact with SiO2, 
leading us to speculate that the proposed epoxide was unstable and could not be isolated. In 
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addition to the predicted inherent instability of epoxide 2.92, the aromatic aldehyde moiety 
of siphonodictyal B (2.91) and it’s epoxidized derivative 2.92 may have been susceptible to 
oxidation upon addition of m-CPBA.  Exploring alternative solvent systems, such as THF 
and dioxane, failed to yield liphagal (2.2) in any isolatable quantity. Only conditions 
employing THF afforded a series of complex fractions, that upon purification were revealed 
to possess trace spectral peaks characteristic of liphagal (2.2), as highlighted by 1H NMR 
analysis (scheme 2.28). 
 Investigation into a Simplified Liphagal System  
As the aromatic aldehyde moiety of siphonodictyal B (2.91) was suspected to undergo 
degradation during the epoxidation event, we set out to trial our one-pot, oxidative-acidic 
conditions on a simpler system. Alkene 2.139 was chosen as a simplified model system on 
which to trial our one-pot m-CPBA/TFA conditions. Subjecting alkene 2.139 to a mixture 
of m-CPBA and NaHCO3 in CH2Cl2, followed by the subsequent addition of TFA afforded 
ring expanded ketones 2.153 and 2.154, that were separated and characterised by NMR 
analysis (scheme 2.29). Examination of the NOESY spectra elucidated that ketones 2.153 
and 2.154 were in fact epimers of one another, consistently isolated in a 2:1 ratio in favour 
of 2.153. 
 
Scheme 2.29: Model investigation of a one-pot, epoxidation and acid catalysed biogenic 
transformation of siphonodictyal B precursor 2.139 to ring expanded ketones 2.153 and 2.154. 
As 2.153 and 2.154 are benzylic ketones, one would expect that under acidic conditions, 
such as those employed, ketones 2.153 and 2.154 could freely interchange with one another 
via an acid facilitated keto-enol tautomerisation (scheme 2.29). Hence, the simplest 
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explanation for the consistently isolated  2:1 ratio observed for 2.153 and 2.154 respectively, 
would be a non-equivalent population equilibrium in favour of 2.153, presumably driven by 
steric strain attributed to the large substituted aromatic moiety. However, both Katoh’s and 
Alvarez-Manzaneda’s reported syntheses of liphagal (2.2) contradict this rationale. Katoh et 
al synthesised an analogous ring expanded ketone (2.133) as a single diastereomer under 
almost identical conditions to our own, employing m-CPBA and TFA (scheme 2.20).[127] 
Similarly, Alvarez-Manzaneda reported the isolation of two diastereomeric diols, 2.62 and 
2.63, which upon treatment with phosphorus oxychloride in pyridine, afforded the ring 
expanded benzylic ketones 2.65 and 2.68 (scheme 2.7).[107] Ring expanded ketone 2.65 was 
observed to undergo cyclisation to 2.66 via a one-pot hydrogenation (H2 and Pd/C), and 
subsequent acidification with perchloric acid in MeOH. In contrast, under the same 
conditions, the desired cyclised liphagal scaffold 2.66 could only be isolated in trace 
quantities from ketone 2.68, alongside an unresolvable mixture of products. Despite 
investigating various acidic and basic conditions, Alvarez-Manzaneda concluded that ketone 
2.68 could not be isomerised to its epimer 2.65. Given that benzylic ketones 2.65 and 2.68, 
which are analogous to our own, were not found to readily undergo keto-enol 
tautomerisation under either acidic or basic conditions, we would argue that the 2:1 ratio 
observed for our ketone system (2.153 and 2.154) is most likely not due to an acid catalysed 
in situ epimerisation of the benzylic moiety. Therefore, we suspect that the observed 
preference for the formation of ring expanded ketone 2.153 over 2.154 is most likely due to 
the differing sterically strained nature of the two envisioned competing benzylic carbocation 
intermediates. We predict that the more favourable carbocation intermediate 2.152 would 
possess the benzylic carbocation substituent projecting equatorially from the sesquiterpene 
six-membered ring system, and the less favourable competing carbocation with the bulky 
tri-iso-proxy phenyl moiety projecting in an axial fashion (scheme 2.29). The former (2.152) 
would represent the more stable carbocation of the two competing intermediates due to the 
minimisation of unfavourable steric interactions. Thus, benzylic carbocation intermediate 
2.152 would in theory give rise to ketone 2.153 as the major product, and the more sterically 
strained axial benzylic carbocation intermediate would afford 2.154 (scheme 2.29). 
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Scheme 2.30: Attempted ring expansion of aldehyde 3.146 via one-pot, epoxidative/acidic  
conditions. 
Following the successful ring expansion of alkene 2.139, we set out to determine whether 
the aryl aldehyde moiety of the siphonodictyal-meroterpenoid system was susceptible to 
oxidation/decomposition under our investigated one-pot, epoxidative/acidic conditions, in 
the pursuit of liphagal (2.2) from siphonodictyal B (2.91). As suspected, under the same 
successful conditions for the ring expansion of 2.139, no discernible product was observed 
to form during both the epoxidation and acid catalysed procedures, as determined by TLC 
analysis (scheme 2.30). Upon quenching the reaction mixture, only a mixture of seemingly 
decomposed unidentifiable by-products were isolated following column chromatography.  
Given that the conditions explored thus far failed to epoxidise and transform both 
siphonodictyal B (2.91) and the protected aldehyde 2.146 to their respective products, yet 
were able to afford ring expanded ketones 2.153 & 2.154 from alkene 2.139, we suspected 
that the aryl aldehyde moiety of the siphonodictyal system was susceptible to oxidation upon 
addition of m-CPBA. Although the aryl aldehyde moiety appeared to undergo degradation, 
as evident by the failed transformation of aldehyde 3.146, it was unclear whether the 
phenolic oxygens were also impeding the reaction events from proceeding. Therefore, we 
set out to acquire the previously, yet accidently synthesised deprotected alkene 2.147, which 
was isolated upon investigating Reiche formylation conditions (scheme 2.25). 2.139 was 
deprotected via addition of BCl3 to afford 2.147 (scheme 2.31). However, the transformation 
of acquired analogue 2.147 to the liphagal analogue 2.158 was found to be unsuccessful 
under Kuan’s one-pot protocol.  
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Scheme 2.31: Synthesis of model 2.147 and investigation into our groups one-pot, epoxidative/acidic 
protocol. 
In light of this observation, we set out to investigate an epoxidation procedure developed by 
Alessandra Lattanzi, which detailed a VO(acac)2 catalysed epoxidation with t-BuOOH 
(scheme 2.31).[141] However, upon purification, a mixture of spirocycles 2.159 and 2.160 
were isolated, and no anticipated liphagal analogue 2.158 was observed to have formed. 
Comprehensive NMR analysis revealed the identity of the isolated spirocycles as analogues 
of corallidictyals A (2.3) and B (2.4) (Figures 2.1 and 2.2). In addition, spirocycles 2.159 
and 2.160 were isolated in a 1:2 ratio respectively, analogous to the 3:7 ratio that was 
observed upon isolation of corallidictyals A (2.3) & B (2.4) by Westly.[100] However, efforts 
to acquire 2.159 and 2.160 in significant quantities under the same vanadium oxide 
epoxidation conditions proved difficult. (scheme 2.32). As the VO(acac)2 was added in a 
10% molar equivalence relative to 2.147, we suspect that the vanadium oxide complex 
directly oxidised the siphonodictyal B analogue 2.147. Evidence for our claim stems from 
the emergence of a less polar spot upon TLC analysis, which coincided with a deep red 
colour change of the reaction mixture upon addition of VO(acac)2, preceding the inclusion 
of t-BuOOH. Thus, assuming VO(acac)2 directly oxidised the siphonodictyal B analogue 
2.147 to either an ortho- or a para-quinone, then cyclisation to spirocycles 2.159 and 2.160 
may have ensued upon addition of TFA (scheme 2.32), akin to our proposal for the 
biosynthesis of corallidictyals A (2.3) and B (2.4) (scheme 2.13 and 2.14). 
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Scheme 2.32: Synthesis of spirocycles 2.159 & 2.160 in the attempted one-pot, VO(acac)2 catalysed 
epoxidative/acidic biogenic transformation of siphonodictyal B analogue 2.147. 
As the one-pot, VO(acac)2 facilitated epoxidation/TFA conditions failed to afford the 
anticipated liphagal analogue 2.158, we returned to our previously explored m-CPBA/TFA 
conditions to investigate various solvent and temperature protocols. Changing solvent 
system from CH2Cl2 to CHCl3 was found to afford  the desired analogue 2.158, albeit in a 
yield of 19% (scheme 2.33). Yields were further improved by optimising the temperature 
protocol while employing chloroform as the solvent system. TFA was added to the reaction 
mixture at -20 ˚C and was gradually warmed to 0 ˚C, which gave liphagal analogue 2.158 in 
a yield of 40% (scheme 2.33). 
 
Scheme 2.33: Successful model investigation of a one-pot, epoxidation and acid catalysed biogenic 
transformation of 2.147 to 2.158. 
 Synthesis of Liphagal (2.2) from Siphonodictyal B (2.91) 
Given the successful formation of 2.158 from siphonodictyal B analogue 2.147, we 
suspected that the aryl aldehyde moiety of siphonodictyal B (2.91) was responsible for 
impeding the epoxidation event upon the addition of m-CPBA. Conditions employing 
CH2Cl2 that were cooled to 0 ˚C or colder during the epoxidation protocol led to the isolation 
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of liphagal (2.2) in trace quantities, as indicated by key characteristic spectral peaks by 1H 
NMR analysis (entries 1 and 2, table 2.5). In contrast, temperatures above 0 ˚C during the 
epoxidation of siphonodictyal B (2.91) solely afforded decomposition by-products (entry 5, 
table 2.3). Next, CH2Cl2 was substituted for CHCl3, as explored in our previously successful 
model system (scheme 2.33). We also sought to determine the significance of the NaHCO3 
buffering agent for the epoxidation event. Both epoxidation protocols employing the solvent 
CHCl3, with or without the addition of NaHCO3, afforded liphagal (2.2) from siphonodictyal 
B (2.91) in similarly poor yields. Characterisation data of our synthetic sample of liphagal 
(2.2) was found to match perfectly to that of Andersen’s reported synthetic and natural 
samples (entries 5 and 6, table 2.5). Although both protocols employing CHCl3 gave rise to 
liphagal (2.2), conditions with NaHCO3 led to slightly greater yields (entry 5, table 2.5). We 
suspect NaHCO3 marginally improved yields by buffering against free protons, liberated 
upon the formation of m-chlorobenzoic acid from m-CPBA during the epoxidation of 
siphonodictyal B (2.91). 
Further optimisation of the acid catalysed ring expansion/cascade protocol was investigated 
by trialling varying temperature conditions proceeding the addition of TFA, following the 
epoxidation of siphonodictyal B (2.91). Mirroring the same temperature protocol explored 
for the synthesis of the model liphagal analogue 2.158 (scheme 2.33), liphagal (2.2) was 
obtained in an improved yield of 16% upon cooling the reaction mixture to -20 ˚C preceding 
the addition of TFA, and then warmed to 0 ˚C before being quenched (entry 7, table 2.5). 
Interestingly, for the previously explored model system under the same temperature 
protocol, liphagal analogue 2.158 was acquired in a yield of 40% (scheme 2.33), compared 
to 16% for the synthesis of liphagal (2.2) from siphonodictyal B (2.91) (entry 7, table 2.5). 
As the model system explored differs only by the existence of the aryl aldehyde substituent 
at C20, then it would seem reasonable to conclude that the discrepancy in the isolated yield 
of liphagal (2.2), compared to liphagal model 2.158, is most likely due to the aryl aldehyde 
moiety, which we suspect, is susceptible to an oxidative attack from m-CPBA, akin to a 
Dakin oxidation. Further optimisation led to an improved temperature protocol, where upon 
the addition of TFA, the reaction mixture was gradually warmed from -20 ˚C to room 
temperature and was stirred for 2 hours to afford liphagal (2.2) in a yield of 26% (entry 8, 
table 2.5). Additional attempts to modify the TFA and corresponding temperature protocols 
failed to improve yields of liphagal (2.2), which led us to investigate alternative chlorinated 
solvents. CHCl3 was substituted for CCl4, and following the same previously optimised 
temperature protocol, liphagal (2.2) was isolated in a significantly improved yield of 42% 
(entry 9, table 2.5). Yields could not be improved following the exploration of other various 
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chlorinated solvents (Cl2CHCHCl2) and as such, our investigation into the synthesis of 
liphagal (2.2) from siphonodictyal B (2.91) could not be further optimised. 
 
Table 2.5: Investigation of our one-pot, biogenic synthesis of liphagal (2.2). 
Entry Solvent/Base Conditions for 
epoxidation  






-10 °C, 1 h -20 °C, 1 h trace 
2 CH2Cl2/ 
NaHCO3 
0 °C, 1 h -20 °C, 1 h trace 
3 CH2Cl2/ 
NaHCO3 
10 °C, 1 h -20 °C, 1 h decomposition 
4 THF/ 
NaHCO3 
0 °C, 1 h -20 °C, 1 h trace 
5 CHCl3/ 
NaHCO3 
0 °C, 1 h -20 °C, 1 h 10% 
6 CHCl3 0 °C, 1 h -20 °C, 1 h 8% 
7 CHCl3/ 
NaHCO3 
0 °C, 1 h -20 °C to 0 °C, 20 min then 




0 °C, 1 h 0 °C to rt, 30 min  




0 °C, 1 h 0 °C to rt, 30 min  
then rt, 2 h 
42% 
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 Speculation into the Biogenically Inspired Transformation of 
Siphonodictyal B to Liphagal  
 
Scheme 2.34: Possible mechanistic pathways for our biomimetic synthesis of liphagal (2.2). 
As proposed, there are three possible competing intermediates, carbocation 2.162, o-QM 
2.93 and p-QM 2.94, that may arise following the acid catalysed ring opening of epoxide 
2.92. All three possible intermediates would be expected to give rise to ring expanded ketone 
2.95 and consequently, liphagal (2.2) (scheme 2.34). Given that o-QMs (2.93) or p-QMs 
(2.94) do not exist as charged species, but rather, are in equilibrium with their tautomeric 
Zwitterionic species, they may prove to be more stable alternatives to carbocation 
intermediate 2.162. Therefore, of the three possible intermediates following ring opening of 
epoxide 2.92, the quinone methides, o-QM 2.93 and p-QM 2.94, may be favoured alternative 
intermediates over carbocation 2.162. Additionally, p-QM 2.94 would be expected to 
possess a lower energetic barrier of formation (Ea) and hence, would represent the more 
stable intermediate relative to o-QM 2.93, as indicated by the exclusive emergence of the p-
QM 2.140 upon the attempted elimination of benzyl alcohol 2.138 (scheme 2.23). Therefore, 
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given that the emergence of both quinone methide intermediates (2.93 & 2.94) is possible, 
we would expect that the ring expansion event would proceed via p-QM 2.94, and not o-QM 
2.93 (scheme 2.34).   
 Biomimetic Synthesis of 8-epi-Liphagal (2.163) from 8-epi-
Siphonodictyal B (2.1) 
Continuing from our successful one-pot transformation of siphonodictyal B (2.91) to 
liphagal (2.2), we sought to investigate an analogous one-pot transformation of Faulkner’s 
erroneously assigned 8-epi-siphonodictyal B (2.1) to 8-epi-liphagal (2.163). As there was no 
evidence for the formation of 8-epi-liphagal (2.163) from siphonodictyal B (2.91), we were 
intent on determining if an epimerisation event at the C8 position could occur during a one-
pot transformation of 8-epi-siphonodictyal B (2.1). Therefore, we set out to synthesise 8-epi-
liphagal (2.163) from Faulkner’s erroneously assigned configuration of 8-epi-siphonodictyal 
B (2.1) to confirm that a non-enzymatically mediated epimerisation could not occur under 
our employed oxidative/acidic conditions (scheme 2.35). Following our previously 
optimised protocol (entry 9, table 2.5), 8-epi-siphonodictyal B (2.1) was epoxidized, the 
mixture was cooled to -20 ˚C preceding the addition of TFA, and the resultant mixture was 
gradually warmed to afford 8-epi-liphagal (2.163) in a yield of 41% (scheme 2.35). As 
suspected, evidence for an epimerisation event was not observed as indicated by the lack of 
liphagal (2.2) present within any of the fractions isolated upon purification.  
 
Scheme 2.35: biomimetic transformation of 8-epi-siphonodictyal B (2.1) to 8-epi-liphagal (2.163). 
As suspected, there was no evidence for the simultaneous emergence of both liphagal C8 
epimers, 2.2 & 2.163, arising from either siphonodictyal B (2.91) or 8-epi-siphonodictyal B 
77 |                                                                                                                 A. W. Markwell-Heys 
(2.1) during the investigated one-pot biomimetic reactions (table 2.5 or scheme 2.35). 
Therefore, we can confidently conclude that under our non-enzymatic conditions, a C8 
epimerisation event does not occur. Based on these experiments, it would be reasonable to 
assume that the possibility of a non-enzymatic epimerisation event occurring in nature 
during the biosynthesis of liphagal (2.2) from siphonodictyal B (2.91), is highly unlikely. As 
of the writing of this literature, liphagal (2.2) does not appear to target any specific system 
or fulfil a necessary biological role, i.e. strong anti-bacterial activity etc. (Aka coralliphaga). 
Therefore, liphagal (2.2) does not appear to provide any specific benefit, and does not appear 
to be crucial to the survival of the host organism, unlike the contrasting example of the family 
of penicillin producing fungi, Penicillium.[24] Hence, if the above premises are true, and there 
is no clear selective pressure for the emergence of liphagal (2.2), then we must conclude that 
the likelihood for the evolution of dedicated substrate-specific enzymes that would closely 
regulate the biosynthesis of liphagal (2.2) is remote. Based on this rationale, theorising the 
existence of specific epimerising enzymes, under Andersen’s biosynthetic pathway A, 
introduces unnecessary complexity to a metabolic system, while also leading to 
unfavourable resource management issues for the host organism. However, it would appear 
plausible that the epoxidation event of siphonodictyal B (2.91) may be mediated by more 
promiscuous cytochrome P450 enzymes. The resultant siphonodictyal B epoxide 2.92 most 
likely undergoes a non-enzymatic, spontaneous ring opening and cascade sequence to afford 
liphagal (2.2) in nature. 
 Synthetic Investigation of Siphonodictyals B1 – B3  
Following the successful biogenically inspired synthesis of liphagal (2.2), we set out to 
synthesise the series of naturally occurring sulphated siphonodictyal B (2.91) analogues, 
siphonodictyals B1 – B3, 2.106 – 2.108, in accordance with our proposal (scheme 2.15), 
following the successful stereochemical reassignment of siphonodictyal B (tables 2.3 & 2.4). 
Synthetic access to the sulfated siphonodictyals was envisioned by an initial sulfation of 
siphonodictyal B (2.91) at C21 to give siphonodictyal B2 2.107, with a second subsequent 
sulfation at C18 to afford siphonodictyal B3 2.108. Siphonodictyal B1 2.106 could be 
potentially accessed via an imine condensation of siphonodictyal B2 2.107 with 2-
aminoethanesulfonic acid (scheme 2.36). However, a regioselective sulfation at C21, and 
another successive sulfation at C18, would prove difficult under non-enzymatically 
mediated methods. Nonetheless, we set out to acquire siphonodictyal B2 2.107 & B3 2.108 
via sulfation of siphonodictyal B (2.91) in a non-selective manner, then given the anticipated 
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success of the sulfation procedure, to attempt the synthesis of siphonodictyal B1 2.106 by 
an imine condensation of 2.107 and 2-aminoethanesulfonic acid. 
 
Scheme 2.36: Biosynthesis of siphonodictyals B1 – B3 (2.106 – 2.108) from siphonodictyal B (2.91), 
in accordance with our proposed stereochemical reassignment.  
The search of mild conditions throughout the literature for the sulfation of phenolic alcohols, 
that would also be compatible with the sensitive alkenyl moiety of siphonodictyal B (2.91), 
appeared to be limited to only a handful of sulfating agents. A procedure by Wolfenden for 
acquiring sulfated phenolic esters detailed the use of commercially available SO3.pyridine 
in a pyridine solution with a given phenol.[142] Following Wolfenden’s protocol,[142] 
siphonodictyal B (2.91) was heated as a mixture with SO3.pyridine in pyridine, and was 
stirred for two hours (scheme 2.37). As the sulfated siphonodictyal B derivatives were 
expected to be water soluble, the solvent was removed under reduced pressure following the 
addition of sodium bicarbonate, before loading the crude mixture onto a HPLC column and 
eluting with a MeCN:H2O solvent gradient. Given that the crude sulfated mixture was loaded 
directly onto the HPLC column, we chose not to use Kӧck’s MeCN/NH4OAc gradient 
mixture, due to concerns of blocking eluent flow.[96]  Instead, a MeCN/H2O eluent gradient 
was chosen to minimise potential precipitation of any salts and non-polar by-products 
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introduced upon loading the crude mixture onto the column (table 2.6). The acquired 
retention times for our unknown sulfated reaction mixture were compared to those reported 
by Kӧck for the elution of siphonodictyals B2 (2.107) and B3 (2.108) via HPLC-MS. 
However, comparison of our acquired retention times proved difficult due to the variance in 
our HPLC method, column length and type, as well as the composition of the crude reaction 
mixture itself. However, speculation into the comparison of Kӧck’s method, and our own, 
hinted as the potential identity of the acquired fractions (table 2.6). 
 
Scheme 2.37: Attempted synthesis of siphonodictyals B2 and B3, 2.107 and 2.108, from 
siphonodictyal B (2.91). 
Upon the attempted purification of the reaction mixture, the first peak eluted appeared to 
solely possess water soluble impurities that did not display any characteristic spectral peaks 
of either the desired sulfated products or siphonodictyal B (2.91), as indicated by NMR 
analysis (peak 1, table 2.6). We suspect that the second and third peaks to elute contained 
di- (peak 2, table 2.6) and mono-sulfated (peak 3, table 2.6) products of siphonodictyal B 
(2.91) respectively, given their relatively similar retention times for the elution of 
siphonodictyals B3 (2.108) (peak 6, table 2.6) and B2 (2.107) (peak 7, table 2.6) as reported 
by Kӧck.[96] Upon analysis of the freeze dried samples, the second (peak 2, table 2.6) and 
third (peak 3, table 2.6) eluted fractions were only found to possess a few key identifiable 
1H NMR peaks that were characteristic of siphonodictyals B3 (2.108) and B2 (2.107) 
respectively. Both the proceeding  eluted fractions (peaks 4 & 5, table 2.6) were found to be 
unidentifiable complex mixtures, with the fifth (peak 5, table 2.6) fraction possessing a few 
key 1H NMR spectral peaks that were characteristic of siphonodictyal B (2.91). Despite all 
attempts to optimise Wolfenden’s SO3.pyridine and pyridine conditions,
[142] we were unable 
to obtain both siphonodictyal B2 (2.107) & B3 (2.108) and as such, the synthesis of 
siphonodictyal B1 (2.106) could not be attempted. Based on the above results, we predict 
that the biosynthesis of the sulfated siphonodictyal B meroterpenoids, 2.106 – 2.108, may 
be facilitated by either regioselective or promiscuous enzymes in nature. 
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Table 2.6: Above. Our HPLC trace for the attempted synthesis of siphonodictyals B1 2.107 and B2 
2.108. Below. Comparison of HPLC elution rates of Kӧck’s[96] reported isolation of siphonodictyals 
B2 (2.107) and B3 (2.108) against our unknown fractions (below). 
Peak/Compound Author Elution time Eluent ratio 
1 this work 3.9 minutes 10% MeCN/90% H2O 
2 this work 10.5 minutes 30% MeCN/70% H2O 
3 this work 22.0 minutes 65% MeCN/35% H2O 
4 this work 26.7 minutes 82% MeCN/18% H2O 
5 this work 29.8 minutes 97% MeCN/3% H2O 
6 (Siphonodictyal B3: 2.108) Kӧck et al 11.9 minutes 20% MeCN/80% NH4OAc 
7 (Siphonodictyal B2: 2.107) Kӧck et al 17.1 minutes 20% MeCN/80% NH4OAc 
Kӧck et al HPLC protocol: HPLC-MS analyses were performed with an Agilent 1100, HPLC system and a Bruker 
Daltonics microTOFLC mass spectrometer. Separation was achieved by a Waters XTerra RP18 column (3.0×150mm, 3.5 
μm), applying a MeCN/NH4OAc (5 mM in water) gradient (0 min: 20% MeCN/80% NH4OAc; 30 min: 100% MeCN/0% 
NH4OAc; 35 min: 100% MeCN/0% NH4OAc).[96] Our HPLC protocol: HPLC analyses was performed with a Gilson GX-
Prep HPLC system, equipped with a Phemnomenex C18 column (250×21.2 mm), applying a MeCN/H2O gradient (0 min: 
5% MeCN/95% H2O; 3 min: 10% MeCN/90% H2O; 5 min to 30 min: 10% MeCN/90% H2O to 90% MeCN/10% H2O). 
Upon the attempted purification of the reaction mixture, the first peak eluted appeared to 
solely possess water soluble impurities that did not display any characteristic spectral peaks 
of either the desired sulfated products or siphonodictyal B (2.91), as indicated by NMR 
analysis (peak 1, table 2.6). We suspect that the second and third peaks to elute contained 
di- (peak 2, table 2.6) and mono-sulfated (peak 3, table 2.6) products of siphonodictyal B 
(2.91) respectively, given their relatively similar retention times for the elution of 
siphonodictyals B3 (2.108) (peak 6, table 2.6) and B2 (2.107) (peak 7, table 2.6) as reported 
by Kӧck.[96] Upon analysis of the freeze dried samples, the second (peak 2, table 2.6) and 
third (peak 3, table 2.6) eluted fractions were only found to possess a few key identifiable 
1H NMR peaks that were characteristic of siphonodictyals B3 (2.108) and B2 (2.107) 
respectively. Both the proceeding  eluted fractions (peaks 4 & 5, table 2.6) were found to be 
unidentifiable complex mixtures, with the fifth (peak 5, table 2.6) fraction possessing a few 
key 1H NMR spectral peaks that were characteristic of siphonodictyal B (2.91). Despite all 
attempts to optimise Wolfenden’s SO3.pyridine and pyridine conditions,
[142] we were unable 
to obtain both siphonodictyal B2 (2.107) & B3 (2.108) and as such, the synthesis of 
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siphonodictyal B1 (2.106) could not be attempted. Based on the above results, we predict 
that the biosynthesis of the sulfated siphonodictyal B meroterpenoids, 2.106 – 2.108, may 
be facilitated by either regioselective or promiscuous enzymes in nature. 
 Investigation into the Biomimetic Synthesis and 
Biosynthetic Origins of Corallidictyals A – D  
 
Scheme 2.38: Our proposed biosynthetic origin of the corallidictyals A – D (2.3 – 2.6). Black arrows: 
proposed access to corallidictyals A (2.3) & B (2.4) and C (2.5) & D (2.6) by interconversion through 
REDOX conditions and from siphonodictyal B (2.91). Red arrows: corallidictyals C (2.5) & D (2.6) 
accessed exclusively from A (2.3) & B (2.4), which in turn are formed from siphonodictyal B (2.91). 
Blue arrows: corallidictyals A (2.3) & B (2.4) accessed exclusively from C (2.5) & D (2.6), which in 
turn are formed from siphonodictyal B (2.91). 
With the successful conversion of siphonodictyal B (2.91) to liphagal (2.2) (table 2.5), we 
set out to investigate and further validate our divergent biosynthetic proposal by synthesising 
corallidictyals A – D (2.3 – 2.6) directly from siphonodictyal B (2.91). As stated in our 
proposal (schemes 2.13 – 2.15), we hypothesise that the corallidictyals A – D (2.3 – 2.6) are 
derived from siphonodictyal B (2.91) in nature. Here it is worth noting that as both sets of 
corallidictyals A (2.3) & B (2.4) and C (2.5) & D (2.6) can conceivably be interchanged with 
one another under REDOX conditions, and that each set may be accessed from 
siphonodictyal B (2.91) directly, then biosynthetic access to each set of corallidictyals in 
nature appears unclear. Thus, we sought to determine whether both sets of corallidictyals A 
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(2.3) & B (2.4) and C (2.5) & D (2.6) could be acquired from siphonodictyal B (2.91) 
directly, or whether one set, derived from 2.91, may give rise to the other via REDOX 
conditions (scheme 2.38). 
 Investigation into the Biomimetic Synthesis of Corallidictyals A – D 
(2.3 – 2.6) from Siphonodictyal B (2.91) 
Investigation into the synthesis of corallidictyals A (2.3) & B (2.4) was envisioned by an 
initial oxidation of siphonodictyal B (2.91), followed by addition of a Brønsted acid, in an 
attempt to induce a spirocyclisation event via either of the hypothesised ortho- or para-
quinone intermediates, 2.102 or 2.103 (scheme 2.14). DDQ was the first oxidising agent 
considered, which upon addition to siphonodictyal B (2.91), immediately led to 
unidentifiable decomposition by-products (entry 1, table 2.7). As DDQ appeared to be too 
strong of an oxidising agent, Ag2O was investigated as a milder alternative. However, before 
TFA could be added, the reaction mixture appeared to undergo considerable visual 
decomposition (entry 2, table 2.7). Upon 1H NMR analysis of the major fraction isolated, a 
key spectral peaks that were characteristic of corallidictyals A (2.3) & B (2.4) were observed 
as an inseparable mixture with siphonodictyal B (2.91).  
Following the apparent spontaneous formation of corallidictyals A (2.3) & B (2.4) with 
Ag2O, our proposal regarding the requirement of an acid to facilitate the key spirocyclisation 
event, from either 2.102 or 2.103, appeared incorrect (entry 2, table 2.7). However, Ag2O 
was suspected to be too inherently basic, which may have led to the decomposition of 
siphonodictyal B (2.91). Therefore, the mild oxidant Ag2CO3 was added to a mixture of 
siphonodictyal B (2.91) and CeliteTM in benzene in accordance with a standard Fétizon 
oxidation protocol (entry 3, table 2.7).[143] Despite the absence for the development of a new 
Rf value upon TLC analysis, the crude reaction mixture was filtered through CeliteTM to 
reveal corallidictyals A (2.3) & B (2.4) as the exclusive products, in a 1 : 2 ratio respectively, 
similarly to the 3:7 ratio reported by Westly[100] (entry 3, table 2.7). Thus, in contrast to our 
previous proposal (scheme 2.13), the spirocyclisation event, following the oxidation of 
siphonodictyal B (2.91), was confirmed to occur spontaneously and did not require the 
addition of an acid to catalyse the formation of corallidictyals A (2.3) & B (2.4). Ag2O was 
revisited as an oxidising agent, where it replaced Ag2CO3 in the Fétizon oxidation,[143] to 
determine whether the oxidation of siphonodictyal B (2.91) to corallidictyals A (2.3) & B 
(2.4) could occur under more basic conditions. Oxidation with Ag2O led to the isolation of 
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corallidictyals A (2.3) & B (2.4) in a 1:2 ratio respectively, consistent with that observed 
previously (entry 3, table 2.7), albeit in a notably lower yield (entry 4, table 2.7). 
 
Table 2.7: Investigation for the biogenically inspired synthesis corallidictyals A (2.3) & B (2.4), 
from siphonodictyal B (2.91). 
Entry Oxidant Solvent Conditions Outcome/Yield 
1 DDQ CH2Cl2 0 ˚C, 30 min Decomposition 
2 Ag2O CH2Cl2 rt, 60 min Inseparable product with 2.91 and 
decomposition 
3 Ag2CO3/Celite
TM Benzene rt, 90 min 88 % of 2.3 & 2.4 in a 1 : 2 ratio 
4 Ag2O/Celite
TM Benzene rt, 90 min 51 % of 2.3 & 2.4 in a 1 : 2 ratio  
5 Chloranil CH2Cl2 rt, 24 h 62 % of 2.3 & 2.4 in a 1 : 2 ratio 
6 O2 MeOH rt, 8 days 29 % of 2.3 & 2.4 in a 1 : 2 ratio 
 
Following the exploration of silver reagents for the oxidation of siphonodictyal B (2.91), we 
set out to determine whether weaker oxidants under neutral pH conditions could afford 
corallidictyals A (2.3) & B (2.4). Chloranil in CH2Cl2 led to the acquisition of corallidictyals 
A (2.3) & B (2.4) in a yield of 62 %, in the same previously observed diastereomeric ratio 
of 1:2 respectively (entry 5, table 2.7). We suspect the significantly slower reaction rate 
observed upon the addition of chloranil, was primarily attributed to the mild nature of the 
oxidant. However, it is conceivable that either slightly acidic or basic conditions may 
influence the rate of reaction, consequently accelerating the formation of corallidictyals A 
(2.3) & B (2.4) from siphonodictyal B (2.91). 
All of the oxidants trialled so far, possess an oxidative potential that may be observed within 
typical biological oxidative limits. Therefore, biological oxidants, such as NAD+ or NADP+, 
may possess a sufficient oxidative potential to initiate a spontaneous oxidation event of 
siphonodictyal B (2.91), that may not require enzymatic mediation. Thus, we set out to 
investigate whether such a transformation from siphonodictyal B (2.91) could take place 
under mild environmental oxidative conditions. Investigation into the mildest oxidative 
conditions necessary for transformation, may indicate whether the corallidictyals A (2.3) & 
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B (2.4) are exclusively biosynthesised within the host organism, or if they may also be 
afforded upon exposure of siphonodictyal B (2.91) to environmental conditions. For these 
reasons, a freshly synthesised sample of siphonodictyal B (2.91) in MeOH was subjected to 
an atmosphere of pure O2 via a breathable bladder. The resultant solution was stirred at room 
temperature for eight days to afford corallidictyals A (2.3) & B (2.4) in the same previously 
observed ratio of 1:2 respectively, albeit in poor yield (entry 6, table 2.7). Comparatively, 
efforts to oxidise siphonodictyal B (2.91) in the presence of air at room temperature in the 
dark, either in a solution of MeOH or neat, failed to yield any observable quantities of 
corallidictyals A (2.3) & B (2.4). After fourteen days exposed to air, both neat and 
methanolic solvated samples were mostly comprised of siphonodictyal B (2.91), alongside 
some minor unidentifiable decomposition by-products. Additionally, stirring siphonodictyal 
B (2.91) over SiO2 rapidly lead to decomposition, and no characteristic peaks corresponding 
to corallidictyals A (2.3) & B (2.4) were observed.  Based on these experiments, there 
appears to be significant limitations under which the corallidictyals A (2.3) & B (2.4) may 
be afforded from siphonodictyal B (2.91) upon exposure to O2. Therefore, we predict 
corallidictyals A (2.3) & B (2.4) are formed primarily within the host organism via non-
enzymatic or promiscuous enzymatic pathways. However, we also acknowledge that to a 
lesser degree, siphonodictyal B (2.91) may undergo oxidation outside the host cell to afford 
corallidictyals A (2.3) & B (2.4). 
 
Scheme 2.39: Synthesis of corallidictyals C (2.5) & D (2.6) via an acid catalysed spirocyclisation of 
siphonodictyal B (2.91). 
Next, we were interested in determining whether corallidictyals C (2.5) & D (2.6) could be 
accessed from siphonodictyal B (2.91) via an acid catalysed spirocyclisation. Investigation 
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into acidic conditions commenced upon subjecting siphonodictyal B (2.91) to a solution of 
p-TsOH in CH2Cl2, at room temperature and the reaction was monitored by TLC analysis 
(scheme 2.39). The reaction was quenched after three days following the disappearance of 
siphonodictyal B (2.91) to afford corallidictyals C (2.5) & D (2.6) in an equal relative 
diastereomeric ratio. The slow reaction rate observed for acid catalysed spirocyclisation of 
siphonodictyal B (2.91) was most likely due to an unfavourable equilibrium of the two 
competing carbocation transition states, 2.105 & 2.104, in favour of the aromatic stabilised 
benzylic carbocation 2.105. Given that corallidictyals C (2.5) & D (2.6) were the only 
products isolated under acid catalysed conditions, the proposed benzylic carbocation 2.105 
does not appear to lead to a product endpoint. Comparatively, the tertiary carbocation 2.104 
would be expected to afford the desired spirocycles, and thus, such an unfavourable 
equilibrium would introduce a mechanistic bottleneck in the synthesis of corallidictyals C 
(2.5) & D (2.6) from siphonodictyal B (2.91) (scheme 2.39). 
  Investigation into the Interconversion of Corallidictyals A (2.3) & B 
(2.4) with C (2.5) & D (2.6) 
Following the synthesis of corallidictyals A – D (2.3 – 2.6) directly from siphonodictyal B 
(2.91), we set out to observe whether the corallidictyals A (2.3) & B (2.4) and C (2.5) & D 
(2.6) were interconvertible with one another under mild REDOX conditions. Investigation 
into such transformations would potentially allow us to gain biosynthetic insight into the 
origin of these meroterpenoids in nature. First, we set out to reduce corallidictyals A (2.3) & 
B (2.4) to C (2.5) & D (2.6) with a mild reducing agent. NaBH3CN was chosen due to its 
mild reduction potential, which may be representative of biologically relevant reducing 
agents such as NADH. A mixture of corallidictyals A (2.3) & B (2.4), as a 1:2 diastereomeric 
ratio respectively, was subjected to a cooled solution of NaBH3CN in THF. Upon 
purification of the quenched reaction mixture, corallidictyals C (2.5) & D (2.6) were isolated 
in the same conserved 1:2 ratio respectively (scheme 2.40). Next, the oxidation of the 
isolated mixture of corallidictyals C (2.5) & D (2.6) was attempted to obtain corallidictyals 
A (2.3) & B (2.4). Under the previously successful Fétizon oxidative conditions employed 
(entry 3, table 2.7), corallidictyals C (2.5) & D (2.6), as a 1:2 ratio respectively, was 
subjected to a mixture of Ag2CO3 and CeliteTM in benzene (scheme 2.40). Corallidictyals A 
(2.3) & B (2.4) were isolated in the same conserved 1:2 diastereomeric ratio respectively. 
We propose that the mild oxidative conditions investigated may be representative of mild 
biologically relevant oxidants found in nature. 
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Scheme 2.40: Biogenically inspired interconversion of the corallidictyals A – D (2.3 – 2.6), under 
REDOX conditions. 
  Biosynthetic Speculation into the Origins of the Corallidictyals 
Our initial proposal involved the presence of a Brønsted or Lewis acid, that could facilitate 
the spirocyclisation of either of the predicted quinone intermediates 2.102 or 2.103 (scheme 
2.14). Under the previously described proposal, each plausible cyclisation pathway (2.97, 
2.98, 2.99 – 2.101) was proposed to proceed via pronation of the oxygenic quinone moiety 
following the oxidation of siphonodictyal B (2.91), with exception of an anionic 5-endo-trig 
cyclisation (2.96) (schemes 2.13).  
Westly reported that the isolated corallidictyals A (2.3) & B (2.4) could not interconvert via 
ring opening of the spirocycle oxygen moiety, under either thermal or base facilitated 
conditions. Therefore, we may reasonably assume that the formation of the corallidictyals A 
(2.3) & B (2.4) from siphonodictyal B (2.91) is under kinetic control, and thus, Baldwin’s 
rules would appear to apply in their entirety. Given that the above assumptions are true, then 
in the absence of an acidic catalyst, spirocyclisation of ortho-quinone 2.96 via an anionic 5-
endo-trig cyclisation would be disfavoured according to Baldwin’s rules.[111–114] The 
oxidatively induced spirocyclisation of siphonodictyal B (2.91) on addition of silver oxidants 
(Ag2CO3 & Ag2O) occurred rapidly, and as such, indicates the unlikelihood that 
corallidictyals A (2.3) & B (2.4) form via an anionic 5-exo-trig cyclisation from 2.96 
(scheme 2.41). Therefore, given the rapid rate of reaction of siphonodictyal B (2.91) upon 
addition of silver oxidants, we propose that in the presence of a metal cation (Ag+, or 
Mg2+/Ca2+ for biological systems), an oxygenic ortho-quinone cation intermediate 2.164 
may be generated, which could proceed to the corallidictyals A (2.3) & B (2.4) via a 
conjugate cationic 5-endo-trig spirocyclisation (scheme 2.41). Alternatively, the previously 
described route in our initial proposal would detail an oxidative concerted spirocyclisation 
of from para-quinone 2.98 (scheme 2.13 and scheme 2.41).  
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Scheme 2.41: Revised proposal for the biogenically inspired, oxidative spirocyclisation mechanism 
of siphonodictyal B (2.91) to corallidictyals A (2.3) & B (2.4). Mn+(-1) = biological metal ion, i.e. 
Mg2+, BH = weak conjugate acid, i.e. H2CO3. 
The last plausible pathway was envisioned to proceed through a step-wise cyclisation 
mechanism, akin to a conjugated Nazarov cyclisation (2.165 to 2.100 then 2.166), which 
conceivably, could be mediated by a metal cation (Ag+, Mg2+, Ca2+ etc.) coordinating to the 
proposed para-quinone 2.165 (scheme 2.41). The tertiary carbocation intermediate 2.166 
could undergo nucleophilic attack from the conjugated carbonyl oxygen at C21 (2.166), 
where the driving force for spirocyclisation is formation of the comparatively stable quinone 
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methide entity, to afford corallidictyals A (2.3) & B (2.4) (scheme 2.41). The concerted 
electrocyclization route (2.98) would be expected to proceed spontaneously, and 
independently of any counter ion (Ag+ or CO3
2-). On the other hand, we predict that the 
proposed 1,6-conjugate Nazarov-like spirocyclisation route (2.165 to 2.100 then 2.166) 
would depend upon the presence of a coordinating cation. Under our proposed competing 
pathways (scheme 2.41), the strength of the oxidant employed would not be the sole 
determining factor in the rate of formation for the corallidictyals A (2.3) & B (2.4). Both the 
oxidative potential of the oxidant and the availability of cationic species (Ag+, Mg2+, Ca2+ 
etc.) would be expected to determine the rate of reaction of siphonodictyal B (2.91). 
Therefore, if more than one oxidative mechanism was possible, then we would expect the 
reaction rate to be determined by the most favourable reaction pathway available to 
siphonodictyal B (2.91). Thus, if the non-metal oxidant conditions explored limited the 
number of permitted favourable reaction pathways available to siphonodictyal B (2.91), then 
we would expect a mechanistic bottleneck to ensue, which may account for the observed 
discrepancy in reaction rates for silver oxidants (entries 3 and 4, table 2.7) compared to non-
metal oxidants (entries 5 and 6, table 2.7). 
Following our successful investigation into the synthesis of the corallidictyals A – D (2.3 – 
2.6) directly from siphonodictyal B (2.91) and through interconversion of each set via 
REDOX conditions, the biosynthetic origins of the corallidictyals appears considerably 
convoluted. In contrast to the natural sample’s reported molar ratio of 2:3 respectively,[96] 
corallidictyals C (2.5) & D (2.6) were afforded in an equal diastereomeric ratio under our 
acid catalysed spirocyclisation conditions (scheme 2.39). Additionally, the reaction rate for 
the acid catalysed spirocyclisation of siphonodictyal B (2.91) was drastically slower than the 
rate of reduction of corallidictyals A (2.3) & B (2.4) (schemes 2.39 & 2.40). Comparatively, 
both the Ag2CO3 and Ag2O mediated oxidative spirocyclisation reactions of siphonodictyal 
B (2.91) afforded corallidictyals A (2.3) & B (2.4) (entries 3 & 4, table 2.7) in a relative ratio 
of 1:2 respectively, analogous with the natural sample’s isolated ratio of 3:7 respectively, as 
reported by Westly.[100] Moreover, the oxidative spirocyclisation of siphonodictyal B (2.91) 
was high yielding, occurred rapidly, and did not afford any undesired by-products, indicating 
the overwhelming favourability of the oxidation reaction pathway. Based on these 
observations, we predict that the corallidictyals C (2.5) & D (2.6) are accessed in nature via 
the reduction of corallidictyals A (2.3) & B (2.4), which in turn are accessed directly from 
siphonodictyal B (2.91) (scheme 2.42). However, it does appear plausible that a portion of 
corallidictyals C (2.5) & D (2.6) may also be accessed directly from siphonodictyal B (2.91) 
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by a Lewis acid mediated spirocyclisation in nature. As such, we predict that corallidictyals 
C (2.5) & D (2.6) are primarily derived via the reduction of corallidictyals A (2.3) & B (2.4) 
in nature, and to a lesser degree, are directly afforded upon spirocyclisation of siphonodictyal 
B (2.91).[96] 
 
Scheme 2.42: Speculation for the biosynthetic origin of the corallidictyals A – D (2.3 – 2.6) from 
siphonodictyal B (2.91). 
Finally, overwhelming evidence indicates that the corallidictyals A (2.3) & B (2.4) are 
biosynthetically derived via the direct oxidation of siphonodictyal B (2.91). However, the 
mechanism, as well as the oxidant source, whether biological or environmental, is somewhat 
less clear. The previously reported screening of oxidative conditions (table 2.7), revealed 
that siphonodictyal B (2.91) was capable of undergoing oxidation under an atmosphere of 
pure O2 (entry 6, table 2.7) to give corallidictyals A (2.3) & B (2.4), albeit in poor yields and 
requiring drastically longer reaction times compared to silver oxidants (entries 3 & 4, table 
2.7). Given that there were significant limitations inherent to the auto-oxidation of 
siphonodictyal B (2.91) in the presence of O2, we propose that the vast majority of 
corallidictyals A (2.3) & B (2.4) are formed within the host organism, and that a measurable 
minority of product may be afforded as an artefact of isolation. Within the cell, we envision 
that corallidictyals A (2.3) & B (2.4) could spontaneously form upon exposure of 
siphonodictyal B (2.91) to biological oxidants (NAD+), or via catalysis from a non-substrate 
specific, promiscuous enzyme.  
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 Summary and Biogenic Analysis of our Synthetic 
Investigations for the Family of Related Meroterpenoid 
Natural Products from Aka coralliphaga 
To summarise this work, we have, for the first time, successfully synthesised, and reassigned 
the stereoconfiguration of siphonodictyal B (2.91) (tables 2.3 & 2.4). In addition, we have 
synthesised and consequently, proven that Faulkner’s assigned configuration of 8-epi-
siphonodictyal B 2.1, is in fact not the true stereoconfiguration of the siphonodictyal B 
(scheme 2.27 & table 2.4). Following the successful reassignment of siphonodictyal B 
(2.91), we embarked upon the investigation of our divergent, biosynthetic proposal, which 
states that siphonodictyal B (2.91) is the biogenic precursor to liphagal (2.2), the 
corallidictyals A – D (2.3 – 2.6), and the siphonodictyals B1 – B3 (2.106 – 2.108) (scheme 
2.43). Our successful biogenically inspired one-pot, two-step epoxidation and acid catalysed 
cascade transformation demonstrated that siphonodictyal B (2.91), in accordance with our 
reassigned stereoconfiguration, is a viable biogenic precursor to liphagal (2.2) (table 2.5). 
Additionally, the epoxidation and acid catalysed transformation of Faulkner’s erroneously 
assigned configuration of 8-epi-siphonodictyal B 2.1 did not afford liphagal (2.2), and 
instead afforded the unnatural epimer, 8-epi-liphagal 2.163, as predicted (scheme 2.35). The 
biogenic conversions of siphonodictyal B (2.91) and its epimer 2.1 to liphagal (2.2) and 
2.157 respectively, confirmed our prediction that a non-enzymatic facilitated epimerisation 
event did not occur under the epoxidative/acidic conditions investigated.  
The synthesis of siphonodictyals B1 – B3 (2.106 – 2.108) from siphonodictyal B (2.91) was 
investigated in an attempt to confirm our proposed stereochemical reassignment of the 
siphonodictyal B meroterpenoids (2.91, 2.106 – 2.108) (scheme 2.43). However, all attempts 
to selectively install sulfonate esters at the C21 and C18 phenolic moieties of siphonodictyal 
B (2.91) failed to afford any isolatable desired products (2.107 and 2.108) (scheme 2.37 and 
table 2.6). 1H NMR analysis of the eluted second (peak 2, table 2.6) and third (peak 3, table 
2.6) fractions revealed that the complex mixtures contained characteristic peaks of 
siphonodictyal B3 (2.108) and B2 (2.107) respectively. Due to the inability to resolve these 
selective sulfonation issues, the attempted synthesis of siphonodictyals B1 – B3 (2.106 – 
2.108) was not further pursued. Continued investigation into the potential stereochemical 
reassignment of siphonodictyals B1 – B3 (2.106 – 2.108) would require installation of the 
sulfonate esters by a selective means, either with milder reagents or perhaps via 
enzymatically catalysed means. 
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Scheme 2.43: Summary of the biogenically inspired total synthesis of liphagal (2.2), and the 
corallidictyals A – D (2.3 – 2.6) from siphonodictyal B (2.91), in accordance with our divergent 
biogenic proposal for the related meroterpenoid natural products isolated from Aka coralliphaga. 
Finally, we have demonstrated that the corallidictyals A – D (2.3 – 2.6) can be accessed 
directly from siphonodictyal B (2.91) in one step, according to our biosynthetic proposal 
(table 2.7 and scheme 2.39). Additionally, we have successfully interconverted 
corallidictyals A (2.3) & B (2.4) with C (2.5) & D (2.6) under mild REDOX conditions 
(scheme 2.40), which may be representative of biologically relevant conditions present 
within the host organism, Aka coralliphaga. Based on our investigation into the biosynthetic 
origin of the corallidictyals, we assert that within the host organism, corallidictyals C (2.5) 
& D (2.6) are most likely derived from corallidictyals A (2.3) & B (2.4) under reductive 
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conditions, which are in turn afforded via an oxidative spirocyclisation of siphonodictyal B 
(2.91) (scheme 2.43).  
As of the writing of this work, the known meroterpenoids derived from Aka coralliphaga 
possess mild to moderate non-selective bioactivity, such as anti-microbial and PI3 kinase 
inhibitory properties.[96–100] However, siphonodictyal B (2.91), siphonodictyals B1 – B3 
(2.106 – 2.108), liphagal (2.2), and corallidictyals A – D (2.3 – 2.6) do not appear to target 
any specific system or threat, which indicates the absence of a notable selective pressure that 
would specifically afford these meroterpenoids in nature. Without an apparent determining 
selective pressure, the likelihood for the emergence of substrate-specific enzymes, dedicated 
to catalysing the biosynthesis of the siphonodictyals (2.91, 2.106 – 2.108), corallidictyals 
(2.3 – 2.6) and liphagal (2.2), appears remote. Biosynthetic pathways governed and closely 
regulated by highly selective, efficient enzymes would only emerge given that the products 
of the metabolic process in question, directly pertain to the survival of the host organism. 
Therefore, without the presence of an existentially driven selective pressure, it would be 
reasonable to assume that the biosynthesis of the meroterpenoids in question are not 
regulated by substrate specific enzymes. Based upon our biogenically inspired synthetic 
investigations, we assert that siphonodictyal B (2.91) is the biogenic precursor to 
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 Experimental 
 General Experimental 
All commercially obtained chemicals were used without further purification. Solvents stated 
as dry, were either collected from a solvent purification system (THF or DMF) or distilled 
under an atmosphere of nitrogen and stored over 3Å molecular sieves. Thin-layer 
chromatography (TLC) was conducted on Merck silica gel 60 F254 aluminium sheets and 
visualised under a UV lamp or with ceric ammonium molybdate (CAM), vanillin or 
potassium permanganate staining followed by heated. All Rf values are rounded to the 
nearest 0.01. Davisil 43-60 micron chromatographic silica media was used for flash 
chromatography. 1H and 13C NMR spectra were either recorded on an Agilent 500 
spectrometer (1H at 500 MHz, 13C at 125 MHz) or on an Agilent spectrometer with a 600 
MHz Oxford magnet, with a cryoprobe (1H at 600 MHz, 13C at 150 MHz) in CDCl3 as the 
solvent, unless specified. 1H and 13C chemical shifts are reported in ppm relative to TMS (δ 
0.0). All J values were quoted to the nearest 0.1 Hz. Multiplicities are reported as (br) Broad, 
(s) singlet, (d) doublet, (t) triplet, (q) quartet, (qnt) quintet, (sext) sextet, (hept) heptet and 
(m) multiplet. IR spectra were recorded on a Perkin-Elmer Fourier-Transform Infrared (FT-
IR) spectrometer on a nickel-selenide crystal as neat compounds. High resolution mass 
spectra were obtained on an Agilent ESI high resolution mass spectrometer. Melting points 
were recorded on a Reichert electrothermal melting point apparatus and are uncorrected. 
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 Experimental Procedures 
3,4-Diisopropoxybenzaldehyde 2.113[118] 
 
to a solution of 3,4-dihydroxybenzaldehyde 2.111 (2.00 g, 14.48 mmol) in DMF (30 mL) 
was added potassium carbonate (6.00 g, 43.4 mmol), 2-bromopropane (4.10 mL, 43.4 mmol) 
and TBAI (0.54 g, 1.49 mmol). The reaction mixture was stirred at 75 °C for 48 h, followed 
by cooling to room temperature. The reaction mixture was diluted with Et2O (100 mL) and 
water (50 mL). The organic phase was separated, and the aqueous phase was extracted with 
Et2O (3 × 50 mL). The organic extracts were combined then dried over MgSO4 and 
concentrated in vacuo to give crude 3,4-diisopropoxybenzaldehyde 2.113 (2.97 g) as a brown 
oil, which was used in the next step without further purification. 
Rf = 0.70 (2:1 Petrol:EtOAc) 
1H NMR (600 MHz, CDCl3): δ 9.83 (s, 1H), 7.45 – 7.43 (m, 2H), 6.99 (d, J = 8.7 Hz, 1H), 
4.64 (hept, J = 6.1 Hz, 1H), 4.53 (hept, J = 6.1 Hz, 1H), 1.39 (d, J = 6.1 Hz, 6H), 1.36 (d, J 
= 6.1 Hz, 6H). 
13C NMR (150 MHz, CDCl3): δ 190.9, 155.0, 149.0, 130.1, 126.4, 116.2, 114.9, 72.5, 71.8, 
22.1, 22.0. 
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3,4-Diisopropoxyphenol 2.114[118,119] 
 
To a solution of 3,4-diisopropoxybenzaldehyde 2.113 (2.97 g, 13.35 mmol) in MeOH (55 
mL) at room temperature, was added conc. H2SO4 (0.60 mL, 10.68 mmol) dropwise. 30% 
aqueous H2O2 solution (10.6 mL, 102.8 mmol) was then added in one portion and the 
resulting reaction mixture was stirred at room temperature for 6 h. Upon completion, the 
reaction mixture was quenched with saturated NaHCO3 solution (10 mL) and extracted with 
CH2Cl2 (3 × 75 mL). The combined organics were dried over MgSO4 and concentrated in 
vacuo to give crude 3,4-diisopropoxyphenol 2.114 as a brown gum (3.04 g). Product was 
used without purification.  
Rf = 0.35 (4:1 Petrol:EtOAc) 
1H NMR (600 MHz, CDCl3): δ 6.79 (d, J = 8.5 Hz, 1H), 6.45 (d, J = 2.9 Hz, 1H), 6.31 (dd, 
J = 8.5, 2.9 Hz, 1H), 4.59 (d, J = 4.6 Hz, 1H), 4.46 (hept, J = 6.1 Hz, 1H), 4.28 (hept, J = 
6.1 Hz, 1H), 1.33 (d, J = 6.1 Hz, 6H), 1.28 (d, J = 6.1 Hz, 6H). 
13C NMR (150 MHz, CDCl3): δ 151.1, 150.7, 142.6, 121.2, 107.0, 105.0, 73.7, 71.5, 22.3, 
22.2. 
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1,2,4-Triisopropoxybenzene 2.115[118] 
 
To a solution of 3,4-diisopropoxyphenol 2.114 (10.5 g, 49.9 mmol) in DMF (150 mL) was 
added K2CO3 (15.6 g, 113 mmol), 2-bromopropane (10.6 mL, 113 mmol) and TBAI (1.40 
g, 3.79 mmol). The reaction mixture was stirred at 75 °C for 24 h, followed by cooling to 
room temperature. The reaction mixture was diluted with Et2O (150 mL) and water (150 
mL). The organic phase was separated, and the aqueous phase was extracted with Et2O (3 × 
150 mL). The organic extracts were combined and washed with water (150 mL) and brine 
(150 mL), dried over MgSO4 and concentrated in vacuo. The residue was purified by flash 
column chromatography on SiO2 (petrol/EtOAc, 4:1) to give 1,2,4-triisopropoxybenzene 
2.115 as a yellow oil (11.2 g, 89%).  
Rf = 0.58 (petrol/EtOAc, 4:1)  
IR (neat): 2975, 2931, 1734, 1606, 1584, 1499, 1466, 1453, 1421, 1382, 1371, 1335, 1300, 
1257, 1214, 1181, 1163, 1109 cm-1 
1H NMR (500 MHz, CDCl3): δ 6.82 (d, J = 8.7 Hz, 1H), 6.49 (s, 1H), 6.39 (d, J = 8.7 Hz, 
1H), 4.50 – 4.40 (m, 2H), 4.30 (qnt, J = 6.1 Hz, 1H). 1.33 – 1.28 (m, 18H). 
13C NMR (125 MHz, CDCl3): δ 153.4, 150.5, 142.8, 120.7, 107.5, 106.7, 73.5, 71.6, 70.5, 
22.3, 22.22, 22.15. 
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1-Bromo 2,4,5-triisopropoxybenzene 2.116[120] 
 
A solution of 1,2,4-triisopropoxybenzene 2.115 (11.2 g, 44.4 mmol) in THF (220 mL) was 
cooled to -78 °C. NBS (7.90 g, 44.4 mmol) was added portion wise over 5 min at -78 °C, 
and the resultant mixture was stirred at this temperature for 15 min. The reaction mixture 
was allowed to warm to room temperature and the solvent was removed in vacuo. The 
residue was diluted with EtOAc (200 mL) and filtered through a pad of neutral alumina, 
followed by concentrating in vacuo. The residue was purified by flash column 
chromatography on SiO2 (petrol/EtOAc, 4:1) to give 1-bromo-2,4,5-triisopropoxybenzene 
2.116 as a yellow oil (14.6 g, 99%).  
Rf = 0.58 (petrol/EtOAc, 4:1)  
IR (neat): 2975, 2931, 1594, 1569, 1486, 1467, 1382, 1372, 1333, 1307, 1254, 1198, 1182, 
1163, 1137, 1106, 1025 cm-1  
1H NMR (500 MHz, CDCl3): δ 7.08 (s, 1H), 6.57 (s, 1H), 4.47 – 4.32 (m, 3H), 1.35 (d, J = 
6.1 Hz, 6H), 1.31 (d, J = 6.4 Hz, 6H), 1.30 (d, J = 6.4 Hz, 6H). 
13C NMR (125 MHz, CDCl3): δ 153.4, 150.5, 142.8, 120.7, 107.5, 106.7, 73.5, 71.6, 70.5, 
22.3, 22.22, 22.15. 
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Ketone 2.118[122,123] 
 
To a solution of (+)-sclareolide 2.52 (10.0 g, 39.9 mmol) in Et2O (150 mL) at -78 °C, was 
added a solution of MeLi (1.5 M in Et2O, 50 mL, 75 mmol). The resulting reaction mixture 
was stirred at -78 °C for 1 h, before the mixture was quenched with 10% aqueous sulfuric 
acid solution (50 mL). The mixture was extracted with Et2O (2 × 100 mL), and the organic 
phase was washed sequentially with saturated aqueous NaHCO3 (150 mL), water (150 mL), 
brine (100 mL). The organic extracts were dried over MgSO4 and concentrated in vacuo to 
give crude ketone 2.118 as a colourless oil (9.98 g). Crude product was used without 
purification.  
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Acetate 2.119[122,123] 
 
To a solution of acetic anhydride (50 mL, 529 mmol) in CH2Cl2 (70 mL) at 5 °C, was added 
35% aqueous H2O2 solution (50 mL, 75 mmol). The mixture was stirred at 5 °C for 1 h, then 
maleic anhydride (30 g, 306 mmol) was added in three portions over 20 min at 8 °C and 
stirred at this temperature for a further 1 h. the reaction mixture was warmed to room 
temperature and stirred for 1 h, before crude ketone 2.118 (9.98 g, 37.6 mmol) in CH2Cl2 
(40 mL) was added dropwise. The resulting reaction mixture was stirred at room temperature 
for 12 h. The mixture was diluted with CH2Cl2 (200 mL) and extracted. The organic phase 
was sequentially washed with water (200 mL), saturated aqueous NaHCO3 solution (2 × 100 
mL), brine (100 mL). Extracts were dried over MgSO4 and concentrated in vacuo to give 
crude acetate 2.119 as a colourless oil (13.95 g). Crude product was used without 
purification.  
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Diol 2.120[122,123] 
 
To a solution of crude ester 2.119 (13.95 g, 37.6 mmol) in MeOH (150 mL) at room 
temperature, was added KOH (10.2 g, 182 mmol). The resulting reaction mixture was stirred 
at room temperature for 2 h. The mixture was diluted with Et2O (150 mL) and extracted. The 
organic phase was sequentially washed with water (2 × 100 mL), brine (100 mL) and the 
organic extracts were dried over MgSO4 and concentrated in vacuo. The residue was purified 
by flash column chromatography on SiO2 (petrol/EtOAc, 3:1) to give pure diol 2.120 as a 
white solid (7.6 g, 73% over 3 steps).  
Rf = 0.08 (petrol/EtOAc, 3:1) 
IR (neat): 3310, 2918, 1458, 1381, 1048 cm-1   
1H NMR (500 MHz, CDCl3):  δ 3.91 (d, J = 7.0 Hz, 2H), 3.58 (br s, 1H), 3.21 (br s, 1H), 
1.88 (dt, J = 12.0, 3.0 Hz, 1H), 1.75 – 1.37 (m, 6H), 1.34 (s, 3H), 1.31 – 1.06 (m, 4H), 0.97 
(dd, J = 12.2, 2.0 Hz, 1H), 0.88 (s, 3H), 0.79 (s, 3H).  
13C NMR (125 MHz, CDCl3): δ 75.1, 61.1, 60.5, 55.9, 44.4, 41.7, 40.0, 37.5, 33.6, 33.3, 
24.3, 21.6, 20.2, 18.6, 16.0.  
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Hydroxy aldehyde 2.121[126] 
 
To a solution of DMSO (1.67 ml, 27.71 mmol) in CH2Cl2 (22 mL) at -78 °C, was added 
(COCl)2 (1.2 mL, 13.86 mmol) and the resulting mixture was stirred for 10 min. Diol 2.120 
(1 g, 4.16 mmol) in CH2Cl2 (22 mL) was added to the mixture and was stirred at -78 °C for 
a further 10 min. Triethylamine (6.36 mL, 46.18 mmol) was added dropwise to the mixture, 
which was then warmed to room temperature. The mixture was quenched with water (50 
mL) and extracted with CH2Cl2 (3 × 80 mL). The organic extracts were combined, dried over 
MgSO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography on SiO2 (petrol/EtOAc, 5:1) to give pure hydroxy aldehyde 2.121 as a 
colourless solid (730 mg, 74%).  
Rf = 0.34 (petrol/EtOAc, 2:1)  
IR (neat): 3441, 2929, 1715, 1467, 1096 cm-1 
1H NMR (500 MHz, CDCl3): δ 10.03 (s, 1H), 3.11 (br s, 1H), 2.08 (s, 1H), 2.00 – 1.94 (m, 
1H), 1.82 (dt, J = 13.0 Hz, J =  3.0 Hz, 1H), 1.73 – 1.67 (m, 1H), 1.54 – 1.43 (m, 3H), 1.38 
(s, 3H), 1.36 – 1.20 (m, 3H), 1.12 (s, 3H), 0.97 (dd, J = 12.0 Hz, J = 2.0 Hz, 1H), 0.90 (s, 
3H), 0.83 (s, 3H).  
13C NMR (125 MHz, CDCl3): δ 208.2, 72.8, 71.3, 55.2, 42.7, 41.6, 39.8, 37.3, 33.3, 33.2, 
25.3, 21.4, 19.9, 18.2, 17.6.  
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endo-Alkenyl aldehyde 2.122[126] 
 
To a solution of hydroxy aldehyde 2.121 (4.5 g, 18.88 mmol) in CH2Cl2 (120 mL) at room 
temperature, was added BF3·OEt2 (4.66 mL, 37.79 mmol) and the resulting mixture was 
stirred for 24 h. The mixture was quenched with saturated aqueous NaHCO3 solution (125 
mL) and extracted with CH2Cl2 (50 mL). The organic extracts were dried over MgSO4 and 
concentrated in vacuo to give crude endo-alkenyl aldehyde 2.122 as a colourless impure 
solid (3.97 g). Crude product was used without purification.  
Rf = 0.48 (petrol/EtOAc, 4:1) 
1H NMR (500 MHz, CDCl3): δ 10.04 (s, 1H), 2.57 – 2.54 (m, 1H), 2.28 – 2.25 (m, 2H), 
2.03 (s, 3H), 1.73 – 1.59 (m, 2H), 1.49 – 1.41 (m, 3H), 1.18 (s, 3H), 1.10 – 0.91 (s, 3H), 0.90 
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endo-Alkene alcohol 2.123[126] 
 
To a solution of aldehyde-alkene 2.122 (3.97 g, 18.02 mmol) in EtOH (90 mL) at 0 °C, was 
added NaBH4 (1.35 g, 35.69 mmol) and the resulting mixture was stirred for 40 min. The 
mixture was quenched with 10% aqueous H2SO4 solution (70 mL) and extracted with Et2O 
(3 × 100 mL) and sequentially washed with saturated aqueous NaHCO3 solution (150 mL), 
water (150mL), brine (150 mL). The organic extracts were dried over MgSO4 and 
concentrated in vacuo. The residue was purified by flash column chromatography on SiO2 
(petrol/EtOAc, 15:1 then 4:1) to give pure endo-alkene alcohol 2.123 as a colourless solid 
(1.88 g, 47% over two steps).  
Rf = 0.37 (petrol/EtOAc, 4:1)  
1H NMR (500 MHz, CDCl3): δ 4.20 (dd, J = 13.2 Hz, J = 3.2 Hz, 1H), 4.04 (dd, J = 13.2 
Hz, J = 3.2 Hz, 1H), 2.17 – 2.01 (m, 2H), 1.91 – 1.88 (m, 1H), 1.72 (s, 3H), 1.70 – 1.62 (m, 
2H), 1.54 – 1.38 (m, 3H), 1.25 (td, J = 12.9 Hz, J =  3.8 Hz, 1H), 1.18 (dd, J = 13.4 Hz, J = 
4.2 Hz, 1H), 1.14 (dd, J = 12.5 Hz, J = 1.7 Hz, 1H), 0.97 (s, 3H), 0.89 (s, 3H), 0.84 (s, 3H).  
13C NMR (125 MHz, CDCl3): δ 141.0, 132.4, 58.3, 51.7, 41.7, 38.1, 36.8, 33.7. 33.26, 
33.25, 21.6, 20.7, 19.3, 19.0, 18.9.  
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Epoxy alcohol 2.124[126]  
 
To a mixture of 3Å (15 g) and D-(-)-diethyl tartrate (0.39 ml, 2.25 mmol) in CH2Cl2 (15 mL) 
at -20 °C, was added Ti(Oi-Pr)4 (0.68 mL, 2.25 mmol) and the resulting mixture was stirred 
for 10 min. t-BuOOH (5.5 M in decane, 1.63 mL, 8.99 mmol) was added dropwise to the 
reaction mixture and was stirred for 30 min at -20 °C. endo-alkene alcohol 2.123 (1.0 g, 
4.496 mmol) in CH2Cl2 (12.5 mL) was added to the reaction mixture and was stirred at -20 
°C for 1 h. The reaction was quenched with 30% aqueous NaOH solution (1 mL) and diluted 
with Et2O (50 mL) and was filtered through a pad of Celite
TM, diluted with Et2O (50 mL) 
and sequentially washed with water (50mL), brine (50 mL). The organic extracts were dried 
over MgSO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography on SiO2 (petrol/EtOAc, 8:1) to give pure epoxy alcohol 2.124 as a 
colourless solid (890 mg, 83%).  
Rf = 0.44 (petrol/EtOAc, 2:1) 
IR (neat): 3412, 2928, 1463, 1373, 1023 cm-1 
1H NMR (500 MHz, CDCl3): δ 3.88 (dd, J = 10.7 Hz, J = 6.4 Hz, 1H), 3.55 (dd, J = 12.5, 
J = 3.2 Hz, 1H), 2.04 – 1.92 (m, 2H), 1.86 – 1.78 (m, 2H), 1.61 – 1.50 (m, 2H), 1.42 – 1.33 
(m, 4H), 1.30 (s, 3H), 1.28 – 1.23 (m, 1H), 1.17 (td, J = 13.2, 5.1 Hz, 1H), 0.97 (s, 3H), 0.84 
(s, 3H), 0.81 (s, 3H).  
13C NMR (125 MHz, CDCl3): δ 71.2, 64.5, 56.9, 43.2, 41.4, 37.1, 33.9, 33.5, 32.9, 29.4, 
21.5, 21.4, 18.3, 17.1, 16.2.  
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1,2-Diol 2.117[106] 
 
To a solution of alcohol-epoxide 2.124 (1.64 g, 6.88 mmol) in tetrahydrofuran (120 mL) at 
room temperature, was added a LiAlH4 solution (2 M in THF, 13.8 mL, 27.6 mmol) and the 
reaction mixture was heated at 60 °C for 1 h while stirred. The reaction mixture was cooled 
to room temperature before being placed on an ice bath and quenched with ethanol (15 mL) 
and 1M aqueous HCl (20 mL). The mixture was extracted with EtOAc (2 × 200 mL) and the 
extracts were sequentially washed with water (2 × 150 mL), and brine (50 mL). The organic 
extracts were dried over MgSO4 and concentrated in vacuo. The residue was purified by 
flash column chromatography on SiO2 (petrol/EtOAc, 10:1) to give pure 1,2-diol 2.117 as a 
white solid (1.5 g, 90%).  
Rf = 0.48 (petrol/EtOAc, 2:1)  
1H NMR (500 MHz, CDCl3): δ 3.73 (dd, J = 10.9 Hz, J = 4.5 Hz, 1H), 3.50 (dd, J = 10.9, 
J = 5.3 Hz, 1H), 2.35 (br s, 1H), 1.80 – 1.74 (m, 2H), 1.58 – 1.55 (m, 2H), 1.49 – 1.45 (m, 
3H), 1.38 – 1.29 (m, 3H), 1.21 – 1.16 (m, 2H), 0.90 (d, J = 6.7 Hz, 3H), 0.88 (s, 6H), 0.83 
(s, 3H).  
13C NMR (125 MHz, CDCl3): δ 75.5, 63.6, 46.4, 42.0, 41.7, 35.6, 33.6, 33.3, 31.9, 31.3, 
22.1, 21.7, 18.6, 16.4, 15.6.  
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Aldehyde 2.112[121] 
 
To a solution of triphenylphosphine (177 mg, 0.675 mmol) in toluene (2.5 mL) at room 
temperature, was added diethyl azodicarboxylate (1.31 mL, 0.675 mmol) and the reaction 
mixture was stirred at this temperature for 15 min. 1,2-diol 2.117 (50 mg, 0.225 mmol) in 
toluene (1.5 mL) was added to the reaction mixture and the resulting mixture was stirred at 
room temperature for 24 h. The mixture was concentrated in vacuo and the residue was 
purified by flash column chromatography on SiO2 (petrol/EtOAc, 30:1) to give aldehyde 
2.112 as a colourless oil (33.5 mg, 67%), which was a mixture of diastereomers and was 
used without purification.  
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Alkenyl alcohol 2.137[144] 
 
To a solution of diol 2.120 (2.67 g, 11.1 mmol) in CH2Cl2 (110 mL) at room temperature, 
was added p-TsOH·H2O (2.11 g, 11.1 mmol) and the reaction mixture was stirred at this 
temperature for 24 h. The mixture was quenched with saturated aqueous NaHCO3 solution 
(80 mL) and extracted with CH2Cl2 (3 × 100 mL). The organic extracts were dried over 
MgSO4 and concentrated in vacuo to give crude alkenyl alcohol 2.137 as a colourless oil 
(2.40 g). Product was used without purification.  
Rf = 0.30 (petrol/EtOAc, 4:1)  
Data for 2.137 matched that which had been previously reported. 
1H NMR (500 MHz, CDCl3): δ 5.54 (br s, 1H), 3.85 (dd, J = 2.1 Hz, J = 11.45 Hz, 1H), 
3.78 – 3.72 (m, 1H), 2.02 – 1.40 (m, 4H), 1.78 (s, 3H), 1.68 – 1.40 (m, 3H), 1.30 – 1.04 (m, 
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Alcohols 2.134 and 2.135 
 
To a de-gassed solution of alkenyl alcohol 2.137 (1.5 g, 6.746 mmol) in CH2Cl2 (120 mL) 
at room temperature, was added Wilkinson’s catalyst (300 mg, 0.324 mmol), followed by 
subjecting the reaction vessel to an atmosphere of hydrogen via a breathable bladder and the 
reaction mixture was stirred at room temperature for 24 h. The mixture was concentrated in 
vacuo and the residue was purified by flash column chromatography on SiO2 (petrol/EtOAc, 
30:1) to give alcohol 2.134 as a white solid (1.35 g, 89% over two steps) and alcohol 2.135 
as a white solid (110 mg, 7% over two steps).  
Partial data for alcohol 2.134:  
Rf = 0.44 (petrol/EtOAc, 4:1)  
1H NMR (500 MHz, CDCl3): δ 3.79 (d, J = 11.4 Hz, 1H), 3.63 (d, J = 11.2 Hz, 1H), 2.17 
(br s, 1H), 1.89 – 1.86 (m, 1H), 1.81 – 1.77 (m, 1H), 1.64 – 1.59 (m, 2H), 1.47 – 1.37 (m, 
2H), 1.33 – 1.25 (m, 1H), 3.79 (d, J = 3.5 Hz, 1H), 1.18 – 1.11 (m, 1H),  1.06 – 1.00 (m, 
3H), 0.97 (d, J = 6.4 Hz, 3H), 0.87 (s, 3H), 0.84 (s, 3H), 0.81 (s, 3H), 0.68 – 0.66 (m, 1H).  
13C NMR (125 MHz, CDCl3): δ 61.9, 60.7, 55.0, 42.1, 39.4, 37.6, 36.8, 33.6, 33.3, 30.8, 
21.9, 21.8, 21.0, 18.8, 15.6.  
Partial data for alcohol 2.135:  
Rf = 0.37 (petrol/EtOAc, 4:1). 
1H NMR (500 MHz, CDCl3): δ 3.86 (dd, J = 10.6 Hz, J = 4.6 Hz, 1H), 3.59 (t, J = 9.9 Hz, 
1H), 2.17 – 2.04 (m, 1H), 1.69 – 1.36 (m, 11H), 1.16 (td, J = 14.2 Hz, J = 4.5 Hz, 1H), 1.01 
(td, J = 12.9 Hz, J = 3.2 Hz, 1H), 0.96 (d, J = 7.6 Hz, 3H), 0.86 (s, 6H), 0.81 (s, 3H).  
13C NMR (125 MHz, CDCl3): δ 61.0, 56.5, 55.7, 42.0, 39.9, 37.6, 34.5, 33.6, 33.3, 28.5, 
21.6, 18.4, 17.5, 17.1, 15.6.  
Data for 2.135 matched that which had been previously reported. 
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Aldehyde 2.112 epimers[144] 
 
To a solution of (COCl)2 (0.44 mL, 5.24 mmol) in CH2Cl2 (17.5 mL) at -78 °C, was added 
DMSO (0.622 mL, 9.41 mmol) and the resulting mixture was stirred for 30 min. Alcohol 
2.134 (819 mg, 3.59 mmol) in CH2Cl2 (17.5 mL) was added to the mixture and was stirred 
at -78 °C  for a further 30 min. Diisopropylamine (3.5 mL, 19.78 mmol) was added dropwise 
to the mixture, which was then warmed to 0 °C. The mixture was stirred at 0 °C for 1 h then 
quenched with water (50 mL) and extracted with CH2Cl2 (3 × 80 mL). The organic extracts 
were dried over MgSO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography on SiO2 (petrol/EtOAc, 30:1) to give pure aldehyde 2.112 as a colourless 
solid (792 mg, 99%).  
Rf = 0.70 (petrol/EtOAc, 4:1)  
1H NMR (500 MHz, CDCl3): δ 9.69 (dd, J = 4.9 Hz, 1H), 2.09 (septet, J = 5.7 Hz, 1H), 
1.91 – 1.88 (m, 1H), 1.63 – 1.50 (m, 4H), 1.42 – 1.35 (m, 3H), 1.28 – 1.19 (m, 3H), 1.09 (s, 
3H), 0.99 (qd, J = 12.6 Hz, J = 4.4 Hz, 1H), 0.86 (s, 3H), 0.84 (s, 3H), 0.79 (d, J = 6.4 Hz, 
3H).  
13C NMR (125 MHz, CDCl3): δ 207.8, 70.3, 54.2, 41.9, 40.2, 38.2, 35.5, 33.5, 33.3, 27.5, 
21.8, 21.6, 20.7, 18.3, 16.0.  
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Aldehyde 2.136 
 
To a solution of (COCl)2 (0.53 ml, 6.36 mmol) in CH2Cl2 (21 mL) at -78 °C, was added 
DMSO (0.76 mL, 11.49 mmol) and the resulting mixture was stirred for 30 min. Alcohol 
2.135 (0.984 g, 4.39 mmol) in CH2Cl2 (21 mL) was added to the mixture and was stirred at 
-78 °C for a further 30 min. Diisopropylamine (4.3 mL, 24.3 mmol) was added dropwise to 
the mixture, which was then warmed to 0 °C. The mixture was stirred at 0 °C for 1 h then 
quenched with water (60 mL) and extracted with CH2Cl2 (3 × 120 mL). The organic extracts 
were dried over MgSO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography on SiO2 (petrol/EtOAc, 30:1) to give pure aldehyde 2.136 as a colourless 
solid (889 mg, 91%).  
Rf = 0.65 (petrol/EtOAc, 4:1)  
[𝛂]𝐃
𝟐𝟓 = +12.6º (c 0.24, CHCl3)  
IR (neat): 2924, 2842, 2854, 1713, 1458, 1387, 1112 cm-1  
1H NMR (500 MHz, CDCl3): δ 9.88 (s, 1H), 2.40 – 2.38 (m, 1H), 1.98 – 1.96 (m, 2H) 1.69 
-1.26 (m, 12H) 1.18 (s, 1H), 1.04 (d, J = 7.2 Hz, 3H), 0.87 (s, 3H), 0.85 (m, 3H).  
13C NMR (125 MHz, CDCl3): δ 206.6, 65.6, 55.7, 41.9, 39.7, 37.1, 34.2, 33.4, 33.2, 29.9, 
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Benzyl alcohol 2.138 
 
To a solution of aryl bromide 2.116 (2.12 g, 6.40 mmol) in anhydrous THF (12 mL), t-BuLi 
(1.0 M in pentane, 5.76 mL, 5.76 mmol) was added dropwise at -78 °C. The reaction mixture 
was stirred at this temperature for 1 h. A solution of aldehyde 2.112 (710 mg, 3.19 mmol) in 
anhydrous THF (12 mL) was then added dropwise over 10 min at -78 °C. The reaction 
mixture was stirred at -78 °C for a further 1 h, and then allowed to warm to room temperature. 
The reaction mixture was quenched with saturated aqueous NH4Cl solution (40 mL) and 
extracted with Et2O (2 × 100 mL). The combined organic extracts were dried over MgSO4 
and concentrated in vacuo. The residue was purified by flash column chromatography on 
SiO2 (petrol/EtOAc, 10:1) to give benzyl alcohol 2.138 as a white solid (1.12 g, 74%).  
Rf = 0.46 (petrol/EtOAc, 10:1)  
[𝛂]𝐃
𝟐𝟓 = +7.9º (c 0.63, CHCl3) 
IR (neat): 3476, 2974, 2931, 1608, 1496, 1382, 1188 cm-1 
1H NMR (500 MHz, CDCl3): δ 7.03 (s, 1H), 6.47 (s, 1H), 5.26 (d, J = 4.0 Hz, 1H), 4.53 
(septet, J = 6.1 Hz, 1H), 4.47 (septet, J = 6.1 Hz, 1H), 4.34 (septet, J = 6.1 Hz, 1H), 2.86 (d, 
J = 4.0 Hz, 1H), 2.01 – 1.87 (m, 2H), 1.78 – 1.74 (m, 1H), 1.69 – 1.55 (m, 2H), 1.50 – 1.35 
(m, 4H), 1.36 (d, J = 6.7 Hz, 3H), 1.35 (d, J = 6.7 Hz, 3H), 1.31 (d, J = 6.2 Hz, 3H), 1.31 (d, 
J = 6.2 Hz, 3H), 1.28 (d, J = 6.0 Hz, 3H), 1.27 (d, J = 6.0 Hz, 3H), 1.19 – 1.00 (m, 3H), 1.11 
(s, 3H), 0.92 – 0.89 (m, 1H), 0.87 (m, 3H), 0.85 (s, 3H), 0.78 (d, J = 6.4 Hz, 3H).  
13C NMR (125 MHz, CDCl3): δ 149.7, 148.2, 141.9, 128.9, 120.3, 105.1, 73.3, 72.3, 70.9, 
67.4, 58.7, 55.3, 42.3, 39.7, 38.9, 37.8, 33.8, 33.5, 28.7, 23.2, 22.4, 22.31, 22.29, 22.27, 22.1, 
21.9, 19.0, 15.3. 
HRMS (ESI): calculated for C30H30O4Na 497.3607 [M+Na]
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Alkene 2.139 and para-QM 2.140 
 
 
To a solution of benzyl alcohol 2.138 (300 mg, 0.632 mmol) in PhMe (24 mL) was added 
p-TsOH·H2O (12 mg, 63.2 μmol) at room temperature. The reaction mixture was heated to 
80 °C for 15 min and the reaction mixture was cooled to room temperature. The reaction 
mixture was quenched with saturated aqueous NaHCO3 solution (100 mL) and extracted 
with EtOAc (2 × 150 mL). The combined organic extracts were sequentially washed with 
water (100 mL), brine (100 mL), dried over MgSO4 and concentrated in vacuo. The residue 
was purified by flash column chromatography on SiO2 (petrol/EtOAc, 10:1) to give alkene 
2.139 as a colourless oil (115 mg, 41%). Further purification lead to isolation of a para-QM 
2.140 by-product (119 mg, 46%).  
Data for alkene 2.139:  
Rf = 0.50 (petrol/EtOAc, 10:1)  
[𝛂]𝐃
𝟐𝟓 = −67.9º (c 0.75, CHCl3)  
IR (neat): 2972, 2929, 2867, 1603, 1567, 1493, 1465, 1400, 1371, 1333, 1310, 1189 cm-1  
1H NMR (500 MHz, CDCl3): δ 6.70 (s, 1H), 6.46 (s, 1H), 6.17 (s, 1H), 4.45 (septet, J = 6.1 
Hz, 1H), 4.34 (septet, J = 6.1 Hz, 1H), 4.26 (septet, J = 6.1 Hz, 1H), 2.68 – 2.64 (m, 1H), 
1.86 – 1.64 (m, 5H), 1.55 – 1.33 (m, 7H), 1.30 (d, J = 6.1 Hz, 6H), 1.29 (d, J = 6.1 Hz, 6H), 
1.25 (d, J = 6.1 Hz, 3H), 1.25 (d, J = 6.1 Hz, 3H), 1.20 (dd, J = 13.4 Hz, J = 13.3 Hz, 1H), 
1.17 (s, 3H), 0.91 (s, 3H), 0.90 (d, J = 7.1 Hz, 3H), 0.88 (s, 3H).  
13C NMR (125 MHz, CDCl3): δ 156.5, 150.2, 147.8, 142.9, 125.0, 122.0, 115.6, 108.8, 
73.0, 72.11, 72.07, 49.5, 42.5, 40.74, 40.73, 39.9, 34.0, 33.3, 32.3, 31.6, 23.1, 22.414, 
22.408, 22.39, 22.30, 22.25, 22.1, 21.7, 19.9, 19.6.  
HRMS (ESI): calculated for C30H48O3 479.3501 [M+Na]+, found 479.3503  
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Data for para-QM 2.140:  
Rf = 0.39 (petrol/EtOAc, 2:1)  
[𝛂]𝐃
𝟐𝟓 = -25º (c 0.2, CHCl3)  
IR (neat): 3253, 2924, 2867, 1626, 1575, 14.54, 1370, 1186, 1106 cm-1  
1H NMR (500 MHz, CDCl3): δ 6.74 (d, J = 11.6 Hz, 1H), 6.37 (s, 1H), 5.72 (s, 1H), 4.46 
(septet, J = 6.0 Hz, 2H), 1.92 – 1.84 (m, 2H), 1.76 – 1.41 (m, 6H), 1.36 (d, J = 6.1 Hz, 6H), 
1.32 (d, J = 6.0, 3H), 1.31 (d, J = 6.0, 3H), 1.24 – 1.02 (m, 4H), 0.99 (s, 3H), 0.92 (m, 1H), 
0.88 (s, 3H), 0.84 (s, 3H), 0.67 (d, J = 6.5, 3H). 
13C NMR (125 MHz, CDCl3): δ 183.1, 161.6, 148.7, 144.6, 129.4, 106.8, 103.8, 71.0, 69.9, 
57.9, 54.9, 42.1, 41.4, 39.2, 36.1, 33.50, 33.47, 32.1, 22.0, 21.7, 21.63, 21.56, 21.49, 21.47, 
21.1, 18.6, 15.1.  
HRMS (ESI): calculated for C27H42O3Na 359.2217 [M+Na]
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para-Phenol 2.141 
 
To a solution of to p-QM 2.140 (200 mg, 0.483 mmol) in ethanol (20 mL) at 0 °C, was added 
NaBH4 (27.4 mg, 0.724 mmol). The resulting reaction mixture was stirred at 0 °C for 2 h. 
The mixture was extracted with ethyl acetate (150 ml) and sequentially washed with 1M HCl 
solution (10 ml), water (2 × 50 ml), and brine (50 ml). The organic extracts were dried over 
MgSO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography on SiO2 (petrol/EtOAc, 8:1) to give para-phenol 2.141 (128 mg, 64%). 
Rf = 0.77 (petrol/EtOAc, 1:2)  
1H NMR (500 MHz, CDCl3): δ 6.75 (s, 1H), 6.48 (s, 1H), 5.50 (br s, 1H), 4.42 (hept, J = 
6.1 Hz, 1H), 4.37 (hept, J = 6.1 Hz, 1H), 2.57 (dd, J = 15.8 Hz, J = 3.0 Hz, 1H), 2.39 (dd, J 
= 15.8 Hz, J = 6.2 Hz, 1H), 1.82 – 1.80 (m, 1H), 1.74 – 1.71 (m, 1H), 1.59 – 1.36 (m, 5H), 
1.33 (d, J = 6.1 Hz, 6H), 1.32 (d, J = 6.1 Hz, 3H), 1.31 (d, J = 6.1 Hz, 3H), 1.30 – 1.26 (m, 
1H), 1.18 – 0.95 (m, 3H), 0.90 (s, 3H), 0.89 – 0.86 (m, 2H), 0.87 (s, 3H), 0.84 (s, 3H), 0.73 
(d, J = 6.4 Hz, 3H).  
13C NMR (125 MHz, CDCl3): δ 149.7, 144.8, 137.7, 125.3, 116.8, 101.5, 73.0, 70.7, 58.4, 
55.5, 42.3, 39.6, 38.6, 37.4, 35.0, 33.61, 33.4, 27.0, 22.34, 22.33, 22.30, 22.28, 21.99, 21.98, 
21.5, 18.9, 14.4. 
[𝛂]𝐃
𝟐𝟓 = -5.6º (c 0.9, CHCl3)  
IR (neat): 3541, 2973, 2930, 2843, 1599, 1504, 1185 cm-1 
HRMS (ESI): calculated for C27H44O3 415.3218 [M-H]
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ortho-QM 2.143 
 
To a solution of THP protected alkene 2.142 (123 mg, 0.24 mmol) in PhMe (4 mL) was 
added p-TsOH·H2O (5 mg, 23.7 μmol) at room temperature. The reaction mixture was 
heated to 90 °C for 15 min and the reaction mixture was cooled to room temperature. The 
mixture was quenched with saturated aqueous NaHCO3 solution (10 mL) and extracted with 
Et2O (3 × 10 mL). The combined organic extracts were dried over MgSO4 and concentrated 
in vacuo. The residue was purified by flash column chromatography on SiO2 (gradient 
elution, petrol/EtOAc, 5:1 → 3:1) to give ortho-QM 2.143 as a yellow film (45.5 mg, 46%). 
Rf = 0.35 (petrol/EtOAc, 4:1)  
1H NMR (500 MHz, CDCl3): δ 7.05 (d, J = 11.0 Hz, 1H), 6.17 (s, 1H), 5.71 (s, 1H), 4.48 
(hept, J = 6.1 Hz, 1H), 4.35 (hept, J = 6.1 Hz, 1H), 1.91 – 1.86 (m, 1H), 1.83 (t, J = 11.0 Hz, 
1H), 1.79 – 1.71 (m, 1H), 1.67 – 1.48 (m, 2H), 1.52–1.49 (m, 1H), 1.43 – 1.30 (m, 4H), 1.36 
(d, J = 6.1 Hz, 6H), 1.34 (d, J = 6.1 Hz, 6H), 1.18 – 1.00 (m, 2H), 1.03 (s, 3H), 0.93 (dd, 
J = 12.5, 2.2 Hz, 1H), 0.88 (s, 3H), 0.84 (s, 3H), 0.66 (d, J = 6.2 Hz, 3H) 
13C NMR (125 MHz, CDCl3): δ 184.3, 164.4, 149.4, 146.0, 133.6, 106.8, 104.8, 71.58, 
71.57, 58.1, 54.9, 42.2, 41.3, 39.3, 36.2, 33.6, 33.5, 31.8, 22.0, 21.7, 21.7, 21.6, 21.6, 21.47, 
21.44, 18.7, 15.2. 
IR (neat): 2925, 2853, 1650, 1619, 1561, 1455, 1425, 1372, 1229 cm−1 
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ortho-Phenol 2.145 
 
To a solution of ortho-QM 2.143 (45 mg, 0.0185 mmol) in ethanol (4 mL) at 0 °C, was added 
NaBH4 (6.2 mg, 0.164 mmol). The resulting reaction mixture was stirred at 0 °C for 2 h. The 
mixture was extracted with ethyl acetate (40 ml) and sequentially washed with 1M HCl 
solution (2 ml), water (2 × 20 ml), and brine (10 ml). Extracts were dried over MgSO4 and 
concentrated in vacuo. The residue was purified by flash column chromatography on SiO2 
(petrol/EtOAc, 8:1) to give ortho-phenol 2.145 (20 mg, 44%). 
Rf = 0.76 (petrol/EtOAc, 1:2)  
[𝛂]𝐃
𝟐𝟓 = -6.7º (c 0.5, CHCl3).  
IR (neat): 3378, 2973, 2930, 2844, 1616, 1514, 1190 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.77 (s, 1H), 6.35 (s, 1H), 4.51 (br s, 1H), 4.42 (hept, J = 
6.1 Hz, 1H), 4.30 (hept, J = 6.1 Hz, 1H), 2.58 (dd, J = 15.8 Hz, J = 2.2 Hz, 1H), 2.25 (dd, J 
= 15.8 Hz, J = 6.5 Hz, 1H), 1.82 – 1.79 (m, 1H), 1.73 – 1.70 (m, 1H), 1.58 – 1.25 (m, 6H), 
1.30 (d, J = 6.1 Hz, 6H), 1.28 (d, J = 6.1 Hz, 6H), 1.22 – 1.13 (m, 2H), 1.04 – 0.90 (m, 3H), 
0.90 (s, 3H), 0.87 (s, 3H), 0.83 (s, 3H), 0.72 (d, J = 6.5 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ 147.8, 142.1, 122.5, 122.3, 105.4, 73.6, 71.7, 57.4, 55.3, 
39.5, 38.6, 42.1, 37.2, 35.2, 33.6, 33.4, 27.3, 22.32, 22.25, 22.21, 21.94, 21.93, 21.4, 18.9, 
14.3. 
HRMS (ESI): calculated for C27H44O3 415.3218 [M-H]
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Alkene 2.139 
 
To a solution of benzyl alcohol 2.138 (1.15 g, 2.42 mmol) in dry PhMe (50 mL) and pyridine 
(3.80 mL, 47.0 mmol), was added POCl3 (0.68 mL, 7.30 mmol) at room temperature. The 
reaction mixture was heated to 80 °C for 1 h and allowed to cool to room temperature. The 
mixture was quenched with saturated aqueous NaHCO3 solution (100 mL) and extracted 
with Et2O (3 × 100 mL). The combined organic extracts were sequentially washed with water 
(3 × 100 mL), brine (50 mL), dried over MgSO4 and concentrated in vacuo. The residue was 
purified by flash column chromatography on SiO2 (petrol/EtOAc, 10:1) to give alkene 2.139 
as a colourless oil (600 mg, 54%). Further elution gave recovered benzyl alcohol 2.138 (410 
mg, 36%).  
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Triphenol 2.147 
 
To a solution of alkene 2.139 (36 mg, 0.081 mmol) and dichloromethyl methyl ether (0.011 
mL, 0.11 mmol) in anhydrous CH2Cl2 (2 mL) at 0 °C, was added BCl3 (1.0 M in CH2Cl2, 
0.5 ml, 0.5 mmol) dropwise. The reaction mixture was stirred at 0 °C for 20 min, then 
quenched with saturated aqueous NaHCO3 solution (10 ml) and extracted with CH2Cl2 (3 × 
10 mL). The combined organic extracts were dried over MgSO4 and concentrated in vacuo. 
The residue was purified by flash column chromatography on SiO2 (petrol/EtOAc, 4:1) to 
give triphenol 2.147 as an amorphous, yellow film (8.6 mg, 32%). 
Rf = 0.41 (petrol/EtOAc, 4:1)  
MP: product begin to decompose at 76 C 
1H NMR (500 MHz, CDCl3): δ 6.52 (s, 1H), 6.44 (s, 1H), 5.97 (s, 1H), 5.21 (br s, 1H), 4.76 
(br s, 1H), 4.66 (br s, 1H), 2.61 – 2.55 (m, 1H), 1.76 – 1.05 (m, 11H), 1.17 (s, 3H), 0.90 (s, 
3H), 0.88 (s, 3H), 0.77 (d, J = 6.9 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ 164.1, 146.7, 143.3, 136.3, 118.2, 116.3, 111.0, 101.9, 
52.1, 42.3, 41.7, 39.2, 34.6, 34.1, 33.8, 33.2, 22.7, 21.7, 21.10, 21.08, 19.5.  
HRMS (ESI): calculated for C21H30O3, 329.2122 [M-H]
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Aryl aldehyde 2.146 
 
To a solution of alkene 2.139 (600 mg, 1.31 mmol) in anhydrous THF (22 mL) and TMEDA 
(0.34 mL, 2.27 mmol) at 0 °C, was added n-BuLi (2.0 M in hexanes, 3.25 mL, 6.50 mmol) 
dropwise. The resultant mixture was stirred at 0 °C for 1 h. DMF (1.0 mL, 12.9 mmol) was 
then added dropwise, and the reaction mixture was allowed to stir for 5 min. The reaction 
was quenched with saturated aqueous NH4Cl solution (40 mL) and extracted with Et2O (2 × 
100 mL). The combined organic extracts were washed with water (3 × 100 mL), brine (2 × 
100 mL), dried over MgSO4 and concentrated in vacuo. The residue was purified by flash 
column chromatography on SiO2 (petrol/EtOAc, 30:1) to give aryl aldehyde 2.146 as a 
colourless oil (410 mg, 65%). Further elution gave recovered alkene 2.139 (140 mg, 23%). 
Rf = 0.31 (petrol/EtOAc, 10:1) 
[𝛂]𝐃
𝟐𝟓 = +9.6º (c 0.50, CHCl3)  
IR (neat): 2973, 2928, 2870, 1696, 1565, 1498, 1453, 1381, 1371, 1332, 1306, 1252, 1224, 
1201, 1106, 1028 cm-1  
1H NMR (500 MHz, CDCl3): δ 10.43 (s, 1H), 6.90 (s, 1H), 6.19 (s, 1H), 4.58 (septet, J = 
6.2 Hz, 1H), 4.47 (septet, J = 6.0 Hz, 1H), 4.31 (septet, J = 6.2 Hz, 1H), 2.68 – 2.62 (m, 1H), 
1.82 – 1.69 (m, 4H), 1.61 – 1.33 (m, 7H), 1.31 (d, J = 6.0 Hz, 6H), 1.29 (d, J = 6.0 Hz, 3H), 
1.27 (d, J = 6.0 Hz, 3H), 1.23 (d, J = 6.2 Hz, 3H), 1.20 (d, J = 6.0 Hz, 3H), 1.17 (s, 3H), 0.91 
(s, 3H), 0.89 (s, 3H), 0.87 (d, J = 7.2 Hz, 3H).  
13C NMR (125 MHz, CDCl3): δ 191.3, 157.3, 150.9, 148.7, 146.0, 130.0, 125.9, 125.7, 
115.2, 76.2, 75.6, 72.3, 50.5, 42.4, 41.1, 39.7, 34.0, 33.3, 32.82, 32.79, 22.5, 22.34, 22.29, 
22.24, 22.21, 21.99, 21.95, 21.71, 20.4, 19.6.  
HRMS (ESI): calculated for C31H48O4Na 507.3450 [M+H]
+, found 507.3456 
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Siphonodictyal B 2.91 
 
To a solution of aryl aldehyde 2.146 (350 mg, 0.72 mmol) in anhydrous CH2Cl2 (12 mL) at 
0 °C, was added BCl3 (1.0 M in CH2Cl2, 3.60 mL, 3.60 mmol) dropwise. The reaction 
mixture was stirred at 0 °C for 20 min, then quenched with saturated aqueous NaHCO3 
solution (40 ml) and extracted with CH2Cl2 (3 × 40 mL). The combined organic extracts 
were dried over MgSO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography on SiO2 (petrol/EtOAc, 8:1) to give siphonodictyal B 2.91 as an amorphous 
yellow solid (200 mg, 77%).  
Rf = 0.31 (petrol/EtOAc, 2:1)  
MP: product begin to decompose at 80 C 
[𝛂]𝐃
𝟐𝟓 = −61.2º (c 0.67, CHCl3)  
IR (neat): 3430, 3128, 2926, 1637, 1617, 1453, 1254 cm-1 
1H NMR (500 MHz, CDCl3): δ 11.46 (s, 1H), 10.31 (s, 1H), 6.84 (s, 1H), 5.92 (s, 1H), 5.43 
(s, 1H), 5.13 (s, 1H), 2.59 (m, 1H), 1.83 – 1.14 (m, 11H), 1.18 (s, 3H), 0.91 (s, 3H), 0.88 (s, 
3H), 0.77 (d, J = 7.0 Hz, 3H).  
13C NMR (125 MHz, CDCl3): δ 194.5, 165.8, 148.5, 147.6, 136.9, 123.7, 116.7, 109.4, 
109.1, 52.4, 42.3, 41.9, 39.2, 34.8, 34.2, 33.9, 33.2, 22.6, 21.7, 21.2, 21.1, 19.4.  
1H NMR (500 MHz, CD3OD): δ 10.34 (s, 1H), 6.81 (s, 1H), 6.05 (s, 1H), 2.65 (m, 1H), 
1.84 – 1.21 (m, 11H), 1.19 (s, 3H), 0.93 (s, 3H), 0.89 (s, 3H), 0.87 (d, J = 7.1 Hz, 3H).  
13C NMR (125 MHz, CD3OD): δ 195.9, 159.8, 152.9, 149.5, 137.3, 127.6, 119.0, 114.4, 
111.5, 51.8, 43.6, 42.2, 40.6, 34.9, 34.2, 34.1, 33.7, 23.2, 22.4, 22.1, 21.6, 20.6.  
1H NMR (500 MHz, DMSO-d6): δ 10.91 (s, 1H), 10.25 (s, 1H), 10.03 (s, 1H), 9.02 (s, 1H), 
6.84 (s, 1H), 6.03 (s, 1H), 2.62 (m, 1H), 1.79 – 1.62 (m, 4H), 1.51 – 1.48 (m, 2H), 1.39 – 
1.27 (s, 5H), 1.12 (s, 3H), 0.88 (s, 3H), 0.87 (d, J = 7.0 Hz, 3H), 0.85 (s, 3H).  
121 |                                                                                                                 A. W. Markwell-Heys 
13C NMR (125 MHz, DMSO-d6): δ 194.8, 157.0, 151.3, 147.8, 136.1, 126.2, 116.6, 113.4, 
110.2, 49.1, 41.9, 40.4, 39.1, 33.6, 33.0, 31.8, 31.2, 22.9, 21.9, 21.5, 19.4, 19.0.  
HRMS (ESI): calculated for C22H29O4 357.2071 [M−H]
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Benzyl alcohol 2.148 
 
To a solution of aryl bromide 2.116 (2.80 g, 8.45 mmol) in anhydrous THF (15 mL), t-BuLi 
(1.0 M in pentane, 7.80 mL, 7.80 mmol) was added dropwise at -78 °C and the reaction 
mixture was stirred at this temperature for 1 h. A solution of aldehyde 2.136 (900 mg, 4.05 
mmol) in anhydrous THF (15 mL) was then added dropwise over 10 min at -78 °C. The 
reaction mixture was stirred at -78 °C for a further 1 h, and then allowed to warm to room 
temperature. The reaction mixture was quenched with saturated aqueous NH4Cl solution (50 
mL) and extracted with Et2O (2 × 100 mL). The combined organic extracts were dried over 
MgSO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography on SiO2 (petrol/EtOAc, 10:1) to give benzyl alcohol 2.148 as a white solid 
(1.58 g, 82%). 1H NMR showed a mixture of two diastereoisomers, therefore 2.148 was not 
fully characterized.  
Rf = 0.53 (petrol/EtOAc, 10:1)  
IR (neat): 2973, 2929, 1591, 1493, 1361, 1190 cm-1  
HRMS (EI): calculated for C30H48O3 456.3603 [M−H2O]
+, found 456.3615  
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Alkene 2.149 
 
To a solution of benzyl alcohol 2.148 (1.58 g, 3.33 mmol) in PhMe (50 mL) was added p-
TsOH·H2O (63 mg, 0.33 mmol) at room temperature. The reaction mixture was heated at 80 
°C for 15 min, followed by cooling to room temperature. The reaction mixture was then 
quenched with saturated aqueous NaHCO3 solution (100 mL) and extracted with EtOAc (2 
× 150 mL). The combined organic extracts were sequentially washed with water (100 mL), 
brine (100 mL), dried over MgSO4 and concentrated in vacuo. The residue was purified by 
flash column chromatography on SiO2 (petrol/EtOAc, 10:1) to give alkene 2.149 as a 
colourless oil (1.15 g, 76%).  
Data for 2.149:  
Rf = 0.56 (petrol/EtOAc, 10:1)  
[𝛂]𝐃
𝟐𝟓 = +56.0º (c 0.24, CHCl3)  
IR (neat): 2972, 2929, 2867, 1603, 1567, 1493, 1465, 1400, 1371, 1333, 1310, 1189 cm-1  
1H NMR (500 MHz, CDCl3): δ 6.73 (s, 1H), 6.51 (s, 1H), 6.16 (s, 1H), 4.45 (septet, J = 6.1 
Hz, 1H), 4.33 (septet, J = 6.1 Hz, 1H), 4.22 (septet, J = 6.1 Hz, 1H), 3.03 (m, 1H), 1.81 – 
1.60 (m, 3H), 1.54 – 1.40 (m, 7H), 1.32 (d, J = 6.0 Hz, 3H), 1.30 (d, J = 6.3 Hz, 3H) 1.30 (d, 
J = 6.1 Hz, 3H), 1.28 (m, 3H), 1.27 (d, J = 6.1 Hz, 3H), 1.25 (d, J = 6.0 Hz, 3H), 1.23 (d, J 
= 7.5 Hz, 3H), 1.19 (s, 3H), 0.99 (dd, J = 11.8 Hz, J = 11.9 Hz, 1H), 0.89 (s, 3H), 0.88 (s, 
3H). 
13C NMR (125 MHz, CDCl3): δ 155.3, 150.7, 147.8, 143.3, 124.5, 121.0, 115.7, 109.5, 
73.1, 72.9, 72.2, 54.8, 42.3, 40.9, 38.7, 34.1, 34.0, 33.5, 30.8, 22.8, 22.6, 22.5, 22.40, 22.35, 
22.30, 22.28, 22.25, 21.8, 19.0, 17.9. 
HRMS (EI): calculated for C30H48O3 456.3603 [M]
+, found 456.3600  
 
 
124 |                                                                                                                 A. W. Markwell-Heys 
Aldehyde 2.150 
 
To a solution of alkene 2.149 (1.15 g, 2.52 mmol) in anhydrous THF (42 mL) and TMEDA 
(0.76 mL. 5.07 mmol) at 0 °C, was added n-BuLi (2.0 M in hexanes, 6.30 mL, 12.6 mmol) 
dropwise. The resultant mixture was stirred at 0 °C for 1 h. DMF (2.0 mL, 25.8 mmol) was 
then added dropwise, and the reaction mixture was allowed to stir for 5 min. The reaction 
was quenched with saturated aqueous NH4Cl solution (70 mL) and extracted with Et2O (2 × 
200 mL). The combined organic extracts were washed with water (3 × 200 mL), brine (2 × 
200 mL), dried over MgSO4 and concentrated in vacuo. The residue was purified by flash 
column chromatography on SiO2 (petrol/EtOAc, 30:1) to give aldehyde 2.150 as a colourless 
oil (628 mg, 52%). Further purification gave recovered alkene 2.149 (368 mg, 32%).  
Rf = 0.47 (petrol/EtOAc, 10:1)  
[𝛂]𝐃
𝟐𝟓 = −53.0º (c 0.8, CHCl3)  
IR (neat): 2973, 2928, 2870, 1696, 1565, 1498, 1453, 1381, 1371, 1332, 1306, 1252, 1224, 
1201, 1106, 1028 cm-1  
1H NMR (500 MHz, CDCl3): δ 10.44 (s, 1H), 6.93 (s, 1H), 6.19 (s, 1H), 4.59 (septet, J = 
6.2 Hz, 1H), 4.46 (septet, J = 6.0 Hz, 1H), 4.23 (septet, J = 6.2 Hz, 1H), 2.99 (m, 1H), 1.81 
– 1.40 (m, 11H), 1.33 (d, J = 6.0 Hz, 6H), 1.30 (d, J = 6.2 Hz, 3H), 1.28 (d, J = 6.1 Hz, 3H), 
1.25 (d, J = 6.8 Hz, 6H), 1.25 (d, J = 6.8 Hz, 3H), 1.22 (d, J = 8.0 Hz, 3H), 1.20 (s, 3H), 0.90 
(s, 3H), 0.89 (s, 3H). 
13C NMR (125 MHz, CDCl3): δ 191.2, 156.3, 151.2, 148.8, 146.4, 129.3, 125.8, 124.5, 
116.0, 76.7, 76.3, 72.1, 54.9, 42.3, 41.1, 38.7, 34.1, 34.0, 33.5, 31.2, 22.7, 22.37, 22.35, 
22.27, 22.25, 22.0, 21.8, 18.9, 17.8. 
HRMS (ESI): calculated for C31H49O4 485.3631 [M+H]
+, found 485.3636 
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8-epi-Siphonodictyal B 2.1 
 
To a solution of aldehyde 2.150 (173 mg, 0.357 mmol) in anhydrous CH2Cl2 (6 mL) at 0 °C, 
was added BCl3 (1.0 M in CH2Cl2, 1.80 mL, 1.80 mmol) dropwise. The reaction mixture 
was stirred at 0 °C for 20 min, then quenched with saturated aqueous NaHCO3 solution (20 
ml) and extracted with CH2Cl2 (3 × 20 mL). The combined organic extracts were dried over 
MgSO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography on SiO2 (petrol/EtOAc, 8:1) to give 8-epi-siphonodictyal B 2.1 as an 
amorphous yellow solid (93 mg, 72 %).  
Rf = 0.32 (petrol/EtOAc, 2:1)  
MP: product begin to decompose at 80 C 
[𝛂]𝐃
𝟐𝟓  = +5.3º (c 0.75, CHCl3)  
IR (neat): 3331, 2923, 2854, 1642, 1603, 1453, 1261 cm-1  
1H NMR (500 MHz, CDCl3): δ 11.35 (s, 1H), 10.33 (s, 1H), 6.84 (s, 1H), 5.85 (s, 1H), 5.55 
(s, 1H), 5.09 (s, 1H), 2.72 (m, 1H), 1.86 – 1.58 (m, 7H), 1.54 – 1.41 (m, 4H), 1.22 (s, 3H), 
1.11 (d, J = 7.5 Hz, 3H), 0.91 (s, 6H). 
13C NMR (125 MHz, CDCl3): δ 194.5, 165.94, 148.7, 147.6, 137.1, 123.5, 115.6, 110.7, 
109.3, 55.1, 42.0, 41.3, 38.8, 34.2, 34.0, 33.4, 31.7, 22.7, 22.5, 21.8, 18.8, 17.8. 
1H NMR (500 MHz, CD3OD): δ 10.38 (s, 1H), 6.90 (s, 1H), 6.08 (s, 1H), 2.97 (quintet, J = 
6.7 Hz, 1H), 1.83 – 1.29 (m, 11H), 1.25 (d, J = 6.4 Hz, 3H), 1.25 (s, 3H), 0.95 (s, 3H), 0.92 
(s, 3H). 
13C NMR (125 MHz, CD3OD): δ 195.9, 158.5, 153.5, 149.6, 137.5, 126.9, 118.0, 114.9, 
111.7, 55.9, 43.3, 42.1, 39.7, 35.2, 34.9, 33.9, 32.4, 23.3, 23.24, 22.23, 19.9, 19.0. 
1H NMR (500 MHz, DMSO-d6): δ 11.01 (s, 1H), 10.26 (s, 1H), 10.07 (s, 1H), 9.11 (s, 1H), 
6.91 (s, 1H), 6.01 (s, 1H), 3.35 (quintet, J = 6.9 Hz, 1H), 1.73 – 1.39 (m, 11H), 1.22 (d, J = 
7.4 Hz, 3H), 1.15 (s, 3H), 0.86 (s, 3H), 0.86 (s, 3H). 
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13C NMR (125 MHz, DMSO-d6): 194.8, 155.5, 151.8, 148.0, 136.3, 125.5, 115.6, 113.3, 
110.4, 54.2, 41.7, 40.5, 38.1, 33.7, 33.6, 33.2, 30.5, 22.7, 22.4, 21.6, 18.4, 17.4.  
HRMS (ESI): calculated for C22H31O4 359.2217 [M+H]
























127 |                                                                                                                 A. W. Markwell-Heys 
Methoxy-siphonodictyal B 2.151 
 
To a solution of siphonodictyal B 2.91 (15 mg, 0.042 mmol) and K2CO3 (75 mg, 0.54 mmol) 
in dry acetone (10 mL) at room temperature, was added MeI (0.30 mL, 4.82 mmol). The 
reaction mixture was heated at reflux for 8 h, then allowed to cool to room temperature and 
quenched with 1 M aqueous HCl solution (10 mL). The mixture was extracted with Et2O (30 
mL), followed by washing with water (30 mL) and brine (20 mL) before being dried over 
MgSO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography on SiO2 (petrol/EtOAc, 10:1) to give methoxy-siphonodictyal B 2.151 as a 
colourless oil (3.5 mg, 21%).  
Rf = 0.50 (petrol/EtOAc, 4:1)  
[𝛂]𝐃
𝟐𝟓= −129.6º (c 0.28, CHCl3)  
IR (neat): 2928, 2868, 1695, 1476, 1388, 1228 cm-1  
1H NMR (500 MHz, CDCl3): δ 10.40 (s, 1H), 6.91 (s, 1H), 6.21 (s, 1H), 3.91 (s, 3H), 3.85 
(s, 3H), 3.72 (s, 3H), 2.66 (m, 1H), 1.86 – 1.24 (m, 11H), 1.19 (s, 3H), 0.91 (s, 3H), 0.90 (d, 
J = 6.5 Hz, 3H), 0.89 (s, 3H). 
13C NMR (125 MHz, CDCl3): δ 190.3, 158.7, 152.0, 149.4, 148.3, 130.4, 123.5, 120.6, 
114.0, 62.1, 61.6, 56.5, 50.1, 42.4, 41.0, 39.7, 34.0, 33.2, 32.7, 32.4, 22.8, 22.2, 21.7, 20.2, 
19.5. 
1H NMR (500 MHz, C6D6): δ 10.60 (s, 1H), 6.82 (s, 1H), 6.31 (s, 1H), 3.74 (s, 3H), 3.61 
(s, 3H), 3.29 (s, 3H), 2.63 (m, 1H), 1.79 (m, 1H), 1.73 – 1.27 (m, 10H), 1.15 (s, 3H), 0.97 
(d, J = 7.1 Hz, 3H), 0.89 (s, 3H), 0.88 (s, 3H). 
13C NMR (125 MHz, C6D6): δ 189.3, 158.4, 152.3, 150.4, 148.9, 130.5, 125.1, 120.4, 114.9, 
61.8, 61.7, 56.1, 50.7, 42.7, 41.3, 40.0, 34.1, 33.5, 33.2, 32.9, 22.9, 22.4, 21.9, 20.6, 19.9 
HRMS (ESI): calculated for C25H36O4Na 423.2511 [M+Na]
+, found 423.2505 
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Methoxy-8-epi-siphonodictyal B 2.12 
 
To a solution of 8-epi-siphonodictyal B 2.1 (10 mg, 0.028 mmol) and K2CO3 (50 mg, 0.362 
mmol) in dry acetone (10 mL) at room temperature, was added MeI (0.10 mL, 1.61 mmol). 
The reaction mixture was heated at reflux for 8 h, then allowed to cool to room temperature 
and quenched with 1 M HCl solution (10 mL). The mixture was extracted with Et2O (30 
mL), followed by washing with water (30 mL) and brine (20 mL) before being dried over 
MgSO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography on SiO2 (petrol/EtOAc, 10:1) to give methoxy-8-epi-siphonodictyal B 2.12 
as a colourless oil (5 mg, 45%).  
Rf = 0.70 (petrol/EtOAc, 4:1)  
[𝛂]𝐃
𝟐𝟓 = +100.0º (c 0.16, CHCl3)  
IR (neat): 2942, 2853, 1674, 1566, 1498, 1371, 1234 cm-1  
1H NMR (500 MHz, CDCl3): δ 10.43 (s, 1H), 6.95 (s, 1H), 6.21 (s, 1H), 3.93 (s, 3H), 3.86 
(s, 3H), 3.74 (s, 3H), 2.96 (quintet, J = 6.7 Hz, 1H), 1.83 – 1.44 (m, 9H), 1.28 (d, J = 7.5 Hz, 
3H), 1.27 – 1.25 (m, 1H), 1.23 (s, 3H), 0.99 (d, J = 11.0 Hz, 1H), 0.92 (s, 3H), 0.90 (s, 3H). 
13C NMR (125 MHz, CDCl3): δ 190.2, 157.9, 152.7, 149.4, 148.6, 129.4, 123.7, 119.9, 
114.5, 62.1, 56.4, 54.9, 42.1, 41.0, 38.7, 34.1, 34.0, 33.4, 31.2, 29.7, 22.8, 22.4, 21.9, 18.9, 
17.8.  
1H NMR (500 MHz, C6D6): 10.60 (s, 1H), 6.84 (s, 1H), 6.36 (s, 1H), 3.74 (s, 3H), 3.62 (s, 
3H), 3.33 (s, 3H), 3.01 (m, 1H), 1.78 – 1.26 (m, 11H), 1.19 (s, 3H), 1.18 (d, J = 7 Hz, 3H), 
0.89 (s, 3H), 0.88 (s, 3H).  
13C NMR (125 MHz, C6D6): δ 189.2, 157.6, 153.1, 150.3, 149.2, 129.5, 125.4, 119.8, 115.6, 
62.0, 61.7, 56.0, 55.3, 42.5, 41.3, 39.1, 34.5, 34.2, 33.6, 31.7, 22.9, 22.7, 22.1, 19.3, 18.2.  
HRMS (ESI): calculated for C25H36O4Na 423.2506 [M+Na]
+, found 423.2511 
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Ring expansion ketones 2.153 & 2.154 
 
To a solution of alkene 2.139 (33.7 mg, 0.0738 mmol) and NaHCO3 (9.4 mg, 0.154 mmol) 
in CH2Cl2 (5 mL) at 0 °C, was added m-CPBA (21.0 mg, 0.1217 mmol) in one portion. The 
resulting reaction mixture was stirred at 0 °C for 40 mins. TFA (0.03 ml, 5.13 mmol) was 
added dropwise to the reaction mixture, and was stirred at 0 °C for a further 40 min. The 
reaction mixture was quenched with saturated aqueous Na2CO3 solution (10ml), followed 
by extraction with EtOAc (100ml). The organic extracts were sequentially washed with 
water (25 mL), brine (10 mL), dried over MgSO4 and concentrated in vacuo. The residue 
was purified by flash column chromatography on SiO2 (petrol/EtOAc, 10:1) to give ketones 
2.153 (10 mg, 29%) and 2.154 (5 mg, 14%) as white, gum-wax like solids. 
Ring expanded ketone 2.153 
Rf = 0.39 (petrol/EtOAc, 10:1)  
IR (neat): 2972, 2927, 2868, 1703, 1606, 1498, 1370 cm-1 
1H NMR (500 MHz, CDCl3): δ 7.42 (s, 1H), 6.43 (s, 1H), 4.70 (s, 1H), 4.45 (sep, J = 6.1 
Hz, 1H), 4.37 (sep, J = 5.6 Hz, 2H), 2.43 – 2.39 (m, 1H), 2.08 – 2.02 (m, 1H) 1.98 – 1.94 
(m, 1H), 1.53 – 0.85 (m, 9H), 1.37 (d, J = 6.0 Hz, 3H ), 1.33 – 1.26 (m, 9H), 1.30 (d, J = 6.6 
Hz, 6H ), 1.03 (d, J = 7.1 Hz, 3H), 0.99 (s, 3H), 0.96 (s, 3H), 0.79 (s, 3H). 
13C NMR (125 MHz, CDCl3): δ 216.0, 150.1, 147.7, 142.2, 122.7, 121.0, 105.2, 72.7, 72.3, 
70.7, 62.6, 53.0, 49.8, 42.2, 41.3, 38.2, 35.2, 34.2 29.7, 24.6, 22.56, 22.50, 22.45, 22.42, 
22.34, 22.33, 21.8, 19.5, 19.1, 17.5. 
[𝛂]𝐃
𝟐𝟓 = -88.2º (c 0.5, CHCl3) 
HRMS (ESI): calculated for C30H48O4 473.3625 [M+H]
+, found 473.3624 
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Ring expanded ketone 2.154 
Rf = 0.45 (petrol/EtOAc, 10:1)  
IR (neat): 2971, 2928, 2870, 1708, 1606, 1499, 1371 cm-1 
1H NMR (500 MHz, CDCl3): δ 7.59 (s, 1H), 6.44 (s, 1H), 4.75 (s, 1H), 4.45 (sep, J = 6.0 
Hz, 1H), 4.37 (sep, J = 6.0 Hz, 2H), 2.70 – 2.63 (m, 1H), 2.23 – 2.19 (m, 1H), 1.79 – 0.84 
(m, 10H), 1.34 – 1.26 (m, 18H), 0.95 (d, J = 6.2 Hz, 3H), 0.86 (s, 3H), 0.85 (s, 3H), 0.84 (s, 
3H).  
13C NMR (125 MHz, CDCl3): δ 215.3, 150.8, 147.9, 142.0, 123.3, 117.6, 105.0, 72.6, 72.5, 
70.7, 55.9, 54.1, 49.4, 41.3, 41.2, 37.1, 33.6, 32.9, 22.70, 22.54, 22.46, 22.41, 22.35, 22.32, 
22.21, 21.7, 20.1, 19.0, 16.1. 
HRMS (ESI): calculated for C30H48O4 473.3625 [M+H]
+, found 473.3634. 
[𝛂]𝐃
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Triphenol 2.147 
 
To a solution of alkene 2.139 (266 mg, 0.582 mmol) in anhydrous CH2Cl2 (20 mL) at 0 °C, 
was added BCl3 (1.0 M in CH2Cl2, 1.9 ml, 1.9 mmol) dropwise. The reaction mixture was 
stirred at 0 °C for 20 min, then quenched with saturated aqueous NaHCO3 solution (16 ml) 
and extracted with CH2Cl2 (3 × 50 mL). The combined organic extracts were dried over 
MgSO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography on SiO2 (petrol/EtOAc, 4:1) to give triphenol 2.147 as an amorphous, 
yellow solid (110 mg, 57%). 
Rf = 0.41 (petrol/EtOAc, 4:1)  
MP: product begin to decompose at 76 C 
1H NMR (500 MHz, CDCl3): δ 6.52 (s, 1H), 6.44 (s, 1H), 5.97 (s, 1H), 5.21 (br s, 1H), 4.76 
(br s, 1H), 4.66 (br s, 1H), 2.61 – 2.55 (m, 1H), 1.76 – 1.05 (m, 11H), 1.17 (s, 3H), 0.90 (s, 
3H), 0.88 (s, 3H), 0.77 (d, J = 6.9 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ 164.1, 146.7, 143.3, 136.3, 118.2, 116.3, 111.0, 101.9, 
52.1, 42.3, 41.7, 39.2, 34.6, 34.1, 33.8, 33.2, 22.7, 21.7, 21.10, 21.08, 19.5. 
 
HRMS (ESI): calculated for C21H30O3, 329.2122 [M-H]
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Spirocycles 2.159 & 2.160 
 
To a solution of triphenol 2.147 (20.0 mg, 0.0605 mmol) in CH2Cl2 (4 mL) at 40 °C, was 
added VO(acac)2 (1.6 mg, 0.00605 mmol) and t-BuOOH (5.0 M in decane, 0.03 mL, 0.15 
mmol). The resulting reaction mixture was stirred at 40 °C for 60 min, before the mixture 
was cooled to room temperature. TFA (0.05 ml, 0.653 mmol) was added to the reaction 
mixture, and was stirred at room temperature for 5 min before being quenched with saturated 
aqueous NaHCO3 solution (2 ml). The mixture was extracted with ethyl acetate (50 ml), and 
the organic phase was washed sequentially with water (2 × 50ml), brine (20 ml). Extracts 
were dried over MgSO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography on SiO2 (petrol/EtOAc, 8:1) to give the product as a brown solid, 
spirocycles 2.159 & 2.160 a mixture of diastereoisomers in a 1:2 ratio respectively (9.0 mg, 
45%). 
Rf = 0.21 (petrol/EtOAc, 2:1)  
NMR data for spirocycle 2.159; 
1H NMR (500 MHz, CDCl3): δ 7.41 (br s, 1H), 7.21 (s, 1H), 6.36 (s, 1H), 5.91 (s, 1H), 2.49 
– 2.41 (m, 1H), 1.94 – 1.91 (m, 1H), 1.78 – 1.70 (m, 1H), 1.58 – 1.19 (m, 9H), 1.25 (s, 3H), 
0.92 (s, 3H), 0.88 (s, 3H), 0.55 (d, J = 6.5 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ 181.7, 175.4, 150.7, 143.3, 131.5, 108.8, 96.7, 95.5, 51.9, 
44.2, 41.8, 35.51, 33.70, 33.48, 33.35, 29.7, 21.86, 21.54, 18.3, 16.2, 15.5. 
NMR data for spirocycle 2.160; 
1H NMR (500 MHz, CDCl3): δ 7.41 (br s, 1H), 6.96 (s, 1H), 6.31 (s, 1H), 5.98 (s, 1H), 2.34 
– 2.27 (m, 1H), 1.78 – 1.70 (m, 2H), 1.64 – 1.62 (m, 1H), 1.58 – 0.93 (m, 8H), 1.21 (s, 3H), 
0.93 (s, 3H), 0.86 (s, 3H), 0.56 (d, J = 6.6 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ 181.7, 175.4, 150.7, 145.5, 131.3, 107.1, 96.6, 95.7, 47.3, 
43.5, 41.4, 34.0, 33.68, 33.29, 32.7, 32.1, 21.90, 21.46, 19.0, 18.2, 15.6. 
HRMS (ESI): calculated for C21H28O3, 329.2111 [M+H]
+, found 329.2115 
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Analogue 2.158 
 
To a solution of triphenol 2.147 (35.0 mg, 0.1059 mmol) and NaHCO3 (15.2 mg, 0.181 
mmol) in CHCl3 (4 mL) at 0 °C, was added m-CPBA (28.5 mg, 0.165 mmol) in one portion. 
The resulting reaction mixture was stirred at 0 °C for 30 min, before cooling the mixture to 
-20 °C. TFA (0.1 mL, 1.307 mmol) was added dropwise to the reaction mixture at -20 °C, 
followed by slowly warming the mixture to 0 °C, over 30 min. The reaction was quenched 
with saturated aqueous NaHCO3 solution (10 mL) and extracted with Et2O (2 × 30 mL). The 
organic extracts were washed sequentially with water (2 × 50 mL), brine (30 mL). Extracts 
were dried over MgSO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography on SiO2 (petrol/EtOAc, 8:1) to give liphagal analogue 2.158 as yellow solid 
(13.8 mg, 40%). 
Rf = 0.43 (petrol/EtOAc, 2:1)  
1H NMR (500 MHz, CDCl3): δ 7.20 (s, 1H), 6.90 (s, 1H), 5.33 (br s, 1H), 5.01 (br s, 1H), 
3.17 – 3.13 (m, 1H), 2.57 – 2.54 (m, 1H), 2.16 – 2.13 (m, 1H), 1.84 – 1.17 (m, 9H), 1.40 (d, 
J = 7.2 Hz, 3H), 1.34 (s, 3H), 0.97 (s, 3H), 0.94 (s, 3H). 
13C NMR (125 MHz, CDCl3): δ 156.1, 148.4, 140.8, 138.8, 125.1, 121.4, 108.1, 97.7, 
53.6, 42.0, 40.2, 34.8, 33.6, 33.3, 33.2, 29.7, 24.2, 22.0, 21.8, 20.1, 18.8. 
 
HRMS (ESI): calculated for C21H28O3, 329.2111 [M+H]
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Liphagal 2.2 
 
To a solution of siphonodictyal B 2.91 (20 mg, 0.056 mmol) and NaHCO3 (8 mg, 0.095 
mmol) in CCl4 (2 mL) at 0 °C, was added m-CPBA (14 mg, 0.062 mmol) in one portion and 
the resulting mixture was stirred at 0 °C for 1 h. TFA (0.04 mL, 0.52 mmol) was then added 
dropwise, and the reaction mixture was allowed to slowly warm to room temperature over 
30 min, and stirred for a further 2 h. The mixture was quenched with saturated aqueous 
NaHCO3 solution (20 mL) and extracted with Et2O (2 × 50 mL). The combined organic 
extracts were sequentially washed with water (50 mL), brine (50 mL) then dried over MgSO4 
and concentrated in vacuo. The residue was purified by flash column chromatography on 
SiO2 (petrol/EtOAc, 8:1) to give liphagal 2.2 as a yellow solid (8.3 mg, 42%).  
Rf = 0.45 (petrol/EtOAc, 10:1)  
[𝛂]𝐃
𝟐𝟓  = +22.6 (c 0.50, CHCl3), lit. [𝛂]𝐃
𝟐𝟓  = +25.99 (c 0.072, CHCl3)  
IR (neat): 3417, 2930, 2868, 1654, 1455, 1389, 1328, 1301 cm-1 
1H NMR (500 MHz, CDCl3): δ 11.24 (s, 1H), 10.44 (s, 1H), 7.55 (s, 1H), 5.32 (s, 1H), 3.21 
(sextet, J = 7.0 Hz, 1H), 2.54 (m, 1H), 2.18 (m, 1H), 1.87 (m, 1H), 1.71 (m, 1H), 1.64 – 1.45 
(m, 6H), 1.43 (d, J = 7.0 Hz, 3H), 1.35 (s, 3H), 1.25 (ddd, J = 13.0, 13.0, 3.0 Hz, 1H), 0.98 
(s, 3H), 0.95 (s, 3H). 
13C NMR (125 MHz, CDCl3): δ 192.6, 156.7, 148.2, 145.5, 139.6, 125.7, 120.5, 116.2, 
106.5, 53.9, 42.1, 40.5, 39.7, 35.4, 35.0, 33.9, 33.5, 24.4, 22.2, 21.9, 20.4, 19.0. 
HRMS (ESI): calculated for C22H29O4 357.2066 [M+H]
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8-epi-Liphagal 2.163 
 
To a solution of 8-epi-siphonodictyal B 2.1 (27 mg, 0.075 mmol) and NaHCO3 (11 mg, 0.13 
mmol) in CCl4 (1 mL) at 0 °C, was added m-CPBA (17 mg, 0.075 mmol) in one portion and 
the resulting mixture was stirred at 0 °C for 1 h. TFA (0.10 mL, 1.31 mmol) was then added 
dropwise, and the reaction mixture was allowed to warm to room temperature over 30 min, 
and stirred for a further 2 h. The mixture was quenched with saturated aqueous NaHCO3 
solution (20 mL) and extracted with Et2O (2 × 30 mL). The combined organic extracts were 
sequentially washed with water (50 mL), brine (50 mL) then dried over MgSO4 and 
concentrated in vacuo. The residue was purified by flash column chromatography on SiO2 
(petrol/EtOAc, 8:1) to give 8-epi-liphagal 2.163 as a yellow solid (11 mg, 41%).  
Rf = 0.60 (petrol/EtOAc, 2:1)  
[𝛂]𝐃
𝟐𝟓 = +86.4 (c 0.22, CHCl3)  
IR (neat): 3374, 2927, 2866, 1652, 1454, 1330, 1300, 1188 cm-1  
1H NMR (500 MHz, CDCl3): δ 11.24 (s, 1H), 10.46 (s, 1H), 7.51 (s, 1H), 5.34 (s, 1H), 3.33 
– 3.29 (m, 1H), 2.53 – 2.50 (m, 1H), 2.06 – 1.65 (m, 8H), 1.52 – 142 (m, 2H), 1.39 (s, 3H), 
1.37 (d, J = 6.9 Hz, 3H), 1.00 (s, 3H), 0.97 (s, 3H). 
13C NMR (125 MHz, CDCl3): δ 192.4, 155.3, 147.7, 145.3, 139.5, 124.9, 120.4, 115.5, 
106.4, 50.4, 42.0, 40.2, 39.2, 35.9, 34.6, 33.8, 31.1, 22.8, 22.3, 20.4, 18.8, 18.7.  
HRMS (ESI): calculated for C22H27O4 355.1915 [M−H]
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Corallidictyals A (2.3) and B (2.4) 
 
To a solution of siphonodictyal B 2.91 (7.0 mg, 0.0195 mmol) in benzene (6 mL) at room 
temperature, was added Ag2CO3 (21.5 mg, 0.0780 mmol) and Celite
TM (50 mg). The 
resulting reaction mixture was stirred at room temperature for 90 min. The mixture was 
diluted with diethyl ether (50 ml), filtered through a pad of CeliteTM and concentrated in 
vacuo to give a brown solid, corallidictyals A 2.3 and B 2.4 as a mixture of diastereoisomers 
in a 1:2 ratio respectively (6.1 mg, 88%). 
Rf = 0.58 (petrol/EtOAc, 1:1)  
NMR data for corallidictyal A 2.3; 
1H NMR (500 MHz, CDCl3): δ 10.26 (s, 1H), 7.50 (s, 1H), 7.41 (br s, 1H), 6.48 (s, 1H), 
2.65 – 2.60 (m, 1H), 2.02 – 0.81 (m, 10H), 1.35 (s, 3H), 1.24 (d, J = 4.75 Hz, 1H), 0.93 (s, 
3H), 0.90 (s, 3H), 0.54 (d, J = 6.6 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ 186.6, 180.3, 175.8, 150.31, 147.8, 131.7, 113.1, 107.72, 
98.4, 52.3, 44.9, 41.7, 35.5, 33.8, 33.7, 33.51, 33.48, 29.7, 21.87, 21.49, 16.4, 15.5. 
NMR data for corallidictyal B 2.4; 
1H NMR (500 MHz, CDCl3): δ 10.30 (s, 1H), 7.41 (br s, 1H), 7.24 (s, 1H), 6.43 (s, 1H), 
2.45 – 2.39 (m, 1H), 1.83 – 0.81 (m, 10H), 1.74 (dd, J = 2.3, 12.75 Hz, 1H), 1.27 (s, 3H), 
0.95 (s, 3H), 0.87 (s, 3H), 0.55 (d, J = 6.5 Hz, 3H). 
 
13C NMR (125 MHz, CDCl3): δ 186.2, 180.0, 177.0, 150.26, 149.8, 130.8, 111.2, 107.68, 
98.2, 47.3, 44.0, 41.2, 34.2, 33.7, 33.31, 33.30, 32.0, 30.4, 21.89, 21.47, 19.4, 15.6. 
IR (neat): 3322, 2927, 2856, 1692, 1643, 1598, 1566 cm-1 
HRMS (ESI): calculated for C22H28O4, 355.1915 [M-H]
-, found 355.1911 
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Corallidictyals A (2.3) and B (2.4) 
 
To a solution of siphonodictyal B 2.91 (10.0 mg, 0.0279 mmol) in benzene (8 mL) at room 
temperature, was added Ag2O (12.9 mg, 0.056 mmol) and Celite
TM (50 mg). The resulting 
reaction mixture was stirred at room temperature for 90 min. The mixture was diluted with 
diethyl ether (50 ml), filtered through a pad of CeliteTM and concentrated in vacuo to give a 
brown solid, corallidictyals A 2.3 and B 2.4 as a mixture of diastereoisomers in a 1:2 ratio 
respectively (5.1 mg, 51%). 
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Corallidictyals A (2.3) and B (2.4) 
 
To a solution of siphonodictyal B 2.91 (10.0 mg, 0.0279 mmol) in CH2Cl2 (6 mL) at room 
temperature, was added chloranil (73.0 mg, 0.297 mmol). The resulting reaction mixture was 
stirred at room temperature for 24 h. The reaction mixture was concentrated in vacuo and 
the residue was purified by flash column chromatography on SiO2 (petrol/ethyl acetate, 8:1) 
to give a yellow solid, corallidictyals A 2.3 and B 2.4 as a mixture of diastereoisomers in a 
1:2 ratio respectively (6.2 mg, 62%). 
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Corallidictyals A (2.3) and B (2.4) 
 
A solution of Siphonodictyal B 2.91 (55.8 mg, 0.156 mmol) in MeOH (30 mL) at room 
temperature was stirred under an atmosphere of pure oxygen via a breathable bladder. The 
solution was stirred at room temperature for 8 days, followed by concentration in vacuo and 
purified by flash column chromatography on SiO2 (petrol/ethyl acetate, 4:1) to give an 
inseparable mixture of corallidictyals A 2.3 and B 2.4 in a ratio of 1:2 ratio respectively as a 
light brown solid (16.3 mg, 29 %). 
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Corallidictyals C (2.5) and D (2.6) 
 
To a solution of siphonodictyal B 2.91 (7 mg, 0.0195 mmol) in CH2Cl2 (10 mL) at room 
temperature, was added p-TsOH·H2O (5.2 mg, 0.0302 mmol) in one portion. The resulting 
reaction mixture was stirred at room temperature under a nitrogen atmosphere for 3 days. 
The mixture was extracted with diethyl ether (50 ml) and the combined organic extracts were 
sequentially washed with aqueous Na2CO3 solution (10 ml), water (25 mL), brine (10 mL), 
dried over MgSO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography on SiO2 (petrol/diethyl ether, 3:1) to give corallidictyal C 2.5, corallidictyal 
D 2.6 and an unknown isomer as an inseparable mixture in a ratio of 1:1:0.5 respectively, as 
a yellow solid (5.2 mg, 74%). 
Rf = 0.75 (petrol/EtOAc, 1:1)  
NMR data for corallidictyal C 2.5; 
1H NMR (500 MHz, DMSO-d6): δ 10.53 (br s, 1H), 10.08 (s, 1H), 8.66 (br s, 1H), 6.94 (s, 
1H), 3.05 (d, J = 16.6 Hz, 1H), 2.85 (d, J = 16.6 Hz, 1H), 2.22 – 2.15 (m, 1H), 1.63 – 1.00 
(m, 10H), 1.13 (s, 3H), 1.04 (dd, J = 3.1 Hz, J = 12.5 Hz, 1H), 0.85 (s, 3H), 0.82 (s, 3H), 
0.68 (d, J = 6.6 Hz, 3H). 
13C NMR (125 MHz, DMSO-d6): δ 191.7, 155.0, 147.0, 137.3, 120.6, 117.2, 106.14, 99.8, 
47.1, 43.0, 41.2, 34.6, 33.17, 32.6, 30.5, 30.3, 29.1, 21.5, 20.7, 17.7, 15.0, 14.6.  
1H NMR (500 MHz, CDCl3): δ 11.10 (br s, 1H), 10.13 (s, 1H), 6.96 (s, 1H), 5.01 (br s, 1H), 
3.07 (d, J = 16.3 Hz, 1H), 2.88 (d,  J = 16.3 Hz, 1H), 2.30 – 2.23 (m, 1H), 1.71 – 0.99 (m, 
10 H), 1.17 (s, 3H), 1.04 – 1.00 (m, 1H), 0.88 (s, 3H), 0.86 (s, 3H), 0.74 (d, J = 6.4 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ, 192.87, 156.5, 146.10, 136.7, 119.3, 118.0, 105.6, 100.9, 
48.1, 42.5, 35.1, 33.47, 33.3, 33.0, 31.2, 30.9, 21.6, 21.2, 18.1, 15.3, 14.9.  
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NMR data for corallidictyal D 2.6; 
1H NMR (500 MHz, DMSO-d6): δ 10.53 (br s, 1H), 10.14 (s, 1H), 8.66 (br s, 1H), 6.90 (s, 
1H), 3.09 (d, J = 16.3 Hz, 1H), 2.71 (d, J = 16.3 Hz, 1H), 1.81 – 1.74 (m, 1H), 1.61 – 1.07 
(m, 10H), 1.60 – 1.55 (m , 1H), 0.92 (s, 3H), 0.88 (s, 3H), 0.83 (s, 3H), 0.66 (d, J = 6.6 Hz, 
3H). 
13C NMR (125 MHz, DMSO-d6): δ 192.0, 155.7, 146.9, 137.4, 120.7, 116.8, 106.06, 98.2, 
46.1, 42.0, 41.3, 36.4, 33.23, 32.9, 32.8, 30.70, 30.68, 21.7, 20.9, 17.8, 15.7, 15.5. 
1H NMR (500 MHz, CDCl3): δ 11.08 (br s, 1H), 10.20 (s, 1H), 6.93 (s, 1H), 5.01 (br s, 1H), 
3.15 (d, J = 16.0 Hz, 1H), 2.73 (d,  J = 16.0 Hz, 1H), 1.82 – 1.75 (m, 1H), 1.70 – 0.99 (m, 
10 1.50 – 1.44 (m, 1H), 0.97 (s, 3H), 0.91 (s, 3H), 0.85 (s, 3H), 0.73 (d, J = 6.4 Hz, 3H).  
13C NMR (125 MHz, CDCl3): δ 192.91, 156.9, 146.10, 136.8, 119.3, 117.4, 105.7, 99.3, 
46.8, 41.9, 41.7, 37.1, 33.50, 33.4, 31.3, 31.1, 29.8, 21.9, 21.4, 18.2, 16.2, 15.6. 
HRMS (ESI): calculated for C22H30O4 357.2071 [M-H]
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Corallidictyals C (2.5) and D (2.6) 
 
To a solution of a mixture of corallidictyals A 2.3 and B 2.4 (50 mg, 0.140 mmol) in THF 
(20 mL) at 0 °C, was added sodium cyanoborohydride (48.5 mg, 0.772 mmol). The resulting 
reaction mixture was stirred at 0 °C under a nitrogen atmosphere for 6 h and upon completion 
the mixture was extracted with diethyl ether (100 ml). The combined organic extracts were 
sequentially washed with water (50 mL), brine (25 mL) then dried over MgSO4 and 
concentrated in vacuo. The residue was purified by flash column chromatography on SiO2 
(petrol/diethyl ether, 3:1) to give a yellow solid, corallidictyals C 2.5 and D 2.6 as a mixture 
of diastereoisomers in a 1:2 ratio respectively (19.8 mg, 39%). 
Rf = 0.75 (petrol/EtOAc, 1:1)  
NMR data for corallidictyal C 2.5; 
1H NMR (500 MHz, DMSO-d6): δ 10.53 (br s, 1H), 10.08 (s, 1H), 8.66 (br s, 1H), 6.94 (s, 
1H), 3.05 (d, J = 16.6 Hz, 1H), 2.85 (d, J = 16.6 Hz, 1H), 2.22 – 2.15 (m, 1H), 1.63 – 1.00 
(m, 10H), 1.12 (s, 3H), 1.04 (dd, J = 3.1 Hz, J = 12.5 Hz, 1H), 0.85 (s, 3H), 0.82 (s, 3H), 
0.68 (d, J = 6.7 Hz, 3H).  
13C NMR (125 MHz, DMSO-d6): δ 191.7, 155.0, 147.0, 137.3, 120.6, 117.2, 106.14, 99.8, 
47.1, 43.0, 41.2, 34.6, 33.17, 32.6, 30.5, 30.3, 29.1, 21.5, 20.7, 17.7, 15.0, 14.6. 
1H NMR (500 MHz, CDCl3): δ 11.10 (br s, 1H), 10.13 (s, 1H), 6.96 (s, 1H), 5.04 (br s, 1H), 
3.07 (d, J = 16.3 Hz, 1H), 2.88 (d,  J = 16.3 Hz, 1H), 2.30 – 2.23 (m, 1H), 1.70 – 0.99 (m, 
10 H), 1.17 (s, 3H), 1.01 (dd, J = 3.3 Hz, J = 13.0 Hz, 1H), 0.88 (s, 3H), 0.86 (s, 3H), 0.74 
(d, J = 6.4 Hz, 3H).  
13C NMR (125 MHz, CDCl3): δ, 192.87, 156.5, 146.10, 136.7, 119.3, 118.0, 105.6, 100.9, 
48.1, 42.5, 35.1, 33.47, 33.3, 33.0, 31.2, 30.9, 21.6, 21.2, 18.1, 15.3, 14.9. 
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NMR data for corallidictyal D 2.6; 
1H NMR (500 MHz, DMSO-d6): δ 10.53 (br s, 1H), 10.14 (s, 1H), 8.66 (br s, 1H), 6.90 (s, 
1H), 3.09 (d, J = 16.3 Hz, 1H), 2.71 (d, J = 16.3 Hz, 1H), 1.81 – 1.74 (m, 1H), 1.61 – 1.07 
(m, 10H), 1.60 – 1.55 (m , 1H), 0.92 (s, 3H), 0.88 (s, 3H), 0.82 (s, 3H), 0.66 (d, J = 6.7 Hz, 
3H). 
13C NMR (125 MHz, DMSO-d6): δ 192.0, 155.7, 146.9, 137.4, 120.7, 116.8, 106.06, 98.2, 
46.1, 42.0, 41.3, 36.4, 33.23, 32.9, 32.8, 30.70, 30.68, 21.7, 20.9, 17.8, 15.7, 15.5. 
1H NMR (500 MHz, CDCl3): δ 11.09 (br s, 1H), 10.20 (s, 1H), 6.93 (s, 1H), 5.04 (br s, 1H), 
3.15 (d, J = 16.0 Hz, 1H), 2.73 (d,  J = 16.0 Hz, 1H), 1.82 – 1.75 (m, 1H), 1.70 – 0.99 (m, 
10 H), 1.48 (dd, J = 4.0 Hz, J = 12.9 Hz, 1H), 0.96 (s, 3H), 0.91 (s, 3H), 0.85 (s, 3H), 0.74 
(d, J = 6.4 Hz, 3H).  
13C NMR (125 MHz, CDCl3): δ 192.91, 156.9, 146.10, 136.8, 119.4, 117.4, 105.7, 99.3, 
46.8, 41.9, 41.7, 37.1, 33.50, 33.4, 31.3, 31.1, 29.8, 21.9, 21.4, 18.2, 16.2, 15.6. 
IR (neat): 3340, 2922, 2852, 1732, 1651, 1575, 1466 cm-1 
HRMS (ESI): calculated for C22H30O4 357.2071 [M-H]
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Corallidictyals A (2.3) and B (2.4) from C (2.5) and D (2.6) 
 
To a solution of to a mixture of corallidictyals C 2.5 and D 2.6 in a 1 : 2 ratio  respectively 
(10 mg, 0.0279 mmol) in benzene (3 mL) at room temperature, was added Ag2CO3 (30.8 
mg, 0.112 mmol) and CeliteTM (50 mg). The resulting reaction mixture was stirred at room 
temperature for 90 min. The mixture was diluted with diethyl ether (50 ml), filtered through 
a pad of CeliteTM and concentrated in vacuo to give a brown solid, corallidictyals A 2.3 and 
B  as a mixture of diastereoisomers in a 1:2 ratio respectively (8.1 mg, 81%). 
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 Characterisation Tables of 1H and 13C data  
 
Table 2.8: p-QM 2.140 assignment 
Assignment 13C NMR, CDCl3 
125 MHz  
1H NMR, 500 MHz, CDCl3 COSY HMBC 
C → H 
C-1 42.2 1.42 – 1.31 (m, 1H), 
1.20 – 1.02 (m, 1H) 
- - 
C-2 18.7 1.54 – 1.45 (m, 1H), 
1.42 – 1.31 (m, 1H) 
- - 
C-3 41.4 1.42 – 1.31 (m, 1H), 
0.90 – 0.87 (m, 1H) 
- - 
C-4 33.5 - - - 
C-5 54.9 0.94 (dd, J = 12.6, 2.4 Hz, 
1H) 
- → 9, 14 
C-6 21.1 1.65 – 1.62 (m, 1H),     
1.42 – 1.31 (m, 1H) 
- - 
C-7 36.2 1.92 – 1.88 (m, 1H),  
1.20 – 1.02 (m, 1H) 
- → 9, 13 
C-8 32.1 1.76 – 1.68 (m, 1H) → 9, 13 → 7, 9, 13, 15 
C-9 58.0 1.90 (t, J = 11.0 Hz, 1H) → 8, 15 → 13, 14, 15, 
21 
C-10 39.3 - - → 9, 14, 15 
C-11 33.6 0.88 (s, 3H) - - 
C-12 22.1 0.84 (s, 3H) - - 
C-13 21.5* 0.67 (d, J = 6.5 Hz, 3H) → 8 → 6, 7, 9 
C-14 15.1 0.99 (s, 3H) → 9 → 1, 5, 9 
C-15 144.7 6.74 (d, J = 11.6 Hz, 1H) → 9, 21 → 9, 21 
C-16 161.6 - - → 15, 18, 21 
C-17 129.4 - - → 9, 15, 18, 
21  
C-18 103.8 5.72 (s, 1H) - - 
C-19 183.1 - - → 18, 21 
C-20 148.8 - - → 18, 21 
C-21 106.9 6.37 (s, 1H) → 15 → 15 
C-22 21.5* 1.36 (d, J = 6.1 Hz, 3H) → 23 - 
C-23 70.0** 4.46 (hept, J = 5.7 Hz, 1H) → 22, 24 - 
C-24 21.6* 1.36 (d, J = 6.1 Hz, 3H) → 23 - 
C-25 21.5* 1.32 (d, J = 6.00 Hz, 3H) → 26 - 
C-26 71.0** 4.46 (hept, J = 5.7 Hz, 1H) → 25, 27 - 
C-27 21.7* 1.32 (d, J = 6.00 Hz, 3H) → 26 - 
 
*, ** - These assignments are interchangeable. 
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Table 2.9: o-QM 2.143 assignment 
Assignment 
13




H NMR, 600 MHz, CDCl3 COSY HMBC 
C → H 
C-1 41.3 1.43 – 1.30 (m, 1H), 
 0.94 – 0.91 (m, 1H) 
- - 
C-2 18.7 1.52 – 1.48 (m, 1H),               
1.43 – 1.30 (m, 1H) 
- - 
C-3 42.2 1.43 – 1.30 (m, 1H),  
1.18 – 1.12 (m, 1H) 
- - 
C-4 33.5 - - - 
C-5 54.9 0.93 (dd, J = 12.5, 2.19 Hz, 
1H) 
- → 9, 14 
C-6 21.6** 1.67 – 1.62 (m, 1H),  
1.43 – 1.30 (m, 1H) 
- - 
C-7 36.2 1.91 – 1.82 (m, 1H),  
1.09 – 1.00 (m, 1H) 
- → 9, 13 
C-8 31.8 1.79 – 1.71 (m, 1H) → 13 → 7, 9, 13, 15 
C-9 58.1 1.83 (t, J = 11.0 Hz, 1H) → 13, 15 → 13, 14, 15 
C-10 39.3 - - → 9, 14, 15 
C-11 33.6 0.88 (s, 3H) - - 
C-12 22.0 0.84 (s, 3H) - - 
C-13 21.7** 0.66 (d, J = 6.2 Hz, 3H) → 8, 9 → 6, 7, 9 
C-14 15.2 1.03 (s, 3H) → 8, 9 → 1, 5, 9 
C-15 149.3 7.05 (d, J = 11.0 Hz, 1H) → 9, 21 → 9, 18, 21 
C-16 133.6 - - → 9, 15, 18 
C-17 184.3 - - → 15, 18, 21  
C-18 104.8 5.71 (s, 1H) - - 
C-19 164.4 - - → 18, 21, 23 
C-20 146.0 - - → 18, 21, 26 
C-21 106.8 6.17 (s, 1H) → 15 → 15, 18 
C-22 21.7** 1.36 (d, J = 6.1 Hz, 3H) → 23 - 
C-23 71.57* 4.48 (hept, J = 6.1 Hz, 1H) → 22, 24 - 
C-24 21.6** 1.36 (d, J = 6.1 Hz, 3H) → 23 - 
C-25 21.46** 1.34 (d, J = 6.1 Hz, 3H) → 26 - 
C-26 71.56*  4.35 (hept, J = 6.1 Hz, 1H) → 25, 27 - 
C-27 21.44** 1.34 (d, J = 6.1 Hz, 3H) → 26 - 
 
* - These assignments are interchangeable. 
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Table 2.10: 1H NMR comparison of ortho-phenol 2.145 and para-phenol 2.141 
Assignment 2.145: ortho-phenol  
500 MHz, CDCl3 
2.141: para-phenol  
500 MHz, CDCl3 
H-1      
 
1.82 – 1.79 (m, 1H),                          
0.94 – 0.90 (overlapped m, 1H) 
1.82 – 1.80 (m, 1H),                                 
0.89 – 0.86 (overlapped m, 1H) 
H-2 1.58 – 1.52 (overlapped m, 1H),       
1.43 – 1.37 (overlapped m, 1H) 
1.59 – 1.52 (overlapped m, 1H),       
1.39 – 1.36 (overlapped m, 1H) 
H-3 1.40 – 1.33 (overlapped m, 1H),       
1.22 – 1.13 (overlapped m, 1H) 
1.39 – 1.36 (overlapped m, 1H),       
1.18 – 1.05 (overlapped m, 1H) 
H-5 0.94 – 0.90 (overlapped m, 1H) 0.89 – 0.86 (overlapped m, 1H) 
H-6 1.58 – 1.52 (overlapped m, 1H),       
1.33 – 1.25 (overlapped m, 1H) 
1.59 – 1.52 (overlapped m, 1H),       
1.30 – 1.26 (overlapped m, 1H) 
H-7 1.73 – 1.70 (m, 1H),                          
1.04 – 0.94 ( m, 1H) 
1.74 – 1.71 (m, 1H),                         
1.03 – 0.95 ( m, 1H) 
H-8 1.52 – 1.43 (m, 1H) 1.51 – 1.43 (m, 1H) 
H-9 1.22 – 1.13 (overlapped m, 1H) 1.18 – 1.05 (overlapped m, 1H) 
H-11 0.87 (s, 3H) 0.87 (s, 3H) 
H-12 0.83 (s, 3H) 0.84 (s, 3H) 
H-13 0.72 (d, J = 6.5 Hz, 3H) 0.73 (d, J = 6.4 Hz, 3H) 
H-14 0.90 (s, 3H) 0.90 (s, 3H) 
H-15a,     
H-15b 
2.58 (dd, J = 15.8 Hz, J = 2.2 Hz, 1H),  
2.25 (dd, J = 15.8 Hz, J = 6.5 Hz, 1H) 
2.57 (dd, J = 15.8 Hz, J = 3.0 Hz, 1H), 
2.39 (dd, J = 15.8 Hz, J = 6.2 Hz, 1H) 
H-17(-OH) 4.51 (br s, 1H) - 
H-18 6.35 (s, 1H) 6.48 (s, 1H) 
H-19(-OH) - 5.50 (br s, 1H) 
H-21 6.77 (s, 1H) 6.75 (s, 1H) 
H-23 4.30 (hept, J = 6.1 Hz, 1H) 4.37 (hept, J = 6.1 Hz, 1H) 
H-26 4.42 (hept, J = 6.1 Hz, 1H) 4.42 (hept, J = 6.1 Hz, 1H) 
H-22, H-24 1.28 (d, J = 6.1 Hz, 6H) 1.32 (d, J = 6.1 Hz, 3H), 1.31 (d, J = 6.1 
Hz, 1H) 
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Table 2.11: 13C NMR comparison of ortho-phenol 2.145 and para-phenol 2.141 
Assignment 2.145: ortho-phenol  
125 MHz, CDCl3 
2.141: para-phenol  
125 MHz, CDCl3 
C-1 39.5 39.6 
C-2 18.9 18.9 
C-3 42.1 42.3 
C-4 33.4 33.4 
C-5 55.3 55.5 
C-6 21.93* 21.98* 
C-7 37.2 37.4 
C-8 35.2 35.0 
C-9 57.4 58.4 
C-10 38.6 38.6 
C-11 33.6 33.6 
C-12 21.94* 21.99* 
C-13 21.4 21.5 
C-14 14.3 14.4 
C-15 27.3 27.0 
C-16 122.5*** 125.3 
C-17 122.3 149.7 
C-18 105.4 101.5 
C-19 142.1 144.8 
C-20 147.8 137.7 
C-21 122.5*** 116.8 
C-23 73.6 70.7 
C-26 71.7 73.0 
C-22, C-24 22.32 (overlapped) 22.30**, 22.28** 
C-25, C-27 22.25**, 22.21** 22.34**, 22.33** 
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Siphonodictyal B carbon numbering in accordance to Köck [96]: 
 
Table 2.12: Comparison of the 1H NMR spectrum of natural siphonodictyal B isolated by Köck [96] 
and our synthetic sample. 
Assignment Köck, 
DMSO-d6 
This work, 2.91  
DMSO-d6, 500 MHz 
This work, 2.1  
DMSO-d6, 500 MHz 
H-1a, H-1b 1.78, 1.40 1.79-1.27 (overlapped m) 1.73 – 1.39(overlapped m) 
H-2a, H-2b 1.63, 1.49 1.79-1.27 (overlapped m) 1.73 – 1.39(overlapped m) 
H-3a, H-3b 1.38, 1.16 1.79-1.27 (overlapped m) 1.73 – 1.39(overlapped m) 
H-5 1.30 1.79-1.27 (overlapped m) 1.73 – 1.39(overlapped m) 
H-6a, H-6b 1.71, 1.49 1.79-1.27 (overlapped m) 1.73 – 1.39 (overlapped m) 
H-7a, H-7b 1.72, 1.34 1.79-1.27 (overlapped m) 1.73 – 1.39 (overlapped m) 
H-8 2.62 2.62 (m) 3.35 (quintet, J = 6.9 Hz) 
Me-11 0.89 0.88 (s) 0.86 (s) 
Me-12 0.86 0.85 (s) 0.86 (s) 
Me-13 0.89 0.87 (d, J = 7.0 Hz) 1.22 (d, J = 7.4 Hz) 
Me-14 1.12 1.12 (s) 1.15 (s) 
H-15 6.04 6.03 (s) 6.01 (s) 
H-17 6.85 6.84 (s) 6.91 (s) 
22-CHO 10.26 10.25 (s) 10.26 (s) 
18-OH 10.03 10.03 (br s) 10.07 (br s) 
19-OH 9.00 9.02 (br s) 9.11 (br s) 
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Table 2.13: Comparison of the 13C NMR spectra of natural siphonodictyal B isolated by Köck[96] 
and our synthetic sample. 






















C-1 39.2 39.2 38.8 39.1 39.1 38.1 
C-2 19.4 19.4 17.8 19.0 19.0 17.4 
C-3 42.2 42.2 42.0 41.9 41.9 41.7 
C-4 34.1 34.1 34.0 33.0 33.0 33.2* 
C-5 52.4 52.4 55.1 49.0 49.1 54.2 
C-6 21.7 21.7 18.8 19.4 19.4 18.4 
C-7 34.8 34.7 33.4* 31.2 31.2 30.5 
C-8 33.9 33.9 34.2* 31.7 31.8 33.7* 
C-9 165.8 165.8 165.9 157.0 157.0 155.5 
C-10 41.9 41.9 41.3 40.3 40.4 40.5 
C-11 33.2 33.2 31.7* 33.6 33.6 33.6* 
C-12 21.2 21.2 22.5** 21.4 21.5 21.6** 
C-13 21.1 21.1 21.8** 21.9 21.9 22.4** 
C-14 22.5 22.6 22.7** 22.9 22.9 22.7** 
C-15 109.3 109.4 110.7 113.4 113.4 113.3 
C-16 116.6 116.6 115.6 116.6 116.6 115.6 
C-17 123.6 123.7 123.5 126.2 126.2 125.5 
C-18 136.9 136.9 137.1 136.1 136.1 136.3 
C-19 147.5 147.5 147.6 147.8 147.8 148.0 
C-20 109.0 109.0 109.3 110.2 110.2 110.4 
C-21 148.4 148.5 148.7 151.2 151.3 151.8 
C-22 194.5 194.5 194.5 194.8 194.8 194.8 
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Table 2.14: Comparison of the 1H NMR spectra of our synthetic methylated siphonodictyal B 
epimers (2.91 & 2.1) with Faulkner’s[97] artificially methylated natural sample. 
Assignment Faulkner  
methoxy–
siphonodictyal B  
CDCl3 
 
This work  
2.151: methoxy-
siphonodictyal B  
CDCl3, 500 MHz 
 
This work  
2.12: methoxy-
siphonodictyal B  
CDCl3, 500 MHz 
H-1a, H-1b not reported 1.86 – 1.24 (m, 2H) 1.83 – 1.42  (m, 2H) 
H-2a, H-2b not reported 1.86 – 1.24 (m, 2H) 1.83 – 1.42  (m, 2H) 
H-3a, H-3b not reported 1.86 – 1.24 (m, 2H) 1.27 – 1.25 (m, 1H),  
1.83 – 1.42  (m, 1H) 
H-5 not reported 1.86 – 1.24 (m, 1H) 0.99 (d, J = 11.0 Hz, 1H) 
H-6a, H-6b not reported 1.86 – 1.24 (m, 2H) 1.83 – 1.42  (m, 2H) 
H-7a, H-7b not reported 1.86 – 1.24 (m, 2H) 1.83 – 1.42 (m, 2H) 
H-8 2.65 (m, 1 H) 2.66 (m, 1H) 2.96 (quintet, J = 6.7 Hz, 1H) 
Me-11 0.91 (s, 3 H) 0.91 (s, 3H) 0.92 (s, 3H) 
Me-12 0.89 (s, 3 H) 0.89 (s, 3H) 0.90 (s, 3H) 
Me-13 0.90 (d, 3 H, J = 7 Hz) 0.90 (d, J = 6.5 Hz, 3H) 1.28 (d, J = 7.5 Hz, 3H) 
Me-14 1.19 (s, 3 H) 1.19 (s, 3H) 1.23 (s, 3H) 
H-15 6.21 (s, 1 H) 6.21 (s, 1H) 6.21 (s, 1H) 
H-17 6.91 (s, 1 H) 6.91 (s, 1H) 6.95 (s, 1H) 
22-CHO 10.40 (s, 1 H) 10.40 (s, 1H) 10.43 (s, 1H) 
23-OMe 3.91 (s, 3 H) 3.91 (s, 3H) 3.93 (s, 3H) 
24-OMe 3.85 (s, 3 H) 3.85 (s, 3H) 3.86 (s, 3H) 
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Table 2.15: Comparison of the 13C NMR spectra of our synthetic methylated siphonodictyal B 
epimers, 2.91 & 2.1, with Faulkner’s[97] artificially methylated natural sample. 
Assignment Faulkner 
methoxy–
siphonodictyal B  
Benzene-d6, 125 MHz 
This work  
2.151: methoxy-
siphonodictyal B   
Benzene-d6, 125 MHz 
This work  
2.12: methoxy-
siphonodictyal B  
Benzene-d6, 125 MHz 
C-1 40.0 40.0 39.1 
C-2 20.5** 20.6** 18.2 
C-3 42.7 42.7 42.5 
C-4 34.1  34.1 34.2 
C-5 42.4 61.8 62.0 
C-6 19.9** 19.9** 19.3 
C-7 33.1 33.2 33.6 
C-8 32.7 32.9 31.7 
C-9 158.3 (s) 158.4 157.6 
C-10 41.3 41.3 41.3 
C-11 33.4 33.5  34.5  
C-12 22.9 22.9 22.1* 
C-13 21.9* 21.9* 22.7* 
C-14 22.4* 22.4* 22.9* 
C-15 114.9 (d) 114.9 115.6 
C-16 130.4 (s) 130.5 129.5 
C-17 120.5 (d) 120.4 119.8 
C-18 148.9 (s) 148.9 149.2 
C-19 150.3 (s)  150.4 150.3 
C-20 125.0 (s) 125.1 125.4 
C-21 152.3 (s) 152.3 153.1 
C-22 189.1 (s) 189.3 189.2 
C-23 61.6 (q) 61.7 61.7 
C-24 56.1 (q) 56.1 56.0 
C-25 50.5 (q) 50.7 55.3 
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Ring expanded Ketones 2.153 and 2.154 
   
Table 2.16: 1H NMR comparison of ring expanded ketones  
Assignment 2.153 
500 MHz, CDCl3 
2.154 
500 MHz, CDCl3 
H-1 0.94 – 0.85 (overlapped m, 2H) 1.55 – 1.42 (overlapped m, 1H), 
1.19 – 1.03 (overlapped m, 1H) 
H-2 1.53 – 1.39 (overlapped m, 1H),  
1.23 – 1.15 (overlapped m, 1H) 
1.55 – 1.42 (overlapped m, 1H),  
1.34 – 1.26 (overlapped m, 1H) 
H-3 1.37 – 1.26 (overlapped m, 1H),  
1.23 – 1.15 (overlapped m, 1H) 
1.34 – 1.26 (overlapped m, 1H),  
1.19 – 1.03 (overlapped m, 1H) 
H-5 1.37 – 1.26 (overlapped m, 1H) 0.88 – 0.84 (overlapped m, 1H) 
H-6 1.98 – 1.94 (m, 1H), 
1.23 – 1.15 (overlapped m, 1H) 
1.79 – 1.69 (overlapped m, 1H),  
1.79 – 1.69 (overlapped m, 1H),  
H-7 2.08 – 2.02 (m, 1H), 
1.53 – 1.39 (overlapped m, 1H) 
2.23 – 2.19 (overlapped m, 1H), 
1.19 – 1.03 (overlapped m, 1H). 
H-8 2.43 – 2.39 (m, 1H) 2.70 – 2.63 (m, 1H) 
H-10 4.70 (s, 1H) 4.75 (s, 1H) 
H-12 0.79 (s, 3H) 0.84 (s, 3H) 
H-13 0.96 (s, 3H) 0.86 (s, 3H) 
H-14 1.03 (d, J = 7.1 Hz, 3H) 0.95 (d, J = 6.2 Hz, 3H) 
H-15 0.99 (s, 3H) 0.86 (s, 3H) 
H-17 7.42 (s, 1H) 7.59 (s, 1H) 
H-19 6.43 (s, 1H) 6.44 (s, 1H) 
H-22 4.37 (sep, J = 5.6 Hz, 1H) 4.37 (sep, J = 6.0 Hz, 1H), 
H-23 4.45 (sep, J = 6.1 Hz, 1H) 4.45 (sep, J = 6.0 Hz, 1H) 
H-24 4.37 (sep, J = 5.6 Hz, 1H) 4.37 (sep, J = 6.0 Hz, 1H), 
H-25, H-26 *1.37 (d, J = 6.0 Hz, 3H),  
*1.30 (d, J = 6.6 Hz, 3H) 
1.35 – 1.29 (overlapped m, 6H) 
H-27, H-28 *1.33 – 1.26 (m, 6H) 1.35 – 1.29 (overlapped m, 6H) 
H-29, H-30 *1.33 – 1.26 (m, 3H),  
*1.30 (d, J = 6.6 Hz, 3H) 
1.35 – 1.29 (overlapped m, 6H) 
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Table 2.17: 13C NMR comparison of ring expanded ketones  
Assignment 2.153 
125 MHz, CDCl3 
2.154 
125 MHz, CDCl3 
C-1 38.2 33.6 
C-2 19.1 19.0 
C-3 42.2 41.3 
C-4 29.7 35.2 
C-5 62.6 55.9 
C-6 24.6 22.4 
C-7 34.2 37.1 
C-8 49.8 49.4 
C-9 216.0 215.3 
C-10 53.0 54.1 
C-11 41.3 41.2 
C-12 21.8 21.3 
C-13 35.2 32.9 
C-14 19.5 16.1 
C-15 17.5 20.1 
C-16 121.0 117.6 
C-17 122.7 123.3 
C-18 142.2 142.0 
C-19 147.7 147.9 
C-20 105.2 105.0 
C-21 150.1 150.8 
C-22 72.7 72.6 
C-23 70.7 70.7 
C-24 72.3 72.5 
C-25 22.6** 22.7* 
C-26 22.5** 22.5* 
C-27 22.5** 22.5* 
C-28 22.4** 22.4* 
C-29 22.3** 22.3* 
C-30 22.3** 22.2* 
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Table 2.18: 13C NMR comparison of corallidictyals A (2.3) and B (2.4) to synthesised 20-nor-formyl 
corallidictyal analogues A (2.159) and B (2.160). 
Assignment This work 
 2.3: A, CDCl3 
125 MHz  
This work    
2.4: B, CDCl3 
125 MHz  
This work 
2.159: A analogue 
CDCl3, 125 MHz 
This work      
2.160: B analogue 
CDCl3, 125 MHz  
1 33.64* 30.32 29.7 32.7 
2 18.23 18.18 18.3 18.2 
3 41.68 41.19 41.8 41.4 
4 33.83* 33.75* 33.70 33.68 
5 52.33 47.31 51.9 47.3 
6 21.49 21.47 21.54 21.46 
7 33.50* 31.96 33.48 32.1 
8 35.53 34.20 35.51 34.0 
9 113.11 111.15 108.8 107.1 
10  44.84 43.96 44.2 43.5 
11 33.48* 33.31 33.35 33.29 
12 21.87 21.89 21.86 21.90 
13 15.53 15.62 15.5 15.6 
14 16.44 19.36 16.2 19.0 
15 147.80 149.73 143.3 145.5 
16 131.68 130.81 131.5 131.3 
17 98.40 98.16 96.7 96.6 
18 150.24** 150.29** 150.7 150.7 
19 180.26 179.97 181.7 181.7 
20 107.67*** 107.71*** 95.5 95.7 
21 175.78 177.01 175.4 175.4 
22 186.58 186.15 - - 
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Table 2.19: 1H NMR comparison of our synthesised samples of corallidictyals A (2.3) and B (2.4) 
to the afforded C20 nor-formyl corallidictyal analogues A (2.159) and B (2.160). 
Assignment This work 
2.3: A, CDCl3 
500 MHz  
This work     
2.4: B, CDCl3 
500 MHz  
This work  
2.159: A analogue 
CDCl3, 500 MHz 
This work 
2.160: B analogue 
CDCl3, 500 MHz 
H-1 2.04 – 2.00 
(overlapped m, 




1.48 – 1.41 
(overlapped m, 
1H), 1.31 – 1.22 
(overlapped m, 
1H) 




1.10 – 1.04 
(overlapped m, 1H), 
0.98 – 0.93 
(overlapped m, 1H). 
H-2 1.49 – 1.40 
(overlapped m, 
1H, 1.32 – 1.22 
(overlapped m, 
1H) 
1.55 – 1.47 
(overlapped m, 
1H), 1.38 – 1.33 
(overlapped m, 
1H) 
1.53 – 1.42 
(overlapped m, 
1H),1.42 – 1.29 
(overlapped m, 
1H). 
1.53 – 1.42 
(overlapped m, 1H), 
1.42 – 1.29 
(overlapped m, 1H). 
H-3 1.48 – 1.42 
(overlapped m, 
1H, 1.18 – 1.04 
(overlapped m, 
2H) 
1.38 – 1.33 
(overlapped m, 
1H, 1.19 – 1.11 
(overlapped m, 
1H) 
1.43 – 1.29 
(overlapped m, 
2H). 
1.43 – 1.29 
(overlapped m, 2H). 
H-5 1.23 (d, J = 3.6 
Hz, 1H ) 
1.74 (dd, J = 2.3, 
10.5 Hz, 1H) 
1.27 – 1.22 (m, 
1H) 
1.64 – 1.62 (m, 1H) 
H-6 1.82 – 1.77 
(overlapped m, 
1H),  
1.65 – 1.48 
(overlapped m, 
1H) 
1.84 – 1.77 
(overlapped m, 
1H),  
1.54 – 1.46 
(overlapped m, 
1H) 
1.78 – 1.70 
(overlapped m, 
1H), 
1.58 – 1.50 
(overlapped m, 
1H) 
1.78 – 1.70 
(overlapped m, 1H), 
1.50 – 1.34 
(overlapped m, 1H) 
H-7 2.04 – 2.00 
(overlapped m, 
1H),  
1.30 – 1.20 
(overlapped m, 
1H) 
1.84 – 1.77 
(overlapped m, 
1H),  
1.68 – 1.55 
(overlapped m, 
1H) 
1.94 – 1.91 (m, 
1H), 
1.22 – 1.19 
(overlapped m, 
1H) 
1.78 – 1.70 
(overlapped m, 1H), 
1.50 – 1.34 
(overlapped m, 1H) 
H-8 2.65 – 2.60 (m, 
1H) 
2.45 – 2.41 (m, 
1H) 
2.49 – 2.41 (m, 
1H) 
2.34 – 2.27 (m, 1H) 
H-11 0.93 (s, 3H) 0.95 (s, 3H) 0.92 (s, 3H) 0.93 (s, 3H) 
H-12 0.90 (s, 3H) 0.87 (s, 3H) 0.88 (s, 3H) 0.86 (s, 3H) 
H-13 0.54 (d, J = 6.6 
Hz, 3H) 
0.55 (d, J = 6.5 
Hz, 3H) 
0.55 (d, J = 6.5 Hz, 
3H) 
0.56 (d, J = 6.6 Hz, 
3H) 
H-14 1.35 (s, 3H) 1.27 (s, 3H) 1.25 (s, 3H) 1.21 (s, 3H) 
H-15 7.50 (s, 1H) 7.24 (s, 1H) 7.21 (s, 1H) 6.96 (s, 1H) 
H-17 6.48 (s, 1H) 6.43 (s, 1H) 6.36 (s, 1H) 6.31 (s, 1H) 
18- OH 7.41 (br s, 1H) 7.41 (br s, 1H) 7.41 (br s, 1H) 7.41 (br s, 1H) 
H-20 - - 5.91 (s, 1H) 5.98 (s, 1H) 
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Liphagal (2.2) carbon numbering (according to Andersen[99]) 
 
Table 2.20: Comparison of the 1H NMR spectra of synthetic liphagal (2.2) prepared by Andersen,[99] 
Stoltz[101] and this work. 
Assignment Anderson  
CDCl3, 400 MHz 
Stoltz  
CDCl3, 600 MHz 
This work  
CDCl3, 600 MHz 
H-1a, H-1b 2.54 (m), 1.8–1.5  
(overlapped m) 
2.54 (m), 1.65–1.45 
(overlapped m) 
2.54 (m), 1.64–1.45 
(overlapped m) 
H-2a, H-2b 1.8–1.5 (overlapped 
m) 
1.71 (m), 1.65–1.45 
(overlapped m) 




m), 1.25 (m) 
1.65–1.45 (overlapped m), 
1.25 (ddd, J = 13.3, 13.3, 
3.1 Hz) 
1.64–1.45 (overlapped 
m), 1.25 (ddd, J = 13.0, 
13.0, 3.0 Hz) 
H-5 1.8–1.5 (overlapped 
m) 
1.65–1.45 (overlapped m) 
1.64–1.45 (overlapped 
m) 
H-6a, H-6b 1.86 (m), 1.8–1.5 
(overlapped m) 
1.87 (m), 1.65–1.45 
(overlapped m) 
1.87 (m), 1.64–1.45 
(overlapped m) 
H-7a, H-7b 
2.17 (m), 1.8–1.5 
(overlapped m) 
2.18 (dddd, J = 13.1, 6.4, 
6.4, 3.5 Hz), 1.65–1.45 
(overlapped m) 
2.18 (m), 1.64–1.45 
(overlapped m) 
H-8 3.20 (m) 3.22 (sext, J = 7.0 Hz) 3.21 (sext, J = 7.0 Hz) 
15-OH 11.24 (s) 11.24 (s) 11.24 (s) 
16-OH 5.32 (br s) 5.30 (s) 5.32 (s) 
H-17 7.55 (s) 7.55 (s) 7.55 (s) 
18-CHO 10.45 (s) 10.45 (s) 10.44 (s) 
Me-19 0.98 (s) 0.98 (s) 0.98 (s) 
Me-20 0.95 (s) 0.95 (s) 0.95 (s) 
Me-21 1.43 (d, J = 7.0 Hz) 1.43 (d, J = 7.0 Hz) 1.43 (d, J = 7.0 Hz) 
Me-22 1.34 (s) 1.35 (s) 1.35 (s) 
 
Note; the 1H and 13C NMR spectra of natural liphagal (2.2) were recorded in DMSO-d6. However, 
Andersen and co-workers correlated the NMR spectra of their synthetic sample (recorded in CDCl3 
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Table 2.21: Comparison of the 13C NMR spectra of synthetic liphagal (2.2) prepared by Andersen,[99] 
Stoltz[101] and this work. 
Assignment Anderson  
CDCl3, 100 MHz 
Stoltz  
CDCl3, 150 MHz 
This work  
CDCl3, 600 MHz 
C-1 40.4 40.5 40.5 
C-2 18.9 19.0 19.0 
C-3 42.1 42.1 42.1 
C-4 35.0 35.1 35.0 
C-5 53.9 54.0 53.9 
C-6 24.3 24.4 24.4 
C-7 35.3 35.4 35.4 
C-8 33.8 33.9 33.9 
C-9 156.7 156.7 156.7 
C-10 125.7 125.7 125.7 
C-11 39.6 39.7 39.7 
C-12 120.5 120.5 120.5 
C-13 148.1* 148.2* 148.2* 
C-14 139.6 139.6 139.6 
C-15 145.5* 145.5* 145.5* 
C-16 106.4 106.5 106.5 
C-17 116.1 116.2 116.2 
C-18 192.6 192.7 192.6 
C-19 33.5** 33.5** 33.5** 
C-20 22.1** 22.2** 22.2** 
C-21 21.8 21.9 21.9 
C-22 20.4 20.5 20.4 
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Corallidictyal A (2.3) and B (2.4) carbon numbering (according to Köck [96]): 
 
Table 2.22: Comparison of the 1H NMR spectra of corallidictyals A (2.3) and B (2.4) Westley[100] 





CDCl3, 400 MHz 
This work 2.3: 
corallidictyal A 
CDCl3, 500 MHz 
Westly 2.4: 
corallidictyal B 
CDCl3, 400 MHz 
This work 2.4: 
corallidictyal B 
CDCl3, 500 MHz 
H-1a, H-1b 2.00-0.80 (m) 2.05 – 1.99 
(overlapped m), 
1.67 – 0.77 
(overlapped m) 
2.00 – 0.80 (m) 1.67 – 0.77 
(overlapped m) 
H-2a, H-2b 2.00-0.80 (m) 1.67 – 0.77 
(overlapped m) 
2.00-0.80 (m) 1.67 – 0.77 
(overlapped m) 
H-3a, H-3b 2.00-0.80 (m) 1.67 – 0.77 
(overlapped m) 
2.00-0.80 (m) 1.67 – 0.77 
(overlapped m) 
H-5 1.24 (dd, J = 12.0, 
2.9 Hz) 
1.67 – 0.77 
(overlapped m) 
1.75 (dd, J = 
12.2, 2.7 Hz) 
1.83 – 1.73 
(overlapped m) 
H-6a, H-6b 2.00-0.80 (m) 1.83 – 1.73 
(overlapped m) 
2.00-0.80 (m) 1.83 – 1.73 
(overlapped m), 
1.67 – 0.77 
(overlapped m) 
H-7a, H-7b 2.00-0.80 (m) 2.05 – 1.99 
(overlapped m), 
1.67 – 0.77 
(overlapped m) 
2.00-0.80 (m) 1.83 – 1.73 
(overlapped m), 
1.67 – 0.77 
(overlapped m) 
H-8 2.61 (m) 2.63 (m, 1H) 2.42 (m) 2.43 (m) 
Me-11 0.94 (s) 0.93 (s, 3H) 0.95 (s) 0.95 (s) 
Me-12 0.91 (s) 0.91 (s, 3H) 0.88 (s) 0.87 (s) 
Me-13 0.55 (d, J = 6.6) 0.54 (d, J = 6.6 
Hz, 3H) 
0.56 (d, J = 6.6) 0.54 (d, J = 6.5 
Hz) 
Me-14 1.35 (s) 1.35 (s, 3H) 1.28 (s) 1.27 (s) 
H-15 7.50 (s) 7.50 (s, 1H) 7.25 (s) 7.25 (s) 
H-17 6.48 (s) 6.48 (s, 1H) 6.43 (s) 6.43 (s) 
OH-18 7.40 (br s) 7.42 (br s, 1H) 7.40 (br s) 7.42 (br s) 
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Table 2.23: Comparison of the 13C NMR spectra of corallidictyals A (2.3) and B (2.4) Westley[100] 





CDCl3, 100 MHz 
This work 2.3: 
corallidictyal A 
CDCl3, 125 MHz 
Westly 2.4: 
corallidictyal B 
CDCl3, 100 MHz 
This work 2.4: 
corallidictyal B
 
CDCl3, 125 MHz 
C-1 41.7-18.2 33.6* 41.2-18.2 32.9 
C-2 41.7-18.2 18.23 41.2-18.2 18.18 
C-3 41.7-18.2 41.7 41.2-18.2 41.2 
C-4 41.7-18.2 33.83* 41.2-18.2 33.75 
C-5 52.3 52.3 47.3 47.3 
C-6 41.7-18.2 21.48 41.2-18.2 21.45 
C-7 41.7-18.2 33.50* 41.2-18.2 32.0 
C-8 35.5 35.5 34.2 34.2 
C-9 113.1 113.1 111.1 111.2 
C-10 44.8  44.8 44.0 44.0 
C-11 33.5 33.47* 33.3 33.31 
C-12 21.8 21.86 21.9 21.89 
C-13 15.5 15.5 15.6 15.6 
C-14 16.4 16.4 19.3 19.4 
C-15 147.8 147.9 149.7 149.8 
C-16 131.7 131.7 130.8 130.8 
C-17 98.4 98.5 98.1 98.2 
C-18 150.3 150.27 150.3 150.31 
C-19 180.3 180.3 180.0 180.0 
C-20 107.7 107.68 107.7 107.71 
C-21 175.7 175.8 177.0 177.1 
C-22 186.6 186.6 186.1 186.2 
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Corallidictyal C (2.5) and D (2.6) carbon numbering (according to Köck[96]): 
 
Table 2.24: Comparison of the 1H NMR spectra of corallidictyals C (2.5) and D (2.6) Köck 






This work  




2.6: D  
DMSO-d6  
This work  






2.6: D      
DMSO-d6 
500 MHz  
H-1 1.44, 1.16 1.63 – 1.06 
(overlapped m) 




H-2 1.52, 1.34 1.63 – 1.06 
(overlapped m) 




H-3 1.32, 1.11 1.63 – 1.06 
(overlapped m) 




H-5 1.05 1.04 (dd, J = 3.1 
Hz, J = 12.5 Hz) 




H-6 1.48, 1.37 1.63 – 1.06 
(overlapped m) 




H-7 1.63, 1.05 1.63 – 1.06 
(overlapped m) 




H-8 2.18 2.18 (m) 1.77 1.77 (m) 1.77 (m) 
Me-11 0.86 0.85 (s) 0.88 0.88 (s) 0.88 (s) 
Me-12 0.83 0.82 (s) 0.82 0.82 (s) 0.82 (s) 
Me-13 0.69 0.68 (d, J = 6.7 
Hz) 
0.67 0.66 (d, J = 6.7 
Hz) 
0.67 (d, J 
= 6.5 Hz) 
Me-14 1.13 1.12 (s) 0.93 0.92 (s) 0.93 (s) 
H-15a,  
H-15b 
3.06, 2.85 3.05 (d, J = 16.6 
Hz) 2.85 (d, J = 
16.6 Hz) 
3.10, 2.71 3.09 (d, J = 16.3 
Hz), 2.71 (d, J = 
16.3 Hz) 
3.10 (d, J 
= 16.2 
Hz), 2.71 
(d, J = 
16.2 Hz) 
H-17 6.94 6.94 (s) 6.91 6.90 (s) 6.90 (s) 
OH-18 8.66 8.66 (br s) 8.65 8.66 (br s) - 
OH-19 10.53 10.53 (br s) 10.55 10.53 (br s) - 
22-CHO 10.09 10.08 (s) 10.15 10.14 (s) 10.14 (s) 
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Table 2.25: Comparison of the 13C NMR spectra of corallidictyals C (2.5) and D (2.6) Köck 



















2.6: D, DMSO-d6 
125 MHz 
C-1 30.5 30.5 30.7 30.70* 30.7 
C-2 17.7 17.7 17.7 17.8 17.8 
C-3 41.2 41.2 41.2 41.3 41.3 
C-4 32.6 32.6 32.9 32.9 32.9 
C-5 47.1 47.1 46.1 46.1 46.1 
C-6 20.6 20.7 20.9 20.9 20.9 
C-7 30.2 30.3 30.7 30.68* 30.7 
C-8 34.5 34.6 36.4 36.4 36.4 
C-9 99.8 99.8 98.2 98.2 98.2 
C-10 43.0 43.0 41.9 42.0 42.0 
C-11 33.1  33.17  33.2  33.23  33.2 
C-12 21.4 21.5 21.7 21.7 21.7 
C-13 14.6 14.6 15.4 15.5 15.5 
C-14 14.9 15.0 15.7 15.7 15.7 
C-15 29.1 29.1 32.8 32.8 32.8 
C-16 117.1 117.2 116.8 116.8 116.8 
C-17 120.5 120.6 120.6 120.7 120.6 
C-18 137.3 137.3 137.4 137.4 137.4 
C-19 147.0 147.0 146.9 146.9 146.9 
C-20 106.1 106.14 106.1 106.06 106.1 
C-21 155.0 155.0 155.7 155.7 155.7 
C-22 191.7 191.7 191.9 192.0 191.9 
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 Spiroketal Natural Products, Virgatolides A – C 
 Isolation of the Virgatolides A – C 
The virgatolides A – C (3.1 – 3.3) are a family of benzannulated spiroketal natural products 
that were first isolated by Che from the invasive endophytic fungus, Pestalotiopsis 
virgatula.[145] EtOAc extracts of the fungi cultures were found to be cytotoxic against HeLa 
cells (cervical epithelium), and upon fractionation of the extracts the virgatolides A – C (3.1 
– 3.3) were afforded,[145] along with the previously isolated pestaphthalides A (3.4) & B (3.5) 
(Figure 3.1).[146] The structural configuration of virgatolides A – C (3.1 – 3.3) were 
determined via 2D NMR studies and the relative configurations were based upon X-ray 
crystallographic analysis of virgatolide A (3.1) (Figure 3.1).[145] Virgatolides A & B (3.1 & 
3.2) were found to possess the same isobenzofuranone framework as pestaphthalide A (3.4), 
and virgatolide C (3.3) with that of pestaphthalide B (3.5) (Figure 3.1). The absolute 
configurations of virgatolides A (3.1) & B (3.2) were determined by CD spectral comparison 
with pestaphthalide A (3.4). The absolute configuration of virgatolide C (3.3) was 
determined based on its shared chirality with pestaphthalide B (3.5) via CD spectral analysis 
(Figure 3.1). 
 
Figure 3.1: Isolated natural products, virgatolides A – C (3.1 – 3.3),[145] and pestaphthalides A (3.4) 
& B (3.5) from the fungus Pestalotiopsis virgatula.[146] 
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 Introduction to Spiroketal Natural Products 
 
Scheme 3.1: Examples of cyclisation reactions of spiroketal natural products, a) formal racemic 
synthesis of (±)-γ-rubromycin (3.9) by Brimble et al.[147] b) Two-step gold/acid mediated 
spirocyclisation in the total synthesis of citreoviranol (3.13) by Brimble et al.[148] 
Benzannulated spiroketal natural products, characterised by spiroketal substituents fused 
with aryl moieties, are relatively rare throughout the literature.[149] 5,6 spirocyclic 
benzannulated ketals appear to be the most prevalent natural products discovered in this 
family, followed by 5,5 spiroketal systems. However, fewer examples of 6,6 benzannulated 
spiroketal natural products have been discovered, making them particularly novel amongst 
an already unique and expanding field of secondary metabolites. Various methods of 
synthesising these unique spiroketal natural products have been investigated from the more 
pragmatic acid catalysed spirocyclisation approach (3.6 – 3.8),[147] to unconventional two-
step spirocyclisation methods involving gold catalysts to afford the desired spirolactone 
moiety (3.10 – 3.13) (scheme 3.1).[148]  
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The use of ortho-quinone methides (o-QM) in the synthesis of benzannulated spiroketals, 
acting as dienes that can participate in cycloadditions, has become an increasingly 
investigated viable strategy. However, few successful examples of these spirocyclisation 
transformations, employing o-QMs in the total synthesis of benzannulated spiroketal natural 
products, have been reported. Pettus et al reported a protocol for the synthesis of des-
hydroxy paecilospirone (3.19) via a cycloaddition of an in situ generated o-QM (3.16) from 
phenol 3.14 to afford the key spiroketal moiety 3.18 (scheme 3.2).[150] The o-QM protocol 
developed by Pettus was employed in the synthesis of multiple spiroketal natural products, 
highlighting the versatility of these highly reactive species, and hence, their legitimacy as a 
biosynthetic precursor in nature. 
  
Scheme 3.2: Pettus and co-worker’s formal synthesis of des-hydroxy paecilospirone (3.19) via a 
[4 + 2] cycloaddition, detailing their optimised o-QM protocol.[150]  
 Previous work on Virgatolide B  
In 2013, Brimble and co-workers published the first total synthesis of virgatolide B 
(3.2),[151],[152] which entailed a convergent linear synthetic method (scheme 3.3). The authors 
sought to gradually build up molecular complexity to enable greater synthetic control, which 
led to the synthesis of virgatolide B (3.2) in an overall yield of 3.5% from dihydroxybenzoic 
acid (3.20) via 15 steps. The synthesis of virgatolide B (3.2) was predicated upon the 
acquirement of  3.22 and 3.23, that would serve as Suzuki coupling partners to afford the 
desired carbon scaffold 3.24, which could be gradually, yet selectively built upon. Brimble 
foresaw that the installation of the E-alkene (3.22) was required prior to the Suzuki alkylation 
of 3.22 and 3.23, in preparation of the anticipated Sharpless asymmetric dihydroxylation. 
However, following the Grignard alkylation of aldehyde 3.10, the subsequent elimination 
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was found to afford an inseparable mixture of E/Z isomers, which was resolved to 
exclusively afford the desired E-isomer 3.22 upon the addition of Ru(CO)ClH(PPh3)3.  
 
Scheme 3.3: Total synthesis of virgatolide B 3.2 by Brimble et al.[152] 
In the presence of RuPhos, trifluoroboratoamide 3.23 was coupled to the sterically hindered 
bromide 3.22 under Suzuki conditions, and the afforded amide was cleaved with MeLi 
(scheme 3.3). Dihydroxylation of the resultant E-alkenyl ketone 3.24 with AD-mix-α gave 
3.25, and the isobenzofuranone moiety was installed via a two-step protocol. Diol 3.14 
underwent a regioselective mono-iodination and a subsequent palladium catalysed 
carbonylation to yield phthalide 3.26. In order to install the spiroketal moiety, following 
installation of the isobenzofuranone scaffold, phthalide 3.26 was subjected to a solution of 
TMSOTf in the presence of DMAP. The resultant TMS enol-ether was immediately 
subjected to a Mukaiyama aldol reaction with aldehyde 3.27, and TMS cleavage was 
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achieved upon the addition of K2CO3. 3.28 was hydrogenated to remove the BOM protecting 
groups, and the key spirocyclisation event was achieved via catalytic camphorsulfonic acid, 
which concluded Brimble’s total synthesis of (+)-virgatolide B (3.2). 
 Che’s Biosynthetic Proposal for the Virgatolides 
Che and co-workers detailed a proposal for the biosynthesis of virgatolide B (3.2) within the 
original isolation paper (scheme 3.4). The proposal detailed two successive condensation 
reactions of malonyl CoA (3.30) with acetyl CoA (3.29) to afford pyranol 3.33, which was 
theorised to undergo an electrophilic aromatic substitution with a demethyl pestaphthalide 
3.34. The coupled pyran 3.35 was proposed to undergo a spirocyclisation, and Che argued 
the resulting spiroketal 3.36 would undergo several stereospecific reductions to obtain 
virgatolide B (3.2) in nature.[145] 
 
Scheme 3.4: Proposed biosynthesis of virgatolides B (3.2) and C (3.3) by Che et al.[145] 
Although the above proposed biosynthetic pathway appears plausible, significant issues 
regarding stereochemical control are evident. Given that the virgatolides A – C (3.1 – 3.3) 
were discovered as enantiopure products,[145] stringent biosynthetic mechanistic controls, 
such as substrate-specific enzymes, would need to be introduced for Che’s proposal to be 
plausible. Specialised substrate-specific enzymes could direct the various proposed events 
detailed, such as the spirocyclisation of benzofuranone 3.34 with the enzymatically bound 
pyranol 3.33 and the several proceeding stereoselective reductions of 3.36 to obtain 
enantiopure virgatolide B (3.2). As such, the proposed pathway appears to be unnecessarily 
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convoluted and for these stated reasons, we would argue that Che’s biosynthetic pathway is 
unlikely to occur in nature. 
 Our Proposed Biosynthetic Pathway of Virgatolides 
A – C and Previous Related Work 
 Biomimetic Synthesis of Penilactones and Peniphenones via 
Employment of a Universal o-QM Intermediate 
 
Scheme 3.5: One-pot, biogenically inspired synthesis of the unnatural ent-penilactone A epimer 
(3.42) and penilactone B (3.45), by Spence and George.[153] 
Previously, our group had worked on a series of related natural products that shared similar 
biosynthetic intermediates, namely the penilactones and the peniphenones.[153,154] The link 
between these secondary metabolites was their shared biogenic precursor clavatol 3.46. 
Spence and George published two biogenically inspired syntheses for the total synthesis of 
penilactone B (3.45) alongside the unnatural isomer ent-penilactone A (3.42) in 2013 
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(scheme 3.5),[153] and the peniphenones A – D (3.53, 3.48, 3.50, 3.51) in 2015 (scheme 3.6 
and 3.7).[154] The biogenically inspired synthesis of both the penilactones and peniphenones 
detailed an o-QM intermediate (3.38) that was generated from the clavatol acetate derivative 
3.43. The acetate moiety was shown to serve as a labile leaving group that could eliminate 
under acidic, basic or thermal conditions to generate a highly reactive o-QM intermediate 
(3.38).  
 
Scheme 3.6: Divergent, biogenically inspired synthesis of the peniphenones B – D (3.48, 3.50, 3.51) 
via o-QM precursor 3.43, by Spence and George.[154] 
In Spence and George’s biogenically inspired synthesis of ent-penilactone A (3.42), o-QM 
3.38 was formed in situ from demethyl clavatol 3.37, which spontaneously underwent β-
elimination to generate the active o-QM 3.23 (scheme 3.5).[153] (S)-5-methyltetronic acid 
(3.39) was found to undergo two consecutive Michael additions (3.39 and 3.40) with the in 
situ generated o-QM 3.38, and upon ring closure (3.41), ent-penilactone A (3.42) was 
afforded in 46% yield. In the synthesis of penilactone B (3.45), the one-pot, biogenically 
inspired cascade sequence was restricted to the addition of the clavatol acetate derivative 
3.43, as it could not be generated in situ due to the presence of the carboxylic acid moiety of 
tetronic acid 3.44.[153] Under thermal conditions, addition of tetronic acid 3.44 with o-QM 
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precursor 3.43 led to a reaction cascade to give penilactone B (3.45), analogous to the 
sequence of cascade events (3.39 to 3.41) found with ent-penilactone A (3.42). The total 
synthesises of both ent-penilactone A (3.42) and penilactone B (3.45) serve as intriguing 
biomimetic transformations of o-QMs, adding validity to the ever-expanding proposed 
presence of these highly reactive species as biosynthetic intermediates in nature. Further 
investigation into biogenically viable o-QM intermediates came with our group’s synthesis 
of the peniphenones A – D (3.53, 3.48, 3.50, 3.51), where the previously explored o-QM 
precursor 3.43 was employed in a series of biogenically inspired coupling reactions, lending 
itself as a divergent biosynthetic intermediate (scheme 3.6).[154] 
 
Scheme 3.7: Spence and George’s biosynthetic proposal of peniphenone A (3.53), and their [4 + 2] 
model synthesis of peniphenone A (3.55) via the o-QM precursor 3.43.[154] 
In Addition to accommodating a clavatol moiety, shared between both the peniphenones 
(3.53, 3.48, 3.50, 3.51) and penilactones (3.42 & 3.45),[153] peniphenone D (3.51) was also 
found to possess an abridged 5-methyltetronic acid (3.39) substituent,[154] highlighting the 
two families seemingly related biogenic origins (scheme 3.6). Spence was able to control the 
formation of (S)-peniphenone D (3.51) by addition of both clavatol acetate 3.43 and (S)-5-
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methyltetronic acid (3.39) in an equal molar ratio, which ensured a second Michael reaction 
of did not occur.[154] Peniphenones B (3.48) and C (3.50) were afforded from arylated lactone 
3.47 and triphenol 3.49 respectively, by employing o-QM precursor 3.43 as a universal 
substrate. 
Spence and George proposed that peniphenone A (3.53) could form in nature via a [4 + 2] 
cycloaddition of o-QM 3.38 and Z-exocyclic enol ether (3.52) (scheme 3.7).[154] However, 
the desired Z-exocyclic enol ether 3.52 proved difficult to synthesise, and as such, 
peniphenone A (3.53) was synthesised in a non-biomimetic linear manner in good 
enantioselectivity (3.56 – 3.58) (scheme 3.7). Nonetheless, Spence and George investigated 
a model system, which led to the acquisition of 3.55 via a successful hetero-Diels-Alder 
cyclisation between in situ generated o-QM 3.38 and exocyclic enol ether 3.54. Our group’s 
work on the peniphenones and penilactones demonstrate that in addition to sharing the 
common clavatol subunit, the two families may also share the biogenic o-QM intermediate 
3.38, highlighting their seemingly analogous biosynthetic pathways in nature. 
 Our Proposal for the Biosynthetic Origins of Virgatolides A – C 
Here, we propose an alternative biosynthetic pathway for the virgatolides A – C (3.1 – 3.3), 
that runs counter to Che’s seemingly convoluted proposal (scheme 3.8 – a). Our proposal 
details the involvement of the co-isolated natural products pestaphthalides A (3.4) & B (3.5), 
which would serve as biogenic precursors to the proposed o-QMs 3.59 and 3.62 respectively. 
o-QM 3.59, derived from the oxidation of pestaphthalide A (3.4), would serve as a reactive 
diene to undergo a [4 + 2] hetero-Diels-Alder cycloaddition with the proposed Z-exocyclic 
enol ethers, 3.60 and 3.61, to afford both virgatolides A (3.1) and B (3.2) respectively. 
Additionally, as virgatolides B (3.2) & C (3.3) differ only by their isobenzofuranone moiety, 
our proposal details that o-QM 3.62, derived from pestaphthalide B (3.5), could undergo an 
analogous [4 + 2] cycloaddition with Z-exocyclic enol ether 3.61 to afford virgatolide C (3.3) 
in nature. We hypothesise that our biosynthetic proposal, with a hetero-Diels-Alder reaction 
as the pivotal biogenic step, would lead to the emergence of virgatolides A – C (3.1 – 3.3) 
possessing the correct stereoconfiguration without the need to introduce specific, resource 
demanding enzymes, as detailed in Che’s proposal (scheme 3.4). The stereoconfiguration of 
the proposed o-QMs, 3.59 or 3.62, and the Z-exocyclic enol ethers, 3.59 or 3.61, would in 
theory dictate the stereochemical outcome of the spirocyclisation event (Scheme 3.8 – a).[154]  
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Scheme 3.8, a): Our proposed biosynthesis of virgatolides A – C (3.1 – 3.3) via [4 + 2] cycloaddition 
of o-QM 3.59 or 3.62 with Z-exocyclic enol ether 3.60 or 3.61. b): Alternative proposed biosynthesis 
of virgatolide B (3.2) via a non-concerted stepwise, Michael addition and subsequent ring closure of 
o-QM 3.61 with Z-exocyclic enol ether 3.61. 
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Alternatively, the biosynthesis of the virgatolides (3.1 – 3.3) can be envisioned to proceed 
via a non-concerted, stepwise mechanism in nature (scheme 3.8 – b). Upon the formation of 
3.59 from pestaphthalide A (3.4), o-QM 3.59 may undergo nucleophilic attack from Z-
exocyclic enol ether 3.61 to generate either intermediate 3.59-3.61-a or -b. Both theoretical 
Michael/Mannich manifold intermediates 3.59-3.61-a and -b would be expected to freely 
interchange via rotation of the newly formed carbon-carbon bond, and hence, could 
potentially afford four products (3.2 to 3.2-c), including the desired natural virgatolide 
stereoisomer (3.2: (+)-virgatolide B) 
 Spence’s Unpublished Virgatolide B Model Studies 
 
Scheme 3.9: Unpublished synthesis of the o-QM precursor 3.66, and simplified exocyclic enol ether 
3.54, by Spence and George.[13,154–159]  
Our group has previously investigated a model system of virgatolide B (3.2) in accordance 
with our stated biosynthetic proposal.[154] The model system investigated conditions for the 
proposed [4 + 2] hetero-Diels-Alder cycloaddition between o-QM precursor 3.66 and 
exocyclic enol ether 3.54 to obtain virgatolide B analogue 3.68 (Table 3.1). The o-QM 
precursor 3.66 was synthesised over 11 steps from commercially available methyl 3,5-
dihydroxybenzoate 3.63,[156–159] and the simplified exocyclic enol ether 3.54 was acquired 
from commercially available (2-chloromethyl)tetrahydro-2H-pyran (3.67) (scheme 3.9). 
Due to issues regarding stability, 3.54 was used immediately upon preparation for 
investigations into the model hetero-Diels-Alder spiro-ketalisation reaction.[154,155]  
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Table 3.1: Screening of conditions for the [4 + 2] cycloaddition of o-QM precursor 3.66 and 
simplified exocyclic enol ether 3.54, by Spence and George. 




1 3.66 & 3.54 (1:1) PhMe, 110 °C, 16 h trace 19% (1:1) 
2 3.66 & 3.54 (1:10) PhMe, 110 °C, 16 h 8% (4:1) 2% (N.D.) 
3 3.66 & 3.54 (1:3) Dioxane, 110 °C, 16 h 12% (1:1.2) trace 
4 3.66 & 3.54 Et3N, PhMe, 100 °C, 16 h 0% 0% 
 
Investigation into model [4 + 2] cycloaddition reactions commenced with the screening of 
thermal conditions, following the successful synthesis of the o-QM precursor 3.66 and model 
exocyclic enol ether 3.54 (scheme 3.9). Spence found that heating the reactants 3.66 & 3.54 
in toluene (table 3.1, entry 1) led to isolation of only trace quantities of the desired spiroketal 
as a set of epimers 3.68 & 3.69, and primarily afforded the undesired 6,6 fused ring isomers 
3.71 & 3.72. The emergence of the fused ring by-products was attributed to isomerisation of 
3.54 to endocyclic enol ether 3.70, catalysed by liberated acetic acid following generation of 
o-QM 3.59. However, employment of a 1:10 ratio of reactants, 3.66 to 3.54, led to the 
acquisition of target epimers, 3.68 & 3.69 in a 4:1 ratio respectively (table 3.1, entry 3). 
Spence argued that reducing the equivalents of o-QM precursor 3.66, relative to 3.54, limited 
the number of available protons that could isomerise exocyclic enol ether 3.54, which 
therefore, would reduce the formation frequency of the undesired by-products 3.71 & 3.72. 
Upon changing solvent to dioxane, and further fine tuning the reactant ratio (table 3.1, entry 
2), Spence almost entirely eliminated the formation of the 6,6 fused isomers 3.71 & 3.72, 
while also maximising the formation of the desired virgatolide B epimers 3.68 & 3.69, 
isolated in a 1:1.2 ratio respectively. Finally, attempts at buffering the in situ generated acetic 
acid with Et3N failed to produce any products (3.68, 3.69, 3.71, 3.72) and the reaction 
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mixture was reported to undergo decomposition upon heating. Spence proposed that the 
secondary alcohol at C11 on the o-QM precursor 3.66, was unstable under basic conditions 
and may interfere with formation of the o-QM 3.59. 
 Retrosynthetic Analysis of Virgatolide B 
Based upon Spence’s model studies, we propose a retrosynthetic pathway for virgatolide B 
(3.2) that would lead to the necessary acquisition of a protected Z-exocyclic enol ether 3.74 
and Spence’s o-QM precursor 3.66 (scheme 3.10). As synthesis of the o-QM precursor 3.66 
has been previously explored, we did not seek to further optimised Spence’s developed route. 
 
Scheme 3.10: Retrosynthetic analysis of virgatolide B (3.2). 
Access to Z-exocyclic enol ether 3.74 was envisioned by a Wittig olefination of acetaldehyde 
with Wittig salt 3.75, which in turn could be accessed from a protected endocyclic enol ether 
(3.76) (scheme 3.10). However, there are few examples of compounds akin to that of 3.76 
which have been reported throughout the literature that can be accessed from readily 
available materials.[160] Endocyclic enol ether 3.76 could potentially be accessed from diol 
3.77 via a synthetic route akin to a protocol reported by Paquette.[160] However, issues 
regarding both regioselective installation of a given protecting group, and its stability 
towards acid and base conditions become apparent, upon consideration of the anticipated 
synthesis and activation of the desired Wittig salt (3.75). For the reasons stated above, due 
to their inert nature and selective method of removal, a benzyl ether protecting group strategy 
was selected as our first choice. However, we did foresee issues regarding the removal of a 
benzyl ether protecting group following the anticipated success of the [4 + 2] spirocyclisation 
event, as any spiroketal moiety was suspected to be unstable under both reductive and 
oxidative conditions. 
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 Pursuit of Virgatolide B 
We set out to synthesise virgatolide B (3.2) in accordance with our biosynthetic proposal, 
where a hetero-Diels-Alder cycloaddition between o-QM 3.59 and a protected Z-exocyclic 
enol-ether 3.74 could afford the spiroketal moiety. We sought to mirror Spence’s previously 
developed and modified synthetic protocol for the desired o-QM precursor 3.66 (scheme 
3.9) and to develop a synthetic protocol to access Z-exocyclic enol-ether 3.74 (vide supra).  
 Synthesis of Benzofuranone o-QM Precursor 3.66 
 
Scheme 3.11: Synthesis of E-alkene 3.81 from commercially available methyl 3,5-
dihydroxybenzoate 3.63.[159]  
As detailed in Spence’s protocol, methyl 3,5-dihydroxybenzoate 3.63 was employed as a 
suitable starting material in our pursuit of o-QM precursor 3.66. Following a three step 
protocol to benzaldehyde 3.73 by Bojja, methyl 3,5-dihydroxybenzoate 3.63 was benzylated 
upon addition of BnBr in acetone with K2CO3 under reflux (scheme 3.11).[159] The resultant 
crude benzyl protected ester 3.78 was reduced with excess LiAlH4, and the afforded impure 
alcohol 3.79 was subsequently oxidised via addition of two molar equivalents of PCC in 
CH2Cl2. Freshly acquired aldehyde 3.73 was synthesised in an impressive yield of 93% over 
three steps. Next, we set out to install the required E-alkenyl substituent in anticipation of 
the Sharpless asymmetric dihydroxylation, which would afford the isobenzofuranone 
moiety, characteristic of both virgatolide B (3.2) and pestaphthalide A (3.4). Benzaldehyde 
3.73 was alkylated under standard Grignard conditions with freshly prepared EtMgBr in 
Et2O to give alcohol 3.80. However, more consistent yields were achieved upon changing 
the solvent system to THF, as employment of Et2O in large scale reactions did not afford 
3.80 in reliable yields. We suspect the inability to heat the reaction while employing Et2O 
led to incomplete in situ generation of EtMgBr from EtBr and Mg, thereby reducing the 
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potential yield of alcohol 3.80. Following Spence’s optimised conditions, 3.80 was 
eliminated with p-TsOH under reflux using a Dean-Stark apparatus. Interestingly, the 
isolated ratio of E/Z alkene isomers 3.81 was seemingly dependent on the initial purity of 
the alkyl alcohol 3.80, as indicated by the poor 3:1 E/Z selectivity observed when using 
slightly impure starting material. However, provided that 3.80 was completely void of 
contaminating aldehyde 3.73, reproducible 9:1, E/Z ratios of alkene 3.81 were achieved 
(scheme 3.11). 
 
Scheme 3.12: Installation of the desired lactone moiety to afford 3.84, via a Sharpless asymmetric 
dihydroxylation.[13,156,157,161]  
Introduction of the methyl ester, adjacent to the newly installed E-alkene moiety, was 
required for the desired in situ lactonization to proceed during the Sharpless dihydroxylation 
event, as report by Spence (scheme 3.12). The methyl ester moiety could be introduced via 
three steps, first by regioselective formylation 3.82, followed by a Pinnick oxidation to 
carboxylic acid 3.83 and finally methylation to afford ester 3.64.[156,157,161] We predicted that 
the C4 position of alkene 3.81, during a Vilsmeier-Haack formylation, was sterically 
inaccessible, leaving the C2/C6 positions available to undergo formylation, which proceeded 
to afford benzaldehyde 3.82 exclusively as the desired regioisomer under standard 
conditions. Aldehyde 3.82 was oxidised under Pinnick conditions, and the afforded 
carboxylic acid 3.83 was subsequently methylated with MeI, which gave the desired methyl 
ester 3.64 in a yield of 60% over 2 steps.[156,157,161] NMR analysis of the afforded methyl 
ester 3.64 revealed that the alkene had not undergone isomerisation, maintaining its 
favourable 9:1 E/Z ratio. Under a modified Sharpless asymmetric dihydroxylation protocol, 
methyl ester 3.64 was stereoselectively dihydroxylated upon addition of AD-mix-α in the 
presence of the co-catalyst MeSO2NH2 (scheme 3.12).
[13] NMR analysis of purified 3.84 
confirmed the presence of the desired lactone moiety, thereby verifying Spence’s 
observation of an in situ lactonization during the dihydroxylation of methyl ester 3.64.  
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Scheme 3.13: Synthesis of o-QM precursor 3.66.[153,154,162]  
In preparation of installing the methylene acetate moiety, which would serve to initiate the 
formation of o-QM 3.59, the benzyl ether protecting groups of the acquired lactone 3.84 
were removed via a palladium catalysed hydrogenation to afford isobenzofuranone 3.65 in 
quantitative yield (scheme 3.13). Finally, o-QM precursor 3.66 was prepared upon addition 
of isobenzofuranone 3.84 to a mixture of aqueous 35% formaldehyde solution with NaOAc 
in AcOH, and the resultant mixture was heated overnight.[153,154,162] Formation of the desired 
o-QM precursor 3.66 is postulated to have formed first by formylation of isobenzofuranone 
3.84, which was theorised to undergo spontaneous elimination to generate o-QM 3.59 and 
upon nucleophilic attack from acetate, 3.66 was afforded. 1H and 13C NMR analysis revealed 
that the crude product existed as a mixture of starting material isobenzofuranone 3.65 and 
3.66 in a 1:1 ratio.[153,154] The crude precursor 3.66 could not be recrystallised, and attempts 
to purify the mixture via column chromatography were unsuccessful, most likely due to the 
sensitive nature of the methylene acetate moiety, and therefore, 3.66 was used immediately 
upon isolation. 
 Synthesis of Z-Exocyclic Enol Ether via a Wittig Olefination 
As described in our retrosynthetic analysis (scheme 3.10), an inert yet selectively labile 
protecting group was required in order to synthesise the desired protected Z-exocyclic enol 
ether 3.74. Based on these requirements, benzyl ether was chosen due to its favourable 
stability under acidic and basic conditions. The enantiopure, commercially available 3,4-Di-
O-acetyl-6-deoxy-L-glucal (3.85) served as the starting point of our route to the desired Z-
exocyclic enol ether 3.74. As there was no way to regioselectively remove the acetate ester 
at the C4 position, both esters would need to be hydrolysed, and the C4 alcohol of the 
resulting diol 3.77 would need to be regioselectively protected. Unfortunately, alternative 
commercially available starting materials that could afford our desired Z-exocyclic enol 
ether 3.74 did not appear feasible. However, Paquette et al reported a protocol that detailed 
hydrolysis of the commercially available diester 3.85, and the resultant diol 3.77 was 
regioselectively protected with benzoyl chloride.[160] With this in mind, we anticipated that 
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diol 3.77 may undergo a regioselective protection with benzyl bromide, analogous to 
Paquette’s benzoyl protection method.  
 
Scheme 3.14: Ester hydrolysis, and attempted mono-benzyl protection of diol 3.77.[160] 
In preparation of our attempted regioselective benzylation, 3,4-Di-O-acetyl-6-deoxy-L-
glucal (3.85) was subjected to catalytic NaOMe in MeOH, as described by Paquette (scheme 
3.14).[160] Regioselective benzylation was attempted via the drop-wise addition of BnBr to a 
mixture of diol 3.77 and NaH in DMF. However, despite attempts to minimise the formation 
of undesired protection products 3.87 & 3.88 by the gradual addition of BnBr over 3 hours, 
the desired benzylated regioisomer 3.86 was isolated as the minor product in very poor yield. 
Investigation into alternative aprotic solvents, temperature protocols, bases, and addition of 
TBAI failed to resolve the non-selective issues that appeared inherent with the benzylation 
of diol 3.77. 
 
Scheme 3.15: Ester hydrolysis, regioselective benzoyl protection 3.89, and synthesis of xanthate 
3.91 in preparation of Barton deoxygenation.[160] 
We sought to mirror Paquette’s benzoyl protection protocol to regioselectively protect the 
C4 alcohol of diol 3.77.[160] Following Paquette’s one-pot protocol, 3,4-Di-O-acetyl-6-
deoxy-L-glucal (3.85) was subjected to catalytic NaOMe in MeOH, and the solvent was 
removed. The resultant crude diol 3.77 was taken up in pyridine, cooled and regioselectively 
protected by gradual addition of benzoyl chloride over 3 hours to afford enol ether 3.89 
(scheme 3.15).[160] Continuing in our synthesis from the successful regioselective mono-
benzoylation, installation of a methyl xanthate substituent was required for the anticipated 
Barton deoxygenation at the C3 alcohol, to obtain the characteristic carbon framework of 
our proposed biogenically inspired precursor, Z-exocyclic enol-ether 3.74.[160] The C3-
methyl xanthate was installed via a one-pot, alkylation of the C3 hydroxy (3.89) with CS2, 
to give xanthate 3.90 in situ, which upon addition of MeI, underwent methylation to afford 
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3.91 in near quantitative yield (scheme 3.15). Following Paquette’s protocol, methyl 
xanthate 3.91 was subjected to thermal Barton deoxygenation conditions with Bu3SnH  in 
toluene and the radical initiator AIBN.[160] After 20 minutes, the solvent was removed and 
the resulting residue was rapidly flushed through a column of Et3N neutralised silica due to 
the alleged instability of 3.92, as reported by Paquette. Due to concerns regarding the 
incompatibility of the benzoyl ester in the foreseen Wittig olefination reaction, we attempted 
to change to a more robust protecting group. However, upon subjecting 3.92 to Paquette’s 
previously explored ester hydrolysis conditions employing catalytic NaOMe in MeOH,[160] 
only trace quantities of the alcohol 3.93 could be isolated following column chromatography 
(scheme 3.16). 3.93 was found to be a mixture with the methyl benzoate, which could not 
be removed under reduced pressure due to the apparent volatility of alcohol 3.93. 
 
Scheme 3.16: Barton deoxygenation, and attempted deprotection to obtain alcohol 3.93.[160] 
Due to issues regarding the removal of the benzoyl ester, a more suitable, inert protecting 
group could not be installed, and we therefore proceeded in our pursuit of Wittig salt 3.94 
from benzoyl protected enol ether 3.92 (scheme 3.17). Ley et al reported a procedure in 
1985, that detailed the synthesis of a series useful Wittig salts that could be generated by 
treatment of cyclic enol ethers with gaseous HCl in benzene.[163] Upon addition of PPh3, the 
resulting cyclic chlorinated enol ethers were shown to undergo nucleophilic attack to afford 
the desired Wittig salt.[163] However, we suspected that addition of any gaseous hydrogen 
halide would hydrolyse the benzoyl ester of 3.92, thereby introducing significant issues upon 
base activation of the Wittig salt to the corresponding desired ylide. For this reason, the 
triphenylphosphine conjugate base of hydrogen bromide, PPh3·HBr, was employed in our 
attempts to the synthesise 3.94. As PPh3·HBr was a conjugate base of HBr, we anticipated 
that upon the attempted synthesis of Wittig salt 3.94, the conjugate acid may be more tolerant 
to the benzoyl protecting group of enol ether 3.92.  
 
Scheme 3.17: Attempted synthesis of Wittig salt 3.94 and diphenylphosphine oxide 3.96.[163] 
253 |                                                                                                                 A. W. Markwell-Heys 
Treatment of benzoyl enol ether 3.92 with PPh3·HBr led to the isolation of benzoyl protected 
Wittig salt 3.94 as a mixture with the deprotected salt 3.95, as revealed by 1H and 13C NMR 
analysis of the crude, inseparable salts (scheme 3.17). Decomposition ensued upon efforts 
to activate the Wittig salts (3.94 and 3.95) with strong bases, such as n-BuLi, t-BuLi or LDA, 
and no observable product had formed following the addition of acetaldehyde to the reaction 
mixture.[163] As the Wittig salts could not be separated or successfully activated, we turned 
our attention to obtaining the deprotected diphenylphosphine oxide ether 3.96, which could 
be obtained by heating 3.94 & 3.95 under refluxing aqueous NaOH solution, as reported by 
Ley.[163] The mixture of Wittig salts 3.94 & 3.95 was heated under basic hydrolysing 
conditions to afford the deprotected diphenylphosphine oxide 3.96, which could not be 
adequately purified due to issues regarding its stability. Despite their initial discovery in 
1958 by Horner et al,[164–168] few examples of Horner-Wittig olefinations have been reported 
throughout the literature. Regardless of their lack of usage within the literature, Warren and 
Ley noted that phosphine oxide carbanion species that possess electron donating β-oxygen 
substituents have been observed to suffer thermal instability compared to their ylide 
counterparts.[163,169] Thus, diphenylphosphine oxides that possess β-electron donating 
substituents were claimed to afford more stable carbanion species in situ than ylides. 
With the diphenylphosphine oxide ether 3.96 in hand, we set out to screen olefination 
conditions utilising non-nucleophilic bases that might be more tolerant of the free hydroxy 
group at C4 (table 3.2). Attempts to deprotonate 3.96 to the carbanion with LiHMDS (entry 
1, table 3.2), LDA (entry 2, table 3.2), t-BuOK (entry 3, table 3.2) or NaH (entry 4, table 
3.2) led to the same observed formation of a deep red solution, characteristic of the active 
diphenyl oxyphosphonium carbanion species, as described by Ley.[163] However, despite the 
apparent appearance of this anionic species, addition of acetaldehyde did not yield any 
observable product. Upon investigation of n-BuLi (entry 5, table 3.2), the anticipated 
characteristic red colourisation of the reaction mixture was not observed and decomposition 
of 3.96 ensued. We suspected that the free hydroxy group was deprotonated in preference to 
the electronically withdrawn proton at C2, which may have prevented formation of the active 
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Table 3.2: Screening of conditions for the Horner-Wittig olefination of 3.96 with acetaldehyde. 
Entry Base (eq)/Solvent Conditions Outcome 
1 LiHMDS (2) / THF -78 °C to rt, 1 h complex mixture 
2 LDA (2) / THF  -78 °C to 0 °C, 1 h decomposition 
3 t-BuOK (2) / THF 0 °C to 40 °C, 5 h complex mixture 
4 NaH (2) / THF 0 °C to rt, 8 h complex mixture 
5 n-BuLi (1.5) / THF -78 °C to 0 °C, 1 h decomposition 
 
As diphenylphosphine oxide ether 3.96 could not be selectively deprotonated with any 
conventional base, protecting the free C4 alcohol appeared necessary to continue with our 
olefination route. However, suitable protecting groups were limited, as upon attempting to 
install a chosen protecting group, we would suspect that any reasonably strong base may 
deprotonate the C2 proton of 3.96 to potentially afford the oxyphosphonium carbanion (table 
3.2). Silyl ethers were investigated as a viable protecting group strategy, as few options 
appeared available to us due to the relatively harsh installation conditions required for most 
alternative strategies. Simpler silyl chlorides, such TMSCl and TBSCl, for the protection of 
diphenylphosphine oxide ether 3.96, failed to afford any of the respective anticipated silyl 
ethers. However, changing to a larger silyl chloride, t-butyldiphenylsilyl ether 3.98 was 
afforded upon subjecting 3.96 to a solution of TBDPSCl with imidazole in DMF, albeit in a 
very low yield (scheme 3.18).[170]  
 
Scheme 3.18: Attempted t-butyldiphenylsilyl protection of 3.96.[170] 
 Pursuit of Z-Exocyclic Enol Ether via a Modified-Julia Olefination 
With so many complications inherent to the Wittig and Horner-Wittig olefination route, we 
sought to revise our approach to Z-exocyclic enol ether 3.74. Revision of the literature led 
us to a series of methodology articles reported by Gueyrard that detailed the olefination of 
lactones via a modified-Julia protocol.[171–173] Gueyrard had published multiple articles 
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focused around developing protocols for the olefination of lactones to afford cyclic enol 
ethers akin to our desired Z-exocyclic enol ether 3.74.[173] Therefore, based on Gueyrard’s 
protocol, we set out to synthesise the desired Z-exocyclic enol ether 3.74 from lactone 3.99 
(scheme 3.19). However, acquiring a protected lactone 3.99 from diol 3.77 would prove 
difficult, as the lactone moiety was expected to be incompatible with Paquette’s explored 
route and an alternative starting material did not appear feasible.[174] Therefore, our new 
focus shifted towards developing a protocol for the conversion of endocyclic enol ether 3.92 
to lactone 3.99. We foresaw that the simplest approach to acquiring 3.99 was through 
hydration of endocyclic enol ether 3.92 to a lactol, which could be theoretically oxidised to 
afford the desired lactone (scheme 3.19). 
 
Scheme 3.19: Revised retrosynthesis of 3.74. 
With the new goal of accessing lactone 3.99, we set out to synthesise lactol 3.102-a via 
hydration of benzoyl protected ether 3.92. With few examples for the synthesis of lactols 
from enol ethers akin to our own (3.102-a), we initially set out to investigate relatively mild 
acidic conditions for the hydration of 3.92. Pyridinium p-toluenesulfonate in a mixture of 
THF/H2O (entry 1, table 3.3) led to the slow decomposition of enol ether 3.92, while addition 
of AcOH (entry 2, table 3.3) failed to afford any products, as it was suspected to be 
inadequately acidic. As predicted, all strong acids investigated, such as TFA (entry 3, table 
3.3), p-TsOH·H2O (entry 4, table 3.3), and aq. HCl (entry 5, table 3.3) failed to afford any 
desired lactol 3.102-a and appeared to induce decomposition of the starting endocyclic enol 
ether 3.92. A protocol by Gilmore detailed an alternative hydration method, where exocyclic 
enol-ethers could be treated with Ph3P·HBr in THF to afford their corresponding lactols.
[175] 
As reported by Gilmore, in the form of its triphenylphosphine conjugate base, HBr could 
induce addition across the alkenyl carbons, and the corresponding newly formed C-Br bond 
could subsequently undergo nucleophilic attack by water in situ to afford the desired lactol 
3.102-a (entry 6, table 3.3). However, upon subjecting benzoyl protected enol ether 3.92 to 
Ph3P·HBr, formation of the desired lactol 3.102-a was not observed, and only decomposition 
by-products, unreacted enol ether 3.92, and a mixture of unresolvable by-products were 
isolated. Given that no identifiable products were isolated upon attempting to hydrate 
benzoyl protected enol ether 3.92 (table 3.3), we suspect 3.92 may have undergone an 
elimination sequence, akin to that of 3.102-b to 3.102-d, to generate substituted pyran 3.102-
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d (table 3.1, table 3.3, b). Upon formation of the plausible pyran intermediate 3.102-d, an 
acid catalysed polymerisation could ensue, leading to the degraded unresolvable mixture 
observed for all conditions investigated (table 3.1).   
 
Table 3.3: Attempted hydration of benzoyl protected enol-ether 3.92 to lactol 3.102-a.[175,176] 
Entry Acid (eq)/Solvent  Conditions Outcome 
1 Pyridinium p-toluenesulfonate (2) / THF:H2O rt, 8 h decomposition 
2 AcOH (2) / THF:H2O rt, 16 h  no product 
3 TFA (1.1) / THF:H2O 0 °C to rt, 3 h decomposition 
4 p-TsOH (1.1) / THF:H2O 0 °C to rt, 1 h  decomposition 
5 aq. HCl (1.1) / THF:H2O 0 °C, 1 h decomposition 
6 Ph3P·HBr (1.2) / THF then H2O rt, 3 h  decomposition 
 
b): suspected acid catalysed side reaction, potentially leading to polymerisation via pyran 3.102-b. 
As all the investigated hydration conditions either led to decomposition, or were suspected 
to eliminate the benzoyl moiety, we set out to investigate a new protocol to access the desired 
lactone 3.103 (scheme 3.20). In 1977, Piancatelli reported an unconventional method for 
acquiring lactones and esters from enol ethers directly via oxidation with pyridinium 
chlorochromate (PCC).[177] Following Piancatelli’s general procedure, benzoyl protected 
endocyclic enol ether 3.92 was subjected to a suspension of 1.5 equivalents of PCC in 
CH2Cl2, and the mixture was stirred for 5 hours (scheme 3.20). However, upon the attempted 
purification of the reaction mixture, no desired benzoyl protected lactone 3.103 was 
observed, and only a seemingly degraded, complex mixture of unidentifiable by-products 
was obtained. Similarly, we suspect that PCC may have been too acidic of a reagent, and 
3.92 could have undergone a similar sequence as previously proposed (table 3.3, b) to afford 
pyran 3.102-b, which may have undergone polymerisation to afford the observed 
unresolvable mixture of seemingly degraded by-products. 
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Scheme 3.20: Attempted oxidation of benzoyl protected enol-ether 3.92 to lactone 3.103.[177] 
As investigated hydration conditions and Piancatelli’s protocol with PCC failed to afford 
any desired product, the benzoyl ester was appeared to be highly susceptible to hydrolysis 
under acidic conditions. Therefore, we set out to investigate a new protecting group strategy, 
which would prove more resilient to acidic conditions. Choosing an alternative suitable 
protecting group appeared difficult, as regioselectivity issues had previously proved 
problematic, as was observed in the attempted regioselective benzylation of diol 3.77 
(scheme 3.14). Based on our previous investigations for the protection of diol 3.77, we 
postulated that a reagent that was both sterically hindered and possessed a labile leaving 
group was required in order to achieve regioselective protection of the C4 hydroxyl 
substituent. A given reagent that met these requirements would be expected to react rapidly 
at reduced temperatures in a regioselective manner. Therefore, based on this set of criteria, 
few protecting groups appeared suitable outside of a selection of common silyl ethers. 
TBDPS was the first silyl protecting group investigated in our strategy due to its significantly 
sterically hindered substituents, while also displaying the most inert reactivity towards acidic 
conditions of the other commonly available silyl chlorides. TBDPS protected enol ether 
3.104 was prepared in near quantitative yield by stirring a mixture of diol 3.77, TBDPSCl 
and imidazole in DMF overnight at room temperature (scheme 3.21). The desired C4 silyl 
protected regioisomer 3.104 was confirmed as the exclusive product as indicated by key 
NOE correlations and comparison of the obtained 1H & 13C NMR spectra peaks with that of 
the literature.[178]  
 
Scheme 3.21: Ester hydrolysis, followed by mono-silyl protection of 3.104.[160,178,179] 
Following the successful regioselective silyl protection of diol 3.77, we set out to 
deoxygenate 3.104 under the same Barton conditions that were previously investigated for 
our benzoyl ester route.[160] Following the previously explored two-step, one-pot method for 
the synthesis of benzoyl methyl xanthate 3.91 (scheme 3.15), silyl protected alcohol 3.104 
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was subjected to a suspension of NaH in CS2, followed by addition of MeI to afford 
methylated xanthate 3.105 (scheme 3.21). Upon isolation, methyl xanthate 3.105 was heated 
in toluene with Bu3SnH and AIBN to afford the desired deoxygenated enol ether 3.106. 
 
Scheme 3.21: Synthesis of silyl protected enol ether 3.106 via Barton deoxygenation.[160] 
Employing Piancatelli’s procedure as a template,[177] endocyclic enol ether 3.106 was 
subjected to a suspension of 1.5 equivalents of PCC in CH2Cl2 and the mixture was stirred 
overnight to afford the desired lactone 3.107 in a reasonable yield of 55% (scheme 3.22). 
While monitoring the oxidation of the enol ether 3.106 by TLC analysis, a series of polar 
by-products were observed to form, which were isolated as an inseparable mixture. 13C NMR 
analysis of the mixture revealed multiple sp2 deshielded carbon shifts that were in the range 
of typical carbonyl species. Piancatelli reported the appropriate afforded esters and lactones 
in yields typical of 75 - 95%, which were notably higher yields than achieved for our 
oxidation of 3.106 to 3.107. We suspect the disparity in yields observed with our endocyclic 
enol ether system (3.106) may lie with the apparent lability of the TBDPS ether, where 
cleavage facilitated by chromic acid upon addition of PCC could lead to the formation of a 
mixture of hydrolysed and oxidised undesired by-products (3.108 – 3.110) (scheme 3.22). 
All attempts to further optimise the oxidation protocol, by varying the relative molar 
equivalents of PCC added, along with physical conditions, such as temperature and reaction 
times, failed to afford yields in excess of 55%. 
 
Scheme 3.22: Synthesis of lactone 3.107 via PCC mediated oxidation of endocyclic enol ether 3.106, 
and proposed constituents (3.08 – 3.110) of the inseparable mixture of undesired by-products.[177] 
In his original paper, Piancatelli proposed a mechanism for the direct oxidation of various 
enol ethers with PCC.[177] Piancatelli postulated that the oxidation event could be initiated 
by an electrophilic attack of PCC with a given enol ether (3.106), to generate an unstable 
cyclic intermediate, such as 3.111 (scheme 3.23). Piancatelli theorised the unstable 5-
membered species (3.111) would undergo a spontaneous pericyclic heterolytic cleavage at 
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the Cr-O and C-O bonds, alongside a concerted hydride shift to afford the desired lactone 
(3.107).  
 
Scheme 3.23: Proposed mechanism for oxidation of enol ether 3.106 to lactone 3.107.[177] 
With access to lactone 3.107, we set out to acquire a suitable alkylating reagent for the 
anticipated modified-Julia olefination, and thereby sought to synthesise ethylsulfonyl 
benzothiazole 3.114 in two steps via a literature procedure (scheme 3.24).[173] First, S-
alkylation was achieved via a one-pot protocol, by deprotonation of commercially available 
mercaptobenzothiazole 3.112, and addition of ethyl bromide gave ethylthio-benzothiazole 
3.113 in good yield.[180] Next, the resultant alkylated thio-benzothiazole 3.113 was subjected 
to a mixture of catalytic ammonium heptamolybdate and hydrogen peroxide to afford the 
desired S-oxidised ethylsulfonyl benzothiazole 3.114.[172] Synthesis of ethylsulfonyl 
benzothiazole 3.114 proved to be efficient, simple, and could be prepared in large quantities 
if needed.  
 
Scheme 3.24: Preparation of ethylsulfonyl benzothiazole 3.114.[172] 
With both the lactone 3.107 and ethyl-sulfonylbenzothiazole 3.114 in hand, we set out to 
investigate the synthesis of Z-exocyclic enol ether 3.115 via both standard modified-Julia 
olefination methods and a protocol published by Gueyrard (table 3.4).[171–173] Standard 
modified-Julia olefination protocols have been largely limited to ketone & aldehyde 
substrates, and generally require a strong base, such as LDA or n-BuLi, to deprotonate the 
α-proton of a substituted sulfonylbenzothiazole (3.114).[181,182] However, over the last 
decade, Gueyrard had published a series of articles detailing the optimisation of a modified-
Julia method that could extend the scope of the olefination protocol to lactones and 
anhydrides, by employing BF3·OEt2 as an activating agent.
[171–173,183,184]   
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Table 3.4: Modified-Julia olefination of lactone 3.107, with ethylsulfonyl benzothiozole 3.114.  
Entry Base (eq)/Additive (eq) Conditions Outcome 
Ratio of Z:E (3.115:3.116) 
1 LiHMDS (1.5) THF, -78 °C to rt, 2 h no product, SM 
2 KHMDS (1.5) THF, -78 °C to rt, 2 h no product, SM 
3 LDA (1.2) THF, -78 °C to 0 °C, 2 h decomposition 
4 t-BuLi (1.2) THF, -78 °C to 0 °C, 1 h decomposition 
5 t-BuOK (2) THF, 0 °C to rt, 16 h no reaction, SM 
6 NaH (1.2) THF, 0 °C to rt, 5 h complex mixture,  
no product 
7 LiHMDS (1.3)/BF3·OEt2 (1.3) THF, -78 °C to rt, 1 h 24% (1.4:1) 
8 KHMDS (1.3)/BF3·OEt2 (1.3) THF, -78 °C to rt, 1 h 19% (1.4:1) 
 
We initially sought to trial standard modified-Julia protocols with various bases, to observe 
if our lactone system (3.107) could undergo olefination in the absence of a Lewis acid 
additive.[171,172,182] In the attempted olefination of lactone 3.107 with ethyl 
sulfonylbenzothiazole 3.114, both LiHMDS (entry 1, table 3.4) and KHMDS (entry 2, table 
3.4) failed to afford any observable product and only small quantities of lactone 3.107 were 
recovered upon purification of the reaction mixture. Stronger, yet sterically smaller bases, 
such as LDA (entry 3, table 3.4) and n-BuLi (entry 4, table 3.4), also failed to afford any 
isolatable product and only gradual degradation of the reaction mixture ensued. Additionally, 
both t-BuOK (entry 5, table 3.4) and NaH (entry 6, table 3.4) did not yield any desired Z-
exocyclic enol ether 3.115. Under Gueyrard’s protocol, the employment of BF3·OEt2 as an 
activating agent, with either  LiHMDS (entry 7, table 3.4) or KHMDS (entry 8, table 3.4), 
led to the formation of an inseparable mixture of adducts. According to Gueyrard, this 
mixture of hemiketal-sulfonylbenzothiazole adducts could not undergo spontaneous 
decomposition in situ to the corresponding exocyclic enol ethers, unlike their ketone and 
aldehyde counterparts. Instead, the hemiketal adducts could only be hydrolysed upon stirring 
the crude mixture in a concentrated solution of DBU in THF, following quenching of the 
reaction.[173,183] Thus, following alkylation of 3.107, in the presence of BF3·OEt2 with either 
LiHMDS (entry 7, table 3.4) or KHMDS (entry 8, table 3.4), the crude hemiketal adducts 
were subjected to DBU in THF to afford an inseparable mixture of Z/E-exocyclic enol ethers 
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3.115:3.116 in a 1.4:1 ratio respectively. Gueyrard had also reported an alternative method 
for the olefination of anhydrides, where decomposition of the hemiketal adducts to the 
desired olefins could be achieved upon concentration of the quenched reaction mixture over 
SiO2.[184,185] However, quenching the alkylation reaction with AcOH and concentrating the 
resultant adducts over SiO2 failed to yield any Z/E-exocyclic enol ethers 3.115:3.116, and 
instead only afforded the crude mixture of hemiketal adducts. 
Gueyrard and co-workers had not formerly proposed a mechanism that could rationalise, and 
consequently predict the stereochemical outcome for their BF3·OEt2 mediated olefination 
protocol, and only noted that both lactones & anhydrides did not undergo spontaneous 
decomposition to their corresponding enol-ethers in situ. According to Gueyrard, the 
improved yields of the desired enol-ethers obtained were attributed to the strong electrophilic 
properties of BF3·OEt2, which were suspected to increase the nucleophilic nature of the 
carbonyl moiety of a given lactone substrate, thereby promoting favourable reaction kinetics 
for the olefination event (entries 7 & 8 table 3.4).[173,183] Furthermore, BF3·OEt2 most likely 
partakes in the condensation transition state of lactone 3.107 with benzothiazole 3.114. As 
such, BF3·OEt2 would be expected to replace the base counter ion (LiHMDS or KHMDS) 
within the transition state. Hence, if a chosen base differed solely in the size of its counter 
ion (Li+ or K+), then we would expect that the counter ion, regardless of its size, would not 
influence the ratio of products isolated under Gueyrard’s method.[173,183] As such, the 
employment of BF3·OEt2 may explain the consistent Z/E ratio of enol ethers (3.115:3.116) 
isolated, irrespective of the silylamide base, LiHMDS (entry 7, table 3.4) or KHMDS (entry 
8, table 3.4), employed. Despite attempts to further optimise Gueyrard’s protocol in the 
pursuit of Z-exocyclic enol ether 3.115, issues regarding stereoselectivity and yields could 
not be resolved. Thus, we did not persist in efforts to further optimise the synthesis of Z-
exocyclic enol ether 3.115 and sought to explore our proposed key biomimetic hetero-Diels-
Alder spirocyclisation reaction to obtain virgatolide B (3.2).   
 Attempted Hetero-Diels-Alder Reaction, Virgatolide B  
Despite the inability to further optimise the modified-Julia reaction in the pursuit of Z-
exocyclic enol ether 3.115, we continued with our biogenically inspired synthesis of 
virgatolide B (3.2) via a hetero-Diels-Alder reaction. As Z-exocyclic enol ether 3.115 could 
neither be synthesised in good yield or acquired exclusively as the desired isomer, we 
pressed onward to virgatolide B (3.2), initially investigating Spence’s thermal model 
conditions with our more complex Z-exocyclic enol ether 3.115 system. However, under 
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thermal conditions, neither spirocycle 3.117, virgatolide B (3.2) or other identifiable by-
products were observed to form under various relative molar ratios of 3.66 to 3.115:3.116 
(entries 1, 2, 3, table 3.5). In contrast to Spence’s successful model system, changing 
solvents from toluene to dioxane also failed to yield any identifiable products (entry 4, table 
3.5). All thermal conditions explored failed to afford any desired products (3.2 or 3.117), 
and only unidentifiable complex mixtures were isolated (entries 1 – 4, table 3.5). Under the 
thermal conditions investigated thus far, none of the isolated complex mixtures contained 
any 1H or 13C NMR signals that resembled virgatolide B (3.2) or the desired protected 
precursor 3.117. Next, exploration of alkaline conditions with Et3N led to the gradual 
degradation of the reactants in either toluene or dioxane (entries 6 & 8, table 3.5), and rapid 
decomposition ensued upon heating the reactants (entries 5 & 7, table 3.5). Finally, 
substituting Et3N for NaHCO3 also failed to afford any distinguishable products, and only 
complex mixtures were obtained following purification of the reaction mixture (entries 9 & 
10, table 3.5).  
 
Table 3.5: Attempted synthesis of virgatolide B precursor 3.117 via a 4 + 2 cycloaddition of o-QM 
precursor 3.66 with Z/E-exocyclic enol ethers 3.115:3.116 (1.4:1 ratio respectively). 
Entry Reagents (eq)  Solvent/Conditions Outcome 
1 3.66 and 3.115:3.116 (1:1) PhMe, 110 °C, 16 h complex mixture 
2 3.66 and 3.115:3.116 (1:5) PhMe, 110 °C, 16 h complex mixture 
3 3.66 and 3.115:3.116 (1:10) PhMe, 110 °C, 16 h complex mixture 
4 3.66 and 3.115:3.116 (1:5) dioxane, 110 °C, 16 h complex mixture 
5 3.66 and 3.115:3.116 (1:5) Et3N, PhMe, 100 °C, 6 h decomposition 
6 3.66 and 3.115:3.116 (1:5) Et3N, PhMe, rt, 6 h decomposition 
7 3.66 and 3.115:3.116 (1:5) Et3N, dioxane, 100 °C, 5 h decomposition 
8 3.66 and 3.115:3.116 (1:5) Et3N, dioxane, rt, 16 h decomposition 
9 3.66 and 3.115:3.116 (1:5) NaHCO3, dioxane, 100 °C, 5 h decomposition  
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Consistent with our findings, Spence argued that the secondary alcohol at C11 of 3.66 was 
sensitive under alkaline conditions, and that upon the addition of a base, decomposition 
would ensue. Under basic conditions, the C11 alcohol may have proven to be sufficiently 
nucleophilic, which may have resulted in 3.66 preferentially self-condensing with the in situ 
generated o-QM 3.59 via nucleophilic attack. We suspect that under solvent only conditions 
(entries 1 – 4, table 3.5), Z-exocyclic enol ether 3.115 isomerises to the undesired endo 
isomer in situ, catalysed via acetic acid following β-elimination of 3.66 to o-QM 3.59, as 
observed under Spence’s model system (table 3.1). Isomerisation of the already 
unfavourable mixture of Z/E-exocyclic enol ethers 3.115:3.116, alongside apparent 
decomposition, may have led to the formation of what appeared to be a series of unpurifiable, 
unidentifiable complex mixtures. An alternative explanation may reside with the bulky 
OTBDPS protecting group, which could have prevented the hetero-Diels-Alder transition 
state from proceeding. Therefore, to exclude the possibility of the TBDPS protecting group 
impeding the formation of the hetero-Diels-Alder transition state, we set out to cleave the 
silyl ether of Z/E-exocyclic enol ethers 3.115:3.116 (1.4:1 ratio). However, all attempts to 
cleave the TBDPS ether of 3.115:3.116 failed to afford any observable product, and no 
isolatable products (3.118 & 3.119), including starting material, were recovered following 
the addition of TBAF (scheme 3.25). Thus, virgatolide B (3.2) and the protected precursor 
3.117 could not be synthesised in accordance with our biogenically inspired proposal. 
 
Scheme 3.25: Attempted deprotection of Z/E-exocyclic enol ethers 3.115:3.116 (1.4:1 ratio). 
 Summary and Future Directions 
Despite our proposed, biogenically inspired hetero-Diels-Alder pathway failing to afford 
virgatolide B (3.2), we were able to synthesise both cycloaddition substrates, o-QM 3.66 and 
Z-exocyclic enol ether 3.115. With minor modifications to Spence’s protocol, 
benzofuranone 3.65 was synthesised in 10 synthetic steps, in an overall yield of 36%, slightly 
improving upon Spence’s overall yield of 32% for 3.65. Benzofuranone 3.65 was 
successfully converted to the pivotal o-QM precursor 3.66, albeit as a crude mixture with 
3.65, and could not be purified due to issues regarding the inherent instability of the methenyl 
acetate moiety. The failed attempted synthesis of Z-exocyclic enol ether 3.74, via a 
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Wittig/Horner-Wittig olefination, was attributed to the labile nature of the benzoyl protecting 
group. Due to the restricted viable synthetic route available from 3,4-Di-O-acetyl-6-deoxy-
L-glucal (3.85), alternative protecting group strategies were highly limited. However, upon 
changing to a TBDPS protecting group strategy early in the synthetic route, and shifting our 
focus to a suitable lactone in the pursuit of Z-exocyclic enol ether 3.115, lactone 3.107 was 
acquired from 3,4-Di-O-acetyl-6-deoxy-L-glucal (3.85) over 5 steps, in an overall yield of 
49%. Under Gueyrard’s modified-Julia protocol, lactone 3.107 was demonstrated to undergo 
olefination in the presence of BF3·OEt2 to afford the desired Z/E-exocyclic enol ethers 
3.115:3.116, in a 1.4:1 ratio respectively.  
Finally, investigation into our proposed biogenically inspired hetero-Diels-Alder 
spirocyclisation reaction between Z-exocyclic enol ether 3.115 (as a mixture of Z/E-isomers 
3.115:3.116, in a 1.4:1 ratio) and the in situ generated o-QM 3.59, failed to afford either 
virgatolide B (3.2) or the anticipated TBDPS protected precursor 1.117 (table 3.5). Based 
upon NMR analysis of the isolated fractions, the absence of observable characteristic peaks 
for the expected desired products (3.2 or 1.117) indicated the possibility of multiple 
unfavourable side reactions occurring within the vessel. The failure of the investigated 
conditions was suspected to be primarily attributed to the in situ isomerisation of the Z/E-
exocyclic enol ethers 3.115:3.116 to the endo isomer, akin to Spence’s model system. 
Suspected isomerisation of Z-exocyclic enol ether 3.115 to the endo isomer, analogous to 
Spence’s model system (table 3.1), may have led to consumption of the dienophile 3.115. 
Additionally, the large TBDPS ether protecting group of Z-exocyclic enol ether 3.115 may 
have impeded the hetero-Diels-Alder transition state from forming. However, given that the 
protecting group is relatively distal from the exocyclic alkene, this prediction would appear 
unlikely. Thus, degradation of the reactants (3.115, 3.66, and 3.59) and isomerisation of Z-
exocyclic enol ether 3.115 appears to be the most likely explanation for the failed attempted 
synthesis of spiroketal TBDPS ether 3.117. 
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 Future directions 
 
Scheme 3.26: Potential future biosynthetically inspired total synthesis of virgatolide B (3.2) 
Future investigations into the synthesis of virgatolide B (3.2), in accordance with our 
biosynthetic proposal, would need to address two key issues. First, to investigate an 
alternative pathway to obtain protected Z-exocyclic enol-ether 3.74, either by changing to a 
smaller protecting group for the modified-Julia olefination pathway explored, or to develop 
an entirely new synthetic route. Second, to synthesise an o-QM precursor that could be 
activated to the corresponding o-QM 3.59 under mild conditions. As stated in our proposal, 
pestaphthalide A (3.4) may serve as a direct biogenic source of o-QM 3.59 in the 
biosynthesis of virgatolides A (3.1) and B (3.2). Thus, a selective methylation of 
benzofuranone 3.65, followed by an oxidative dearomatisation of pestaphthalide A (3.4), 
could generate o-QM 3.59 in situ. Additionally, any oxidant employed, such as PIDA 
(phenyliodine(III) diacetate) or lead acetate, must prove tolerant of both the C11 alcohol of 
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 Supporting Information 
 General Experimental 
All commercially obtained chemicals were used without further purification. Solvents stated 
as dry, were either collected from a solvent purification system (THF or DMF) or distilled 
under an atmosphere of nitrogen and stored over 3Å molecular sieves. Thin-layer 
chromatography (TLC) was conducted on Merck silica gel 60 F254 aluminium sheets and 
visualised under a UV lamp or with ceric ammonium molybdate (CAM), vanillin or 
potassium permanganate staining followed by heated. All Rf values were rounded to the 
nearest 0.01. Unless stated otherwise, Davisil 43-60 micron chromatographic silica media 
was used for flash chromatography. 1H and 13C NMR spectra were either recorded on an 
Agilent 500 spectrometer (1H at 500 MHz, 13C at 125 MHz) or on an Agilent spectrometer 
with a 600 MHz Oxford magnet, with a cryoprobe (1H at 600 MHz, 13C at 150 MHz) in 
CDCl3 as the solvent, unless specified. 1H and 13C chemical shifts are reported in ppm 
relative to TMS (δ 0.0). All J values were quoted to the nearest 0.1 Hz. Multiplicities are 
reported as (br) Broad, (s) singlet, (d) doublet, (t) triplet, (q) quartet, (qnt) quintet, (sext) 
sextet and (m) multiplet. IR spectra were recorded on a Perkin-Elmer Fourier-Transform 
Infrared (FT-IR) spectrometer on a nickel-selenide crystal as neat compounds. High 
resolution mass spectra were obtained on an Agilent ESI high resolution mass spectrometer. 
Melting points were recorded on a Reichert electrothermal melting point apparatus and are 
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 Experimental Procedures 
Methyl 3,5-dibenzyloxybenzoate 3.78 
 
To a solution of methyl 3,5-dihydroxybenzoate 3.63 (20.0 g, 119 mmol) and K2CO3 (34.5 g, 
250 mmol) in acetone (200 mL), was added BnBr (29.7 mL, 250 mmol) and the mixture was 
heated under reflux for 24 h. K2CO3 was filtered off, and the filtrate was concentrated in 
vacuo. The resultant residue was taken up in EtOAc (250 mL) and H2O (200 mL). The 
organic layer was separated, and the aqueous phase was extracted with EtOAc (2 × 200 mL). 
The combined organic extracts were washed with brine, dried over MgSO4 and concentrated 
in vacuo. The residue was purified by flash column chromatography on SiO2 (petrol/ethyl 
acetate, 4:1) to give methyl 3,5-dibenzyloxybenzoate 3.78 as an off-white precipitate (41.1 
g, quantitative). The spectroscopic data was consistent with that reported in the literature.[159]  
Rf = 0.5 (petroleum ether/EtOAc, 2:1) 
MP: 68-71 C 
IR (neat): 2950, 1720, 1594, 1443, 1347, 1324, 1299, 1234, 1156, 1055 cm-1 
1H NMR (500 MHz, CDCl3)  7.42 (d, J = 7.1 Hz, 4H), 7.38 (t, J = 7.4 Hz, 4H), 7.34 (d, J 
= 7.1 Hz, 2H), 7.30 (d, J = 2.3 Hz, 2H), 6.80 (t, J = 2.3 Hz, 1H), 5.06 (s, 4H), 3.90 (s, 3H). 
13C NMR (125 MHz, CDCl3)  166.7, 159.8, 136.5, 132.1, 128.6, 128.1, 127.6, 108.4, 
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3,5-Dibenzyloxybenzyl alcohol 3.79 
 
To a suspension of LiAlH4 (3.27 g, 86.2 mmol) in Et2O (200 mL) at 0 C, was added methyl 
3,5-dibenzyloxybenzoate 3.78 (15.0 g, 43.1 mmol) in Et2O (100 mL) dropwise. The reaction 
mixture was warmed to room temperature and stirred for 1 h. The reaction was quenched by 
the dropwise addition of H2O (4 mL) and was stirred for 5 min. 15% NaOH solution (4 mL) 
was added to the quenched mixture, followed by addition of H2O (8 mL) and was further 
stirred for 15 minutes. The formed aluminium precipitate was filtered, and the filtrate was 
concentrated in vacuo to give 3,5-dibenzyloxybenzyl alcohol 3.79 (13.33 g) as a white solid, 
which was used in the next step without purification. The spectroscopic data was consistent 
with that reported in the literature.[159] 
Rf = 0.25 (petroleum ether/EtOAc, 2:1) 
MP: 78-80 C 
IR (neat): 3314, 2904, 1592, 1443, 1369, 1351, 1285, 1152, 1023, 988 cm-1 
1H NMR (600 MHz, CDCl3) δ 7.40 (d, J = 7.2 Hz, 4H), 7.37 (t, J = 7.6 Hz, 4H), 7.31 (t, J 
= 7.2 Hz, 2H), 6.60 (s, 2H), 6.54 (s, 1H), 5.01 (s, 4H), 4.59 (d, J = 5.7 Hz, 2H), 1.80 (t, J = 
5.7 Hz, 1H). 
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3,5-Dibenzyloxybenzaldehyde 3.73 
 
To a solution of 3,5-dibenzyloxybenzyl alcohol 3.79 (13.3 g, 41.5 mmol) in CH2Cl2 (250 
mL), was added pyridinium chlorochromate (11.1 g, 51.5 mmol) and then the reaction 
mixture was stirred at room temperature for 16 h. The resulting mixture was filtered through 
a pad of CeliteTM, and the filtrate was concentrated in vacuo. The crude residue was purified 
by flash column chromatography on SiO2 (petrol/ethyl acetate, 4:1) to give 3,5-
dibenzyloxybenzaldehyde 3.73 (12.8 g, 93% over two steps) as a white solid. The 
spectroscopic data was consistent with that reported in the literature.[159] 
Rf = 0.60 (petroleum ether/EtOAc, 2:1) 
MP: 79-80 C 
IR (neat): 3032, 1687, 1608, 1593, 1448, 1383, 1351, 1297, 1172, 1049 cm-1 
1H NMR (600 MHz, CDCl3)  9.89 (d, J = 0.5 Hz, 1H), 7.42 (d, J = 7.5 Hz, 4H), 7.39 (t, J 
= 7.5 Hz, 4H), 7.34 (t, J = 7.1 Hz, 2H), 7.10 (d, J = 1.6 Hz, 2H), 6.86 (s, 1H), 5.08 (s, 4H). 
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1-(3,5-Dibenzyloxyphenyl)propan-1-ol 3.80 
 
A solution of bromoethane (7.2 mL, 97 mmol) in dry THF (240 mL) was slowly added to 
magnesium turnings (3.2 g, 132 mmol) and stirred at 50 °C until the majority of the 
magnesium turnings had been consumed. 3,5-dibenzyloxybenzaldehyde 3.73 (20.4 g, 64.1 
mmol) in THF (240 mL) was then added dropwise, and the reaction mixture was then stirred 
while heating under reflux for 1 h. The reaction was quenched with sat. aqueous NH4Cl (200 
mL) and the resulting mixture was extracted with Et2O (2 × 300 mL). The combined organics 
were dried over MgSO4 and concentrated in vacuo. The crude product was purified by 
recrystallisation from diethyl ether:petrol to give 1-(3,5-dibenzyloxyphenyl)propan-1-ol 
3.80 (17.29 g, 77%) as a white crystalline solid.  
Rf = 0.45 (petroleum ether/EtOAc, 2:1) 
MP: 72-73 C 
IR (neat): 3257, 2967, 1739, 1609, 1593, 1446, 1357, 1291, 1159, 1039, 833 cm-1 
1H NMR (500 MHz, CDCl3)  7.42 (d, J = 7.4 Hz, 4H), 7.38 (t, J = 7.5 Hz, 4H), 7.32 (t, J 
= 7.1 Hz, 2H), 6.61 (d, J = 2.2 Hz, 2H), 6.54 (t, J = 2.0 Hz, 1H), 5.03 (s, 4H), 4.53 (td, J = 
6.6, 3.5 Hz, 1H), 1.79 (d, J = 3.7 Hz, 1H), 1.84 – 1.67 (m, 2H), 0.91 (t, J = 7.4 Hz, 3H). 
13C NMR (125 MHz, CDCl3)  160.0, 147.2, 136.9, 128.58, 128.56, 128.0, 127.58, 127.56, 
105.1, 101.1, 76.0, 70.1, 31.8, 10.1. 
HRMS (ESI): calculated for C23H24O3, 349.1798 [M+H]
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 (E)-(3,5-Dibenzyloxyphenyl)prop-2-ene 3.81   
 
To a solution of 1-(3,5-dibenzyloxyphenyl)propan-1-ol 3.80 (1.00 g, 2.87 mmol) in toluene 
(110 mL), was added p-TsOH·H2O (55 mg, 0.29 mmol) and the mixture was heated under 
reflux with a Dean-Stark apparatus for 90 min. The solvent was removed under reduced 
pressure and the crude residue was purified by flash column chromatography on SiO2 
(petrol/ethyl acetate, 15:1) to give (E)-(3,5-dibenzyloxyphenyl)prop-2-ene 3.81 (900 mg, 
95%) as a pale yellow oil.  
Rf = 0.60 (petroleum ether/EtOAc, 2:1) 
IR (neat): 3030, 1584, 1453, 1437, 1374, 1282, 1155, 1048, 960 cm-1 
1H NMR (600 MHz, CDCl3)  7.42 (d, J = 7.4 Hz, 4H), 7.38 (t, J = 7.5 Hz, 4H), 7.36 – 7.29 
(m, 2H), 6.59 (d, J = 2.1 Hz, 2H), 6.48 (t, J = 2.1 Hz, 1H), 6.32 (d, J = 15.8 Hz, 1H), 6.20 
(dq, J = 15.6, 6.5 Hz, 1H), 5.03 (s, 4H), 1.86 (d, J = 6.5 Hz, 3H). 
13C NMR (150 MHz, CDCl3)  160.1, 140.1, 137.0, 130.9, 128.6, 128.0, 127.6, 127.5, 
126.4, 105.2, 100.7, 70.1, 18.4. 
HRMS (ESI): calculated for C23H22O2, 331.1693 [M+H]
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 (E)-2,4-Dibenzyloxy-6-(prop-1-en-1-yl)benzaldehyde 3.82 
 
To a solution of (E)-(3,5-dibenzyloxyphenyl)prop-2-ene 3.81 (2.21 g, 6.7 mmol) in DMF 
(35 mL) at 0 °C, was added POCl3 (0.95 mL, 10.2 mmol) and the mixture was stirred for 30 
min. The reaction was then heated at 90 °C and stirred for 1 h. H2O (30 mL) was added and 
the resulting mixture was stirred at room temperature for 1 h. The mixture was diluted with 
EtOAc (150 mL), the organic phases was separated, and the aqueous phase was extracted 
with EtOAc (2 × 100 mL). The combined organic extracts were washed with brine (3 × 100 
mL), dried over MgSO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography on SiO2 (petrol/ethyl acetate, 4:1) to give E)-2,4-dibenzyloxy-6-(prop-1-
en-1-yl)benzaldehyde 3.82 (2.3 g, 96%) as a white solid.  
Rf = 0.50 (petroleum ether/EtOAc, 4:1) 
MP: 82-83 C 
IR (neat): 2897, 1683, 1593, 1567, 1417, 1371, 1336, 1277, 1149, 1039, 964 cm-1 
1H NMR (600 MHz, CDCl3)  10.56 (s, 1H), 7.45 – 7.30 (m, 11H), 6.68 (d, J = 1.9 Hz, 
1H), 6.49 (d, J = 2.1 Hz, 2H), 6.14 (dq, J = 13.3, 6.6 Hz, 1H), 5.10 (s, 2H), 5.09 (s, 2H), 1.91 
(dd, J = 6.7, 1.4 Hz, 3H). 
13C NMR (150 MHz, CDCl3)  190.6, 163.9, 163.5, 143.6, 136.01, 135.99, 130.05, 129.98, 
128.73, 128.69, 128.3, 128.2, 127.6, 127.3, 116.3, 105.3, 98.6, 70.7, 70.2, 18.7. 
HRMS (ESI): calculated for C24H22O3, 359.1642 [M+H]
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(E)-2,4-Bis(benzyloxy)-6-(prop-1-en-1-yl)benzoic acid 3.83 
 
To a solution of aldehyde 3.82 (9.91 g, 27.65 mmol) in DMSO (200 mL) and Acetone (200 
mL) at 0 C, was added 2-methyl-2-butene (17.9 mL, 169.0 mmol). A solution of NaH2PO4 
(19.9 g, 165.9 mmol) and NaClO2·3H2O (15.0 g, 103.8 mmol) in H2O (200 mL), was added 
and the resulting reaction mixture was stirred at 0 C for 30 min. The cooled mixture was 
warmed to room temperature and stirred for a further 2 h. The reaction mixture was diluted 
with H2O (400 mL) and extracted with EtOAc (450 mL). The organic phase was separated, 
and the aqueous phase was re-extracted with EtOAc (2 × 200 mL). The combined organic 
extracts were washed with brine (3 × 350 mL), dried over MgSO4 and concentrated in vacuo 
to give crude carboxylic acid 3.83 (8.35 g), which was carried through to the next step 
without further purification.  
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(E)-Methyl 2,4-bis(benzyloxy)-6-(prop-1-ene)benzoate 3.64 
 
To a solution of carboxylic acid 3.83 (8.35 g, 22.3 mmol) in DMF (165 mL), was added 
K2CO3 (6.1 g, 44.1 mmol) at room temperature and the mixture was stirred for 1 h. 
Iodomethane (2.7 mL, 43.4 mmol) was added and the resultant reaction mixture was further 
stirred at room temperature for 2 h. The reaction was quenched with sat. NH4Cl (100 mL) 
and diluted with EtOAc (450 mL). The organic phase was separated, and the aqueous phase 
was extracted with EtOAc (2 × 200 mL). The combined organic extracts were washed with 
brine (3 × 350 mL), dried over MgSO4 and concentrated in vacuo. The crude residue was 
purified by flash column chromatography on SiO2 (petrol/ethyl acetate, 4:1) to give methyl 
ester 3.64 (6.45 g, 60% over 2 steps) as a yellow solid.  
Rf = 0.45 (petroleum ether/EtOAc, 4:1)  
MP: 90-92 C 
IR (neat): 2947, 1725, 1597, 1580, 1433, 1377, 1263, 1167, 1092, 1040 cm-1 
1H NMR (500 MHz, CDCl3)  7.41 – 7.28 (m, 10H), 6.69 (s, 1H), 6.46 (s, 1H), 6.39 (d, J 
= 15.6 Hz, 1H), 6.22 – 6.15 (m, 1H), 5.04 (d, J = 4.3 Hz, 4H), 3.88 (s, 3H), 1.86 (d, J = 6.7 
Hz, 3H). 
13C NMR (125 MHz, CDCl3)  168.6, 160.4, 157.1, 138.1, 136.6, 136.5, 129.3, 128.7, 
128.5, 128.1, 127.8, 127.7, 127.5, 126.9, 116.1, 103.1, 99.6, 70.5, 70.2, 52.2, 18.7. 
HRMS (ESI): calculated for C25H24O4, 389.1747 [M+H]
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Dibenzyloxy-isobenzofuranone 3.84 
 
To a solution of ester 3.64 (3 g, 7.7 mmol) and methanesulfonamide (0.87 g, 9.15 mmol) in 
t-BuOH (89 mL), H2O (89 mL) and THF (45 mL) at 0 C, was added AD-mix  (21.7 g). 
The reaction mixture was allowed to warm to room temperature and stirred for 30 h. Na2SO3 
(22 g) was added to the reaction mixture and was stirred for 15 min at room temperature. 
The resultant mixture was diluted with H2O (250 mL) and EtOAc (350 mL). The organic 
phase was separated, and the aqueous phase was extracted with EtOAc (2 × 200 mL). The 
combined organic extracts were washed with brine (200 mL), dried over MgSO4 and 
concentrated in vacuo. The residue was purified by flash column chromatography on SiO2 
(petrol/ethyl acetate, 2:1) to give lactone 3.84 (2.81 g, 93%) as a white solid. 




 = -32.1 (c 1.0, CHCl3) 
MP: 110-112 C 
IR (neat): 3415, 2927, 1738, 1603, 1451, 1334, 1210, 1161, 1064, 1021 cm-1 
1H NMR (500 MHz, CD3OD)  6.44 (s, 1H), 6.28 (d, J = 1.5 Hz, 1H), 5.23 (d, J = 3.2 Hz, 
1H), 4.13 (qd, J = 6.5, 3.4 Hz, 1H), 1.23 (d, J = 6.5 Hz, 3H). 
13C NMR (125 MHz, CD3OD)  172.2, 167.2, 159.6, 153.0, 105.4, 103.8, 102.5, 84.7, 68.8, 
18.6.  
 
HRMS (ESI): calculated for C24H22O5, 413.1359 [M+Na]
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Dihydroxy-isobenzofuranone 3.65 
 
Lactone 3.84 (1.00 g, 2.56 mmol) was dissolved in MeOH (100 mL) and the flask was purged 
with N2. Pd/C (100 mg) was added and the flask was purged with H2 (1 balloon). The 
reaction was stirred at room temperature for 2 h. The reaction mixture was then filtered 
through a pad of CeliteTM and washed with MeOH. The filtrate was concentrated in vacuo 
to give deprotected isobenzofuran 3.65 (533 mg, 99%) as a colourless crystalline solid, 
which was used without purification. 




 = +44.9 (c 1.0, MeOH) 
MP: 195-197 C 
IR (neat): 3146, 1720, 1686, 1606, 1478, 1352, 1216, 1162, 1062, 980 cm-1 
1H NMR (500 MHz, CD3OD)  6.46 (s, 1H), 6.31 (s, 1H), 5.24 (d, J = 3.2 Hz, 1H), 4.58 
(br s, 2H), 4.16 – 4.12 (m, 1H), 1.23 (d, J = 6.5 Hz, 3H). 
13C NMR (125 MHz, CD3OD)  172.1, 166.8, 159.6, 153.0, 105.6, 103.7, 102.5, 84.8, 68.8, 
18.6. 
HRMS (ESI): calculated for C10H10O5, 211.0601 [M+H]
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Benzofuranone o-QM precursor 3.66 
 
To a solution of isobenzofuran 3.65 (1.128 g, 5.37 mmol) and NaOAc·3H2O (79 mg, 5.37 
mmol) in AcOH (5 mL), was added formaldehyde solution (37% in H2O, 0.34 mL, 10.76 
mmol) and the resulting reaction mixture was heated at 80 C for 16 h. The mixture was 
poured onto sat. NaHCO3 (250 mL) and diluted with EtOAc (250 mL). The organic phase 
was separated, and the aqueous phase was extracted with EtOAc (2 × 150 mL). The 
combined organic extracts were washed with sat. aqueous NaHCO3 (250 mL), brine (250 
mL), dried over MgSO4 and concentrated in vacuo to give o-QM precursor 3.66 (1.02 g) as 
a yellow brown solid as an inseparable mixture with starting material 3.65. The crude 
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Diol 3.77 
 
To a solution of 3,4-Di-O-acetyl-6-deoxy-L-glucal 3.85 (10 g, 46.7 mmol) in MeOH (250 
mL) at 0 C, was added NaOMe (100 mg, 1.85 mmol, 4 % mol eq) and the resulting mixture 
was stirred at room temperature for 18 h. The reaction mixture was concentrated in vacuo, 
and the residue was purified by flash column chromatography on SiO2 (petrol/ethyl acetate, 
1:1) to give diol 3.77 as a white powder (6.03 g, 99%).  




 = +16.65 (c 0.78, CHCl3) 
1H NMR (500 MHz, CDCl3): δ 6.32 (d, J = 5.95 Hz, 1H ), δ 4.72 (dd, J = 5.95 Hz, J = 1.95 
Hz, 1H ), 4.24 – 4.19 (m, 1H), 3.90 – 3.84 (m, 1H), 3.45 – 3.41 (m, 1H), 2.35 (d, J = 3.45 
Hz, 1H), 1.82 (d, J = 5.9 Hz, 1H), 1.39 (d, J = 6.35 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ 144.8, 102.7, 75.6, 74.4, 70.4, 17.1 
IR (neat): 3263, 1644, 1413, 1226, 1043 cm-1. 
HRMS (ESI): calculated for C6H10O3, 153.0522 [M+Na]
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Benzyl protected enol ether 3.86 
 
To a solution of diol 3.77 (4.52 g, 34.7 mmol) in DMF (250 mL) at 0 C, was added NaH 
(60% dispersion, 1.53g, 38.3 mmol) and the resulting mixture was stirred at 0 C for 1 h. 
BnBr (4.13 ml, 34.8 mmol) was added to the reaction mixture, followed by warming the 
mixture to room temperature and the resultant mixture was further stirred for 18 h. The 
mixture was quenched with sat. NH4Cl aqueous solution (150 mL) while cooling on an ice 
bath. The mixture was then extracted with diethyl ether (400 mL) and the organic extracts 
were washed with water (2 × 100 mL), brine (3 × 100 mL), and the organic extracts were 
dried over MgSO4 and concentrated in vacuo. The resultant residue was purified by flash 
column chromatography on SiO2 (petrol/ethyl acetate, 5:1) to give benzyl protected enol-
ethers 3.86 (0.283 g, 4%), 3.87 (0.562 g, 7%), 3.88 (4.02 g, 37%), and recovered starting 
material diol 3.77 (1.03 g, 23%) as white powders. 
3.86 Rf = 0.40 (petrol/EtOAc, 2:1) 
3.87 Rf = 0.30 (petrol/EtOAc, 2:1) 












 = -12.7 (c 0.83, CHCl3) 
NMR data for 3.86; 
1H NMR (500 MHz, CDCl3): δ 7.38 – 7.28 (m, 3H), 7.36 (d, J = 4.4 Hz, 2H ), 6.35 (dd, J 
= 6.2 Hz, J = 1.2 Hz, 1H), 4.85 (dd, J = 6.2 Hz, J = 2.2 Hz, 1H), 4.71 (d, J = 11.8 Hz, 1H), 
4.55 (d, J = 11.8 Hz, 1H), 4.06 – 4.04 (m, 1H), 3.92 – 3.87 (m, 1H), 3.64 – 3.60 (m, 1H), 
2.17 (d, J = 3.7 Hz, 1H), 1.38 (d, J = 6.4 Hz, 1H). 
13C NMR (125 MHz, CDCl3): δ 144.97, 144.64, 138.31, 128.54, 127.84, 127.81, 99.69, 
82.44, 76.84, 74.43, 72.75, 70.51, 17.14. 
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NMR data 3.87; 
1H NMR (500 MHz, CDCl3): δ 7.38 – 7.29 (m, 5H), 6.32 (d, J = 6.0 Hz, 1H), 4.82 (q, J = 
11.6 Hz, 2H), 4.69 (dd, J = 6.1 Hz, J = 2.3 Hz, 1H), 4.35 (br s, 1H), 3.28 (dd, J = 9.4 Hz, J 
= 7 Hz, 1H), 1.70 (br s, 1H), 1.41 (d, J = 6.4 Hz, 1H). 
13C NMR (125 MHz, CDCl3): δ 144.63, 138.25, 128.57, 127.95, 103.12, 82.44, 74.23, 
74.09, 69.99, 17.63. 
NMR data 3.88; 
1H NMR (500 MHz, CDCl3): δ 7.36 – 7.27 (m, 10H), 6.36 (d, J = 6.2 Hz, 1H), 4.88 (d, J = 
11.4 Hz, 1H), 4.86 (dd, J = 6.5 Hz, J = 2.4 Hz, 1H), 4.71 (d, J = 11.4 Hz, 1H), 4.66 (d, J = 
11.7 Hz, 1H), 4.57 (d, J = 11.7 Hz, 1H), 4.22 – 4.21 (m, 1H), 3.98 – 3.92 (m, 1H), 3.49 (dd, 
J = 8.8 Hz, J = 6.5 Hz, 1H), 1.70 (br s, 1H), 1.18 (d, J = 6.4 Hz, 1H). 
13C NMR (125 MHz, CDCl3): δ 144.76, 138.40, 138.26, 128.37, 128.36, 127.92, 127.71, 
127.59, 100.11, 79.51, 76.42, 74.02, 73.94, 70.50, 17.47. 
3.86 IR (neat): 3064, 2877, 1646, 1454, 1237, 1100, cm-1. 
3.87 IR (neat): 3432, 2862, 1645, 1454, 1232, 1056 cm-1. 
3.88 IR (neat): 3273, 2914, 1645, 1454, 1227, 1114 cm-1. 
3.86 (mono – benzylated) HRMS (ESI): calculated for C13H16O3, 243.0995 [M+Na]
+, 
found 243.0994. 
3.87 (mono – benzylated) HRMS (ESI): calculated for C13H16O3, 243.0995 [M+Na]
+, 
found 243.0998. 
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Benzoyl hydroxy enol ether 3.89 
 
To a solution of 3,4-Di-O-acetyl-6-deoxy-L-glucal 3.85 (5 g, 23.3 mmol) in MeOH (125 
mL) at 0 C, was added NaOMe (50 mg, 0.93 mmol, 4 % mol eq) and the resulting mixture 
was stirred at room temperature for 18 h. The reaction mixture was concentrated in vacuo, 
and the residue was taken up in toluene (40 mL) and the solvent was removed under reduced 
pressure. The crude alcohol was taken up in pyridine (70 mL), and while cooling at -35 C, 
benzoyl chloride (2.6 mL, 22.4 mmol) was added dropwise over 2 h. The reaction mixture 
was stirred for a further 2 h at -35 C, before being warmed to room temperature and stirred 
overnight. MeOH (20 mL) was added to the reaction mixture and was further stirred for 2 h. 
The solvent was removed under reduced pressure, and the crude residue was purified by 
flash column chromatography on SiO2 (petrol/ethyl acetate, 5:1) to give benzoyl hydroxy 
enol ether 3.89 as a white powder (4.36 g, 83%). The spectroscopic data was consistent with 
that reported in the literature.[160]  




 = +87.6 (c 0.65, CHCl3) 
1H NMR (500 MHz, CDCl3): δ 8.05 (d, J = 8.1 Hz, 2H), δ 7.58 (t, J = 7.5 Hz, 1H), δ 7.45 
(d, J = 7.5 Hz, 1H), 7.44 (d, J = 8.1 Hz, 1H), 6.49 (d, J = 6.1 Hz, 1H), 5.48 – 5.46 (m, 1H), 
4.83 (dd, J = 6.1 Hz, J = 2.6 Hz, 1H), 4.04 – 3.98 (m, 1H), 3.78 (dd, J = 8.9 Hz, J = 6.5 Hz, 
1H), 1.45 (d, J = 6.35 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ 168.1, 146.8, 133.6, 133.4, 130.2, 129.8, 129.6, 128.5, 
98.8, 74.8, 74.3, 72.7, 17.1. 
IR (neat): 3449, 3069, 2936, 1716, 1697, 1451, 1271, cm-1. 
HRMS (ESI): calculated for C13H14O4, 257.0790 [M+Na]




282 |                                                                                                                 A. W. Markwell-Heys 
Benzoyl protected S-methyl xanthate 3.91 
 
To a solution of benzoyl protected enol ether 3.89 (4.36 g, 18.6 mmol) in CS2 (130 mL) at 
room temperature, was added NaH (60 % dispersion, 0.80 g, 20.0 mmol) and the resulting 
dispersion was stirred for 30 min. MeI (1.16 mL, 18.6 mmol) was added to the yellow 
dispersion and was stirred at room temperature for 18 h. The mixture was quenched with sat. 
NH4Cl aqueous solution (200 mL) while cooling on an ice bath. The diluted mixture was 
extracted with diethyl ether (400 mL) and the organic extracts were sequentially washed 
with water (200 mL) and brine (3 × 200 mL). The organic extracts were dried over MgSO4 
and concentrated in vacuo. The resulting residue was purified by flash column 
chromatography on SiO2 (petrol/ethyl acetate, 4:1) to give benzoyl protected S-methyl 
xanthate 3.91 as a bright yellow oil (5.9 g, 98%). The spectroscopic data was consistent with 
that reported in the literature.[160]  




 = -8.21 (c 3.0, CHCl3) 
1H NMR (500 MHz, CDCl3): δ 8.00 (d, J = 7.2 Hz, 2H), 7.56 (d, J = 7.4 Hz, 1H), 7.43 (d, 
J = 7.8 Hz, 2H), 6.51 (d, J = 6.2 Hz, 1H), 6.17 (dd, J = 7 Hz, J = 7 Hz, 1H), 5.67 – 5.65 (m, 
1H), 5.00 (dd, J = 6.2 Hz, J = 6.2 Hz, 1H), 4.41 (qnt, J = 6.7 Hz, 1H), 2.56 (s, 3H), 1.46 (d, 
J = 6.27 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ 215.6, 165.8, 146.1, 133.2, 129.9, 129.8, 128.4, 98.4, 79.3, 
72.2, 68.0, 19.3, 16.4. 
IR (neat): 3456, 3063, 2924, 1720, 1646, 1268, cm-1. 
HRMS (ESI): calculated for C15H16O4S2, 325.0563 [M+H]
+, found 325.0549, 326.0595 
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Benzoyl enol ether 3.92  
 
To a solution of benzoyl protected methyl xanthate 3.91 (1.0 g, 3.08 mmol) in toluene (80 
mL) at 80 °C, was added AIBN (0.2 M, 1.6 mL, 0.32 mmol), Bu3SnH (2 mL, 7.42 mmol) 
and the reaction mixture was stirred at 80 C for 20 min, before being cooled to room 
temperature. The resultant mixture was concentrated in vacuo and the residue was purified 
by flash column chromatography on neutralised SiO2 (loaded with 2% Et3N in petrol, ran 
with petrol/ethyl acetate, 10:1) to give benzoyl enol ether 3.92 as a colourless oil (0.62 g, 
92%). 




 = +188.5 (c 0.95, CHCl3) 
1H NMR (500 MHz, CDCl3): δ 8.05 (d, J = 7.3 Hz, 2H), 7.57 (t, J = 7.3 Hz, 1H), 7.45 (t, J 
= 7.6 Hz, 2H), 6.51 (d, J = 6.2 Hz, 1H), 5.67 – 5.64 (m, 1H), 4.90 – 4.88 (m, 1H), 4.27 – 
4.21 (m, 1H), 2.38 (dd, J = 13 Hz, J = 6.5 Hz, 1H), 1.90 – 1.84 (m, 1H), 1.39 (d, J = 6.5 Hz, 
1H). 
13C NMR (125 MHz, CDCl3): δ 166.8, 146.8, 132.9, 130.4, 129.6, 128.3, 100.7, 70.8, 66.1, 
35.1, 20.6. 
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Diphenylphosphine oxide ether 3.96  
 
To a solution of benzoyl enol ether 3.92 (0.62 g, 2.84 mmol) in CH2Cl2 (50 mL) at 0 C, was 
added PPh3·HBr (0.975 g, 2.84 mmol) and the reaction mixture was warmed to room 
temperature and stirred for 18 h. The solvent was concentrated in vacuo to give crude 
triphenyl phosphine bromide salt as an off-white solid which was taken up an aqueous 
solution of NaOH (0.86 g, 21.5 mmol) in water (50 mL). The resulting reaction mixture was 
heated under reflux for 30 min before being cooled to room temperature. The aqueous 
mixture was extracted with CHCl3 (3 × 100 ml) and the extracts were sequentially washed 
with water (150 mL) and brine (100 mL). The extracts were dried over MgSO4 and 
concentrated in vacuo to give diphenylphosphine oxide ether 3.96 as an impure off-white 
waxy oil (0.79 g, 88%), which was used without purification. 
Rf = 0.12 (petrol/EtOAc, 1:1) 
IR (neat): 3384, 3055, 1715, 1590, 1436, 1181, 1118 cm-1. 
HRMS (ESI): calculated for C18H21O3P, 339.1121 [M+Na]
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TBDPS diphenylphosphine oxide ether 3.98  
 
To a solution of diphenylphosphine oxide ether 3.96 (79 mg, 0.25 mmol) and imidazole (26 
mg, 0.38 mmol) in DMF (2 mL) at 0 C, was added TBDPSCl (0.08 mL, 0.29 mmol). The 
resulting reaction mixture was warmed to room temperature and stirred for 18 h. The mixture 
was taken up in water (15 mL) and was extracted with CHCl3 (2 × 10 mL). The extracts were 
sequentially washed with water (15 mL), brine (3 ×10 mL), then dried over MgSO4 and 
concentrated in vacuo. The crude residue was purified by flash column chromatography on 
SiO2 (petrol/ethyl acetate, 2:1) to give TBDPS diphenylphosphine oxide ether 3.98 (11.5 
mg, 8 %) as off-white waxy oil, and starting material 3.96, was re-isolated as an impure, 
partially degraded mixture of unknown products (8.0 mg, 10%). 
Rf = 0.12 (petrol/EtOAc, 2:1) 
1H NMR (500 MHz, CDCl3): δ 7.85 – 7.81 (m, 2H), 7.65 – 7.31 (m, 18H), 4.76 (t, J = 5.3 
Hz, 1H), 4.66 – 4.61 (m, 1H), 4.20 – 4.16 (m, 1H), 1.92 – 1.71 (m, 3H), 1.42 – 1.36 (m, 1H), 
1.15 (d, J = 6.4 Hz, 3H), 1.05 (s, 9H). 
13C NMR (125 MHz, CDCl3): δ 135.7, 134.2, 134.1, 131.8, 131.68, 131.65, 131.60, 131.58, 
131.12, 131.05, 130.9, 129.58, 129.56, 128.6, 128.5, 128.4, 128.3, 127.58, 127.57, 70.5, 
69.9, 69.71, 69.67, 65.4, 65.3, 40.5, 32.7, 32.6, 27.0, 21.1, 19.2. 
IR (neat): 3342, 3071, 2931, 1721, 1437, 1199, 1104, 1061 cm-1. 
HRMS (ESI): calculated for C34H39O3PSi, 577.2298 [M+Na]
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TBDPS hydroxy enol ether 3.104  
 
To a solution of diol 3.77 (6.08 g, 46.7 mmol) and imidazole (4.08 g, 60 mmol) in DMF (50 
mL) at 0 C, was added TBDPSCl (14.6 mL, 56 mmol) and the resulting mixture was stirred 
at room temperature for 18 h. The mixture was diluted with water (500 mL) and extracted 
with diethyl ether (600 mL). The organic extracts were sequentially washed with 1 M HCl 
aqueous solution (100 mL), brine (2 × 200 mL). The organic extracts were dried over MgSO4 
and concentrated in vacuo. The residue was purified by flash column chromatography on 
SiO2 (petrol/ethyl acetate, 10:1) to give TBDPS hydroxy enol ether 3.104 as a colourless oil 
(16.99 g, 99%). The spectroscopic data was consistent with that reported in the literature.[178]  




 = +24.4 (c 0.36, CHCl3) 
1H NMR (500 MHz, CDCl3): δ 7.72 – 7.69 (m, 4H), 7.46 – 7.38 (m, 6H), 6.19 (d, J = 6.4 
Hz, 1H), 4.55 (dd, J = 6.4 Hz, J = 2.1 Hz, 1H), 4.27 – 4.23 (m, 1H), 3.83 – 3.77 (m, 1H), 
3.62 – 3.58 (m, 1H), 1.83 (d, J = 4.2 Hz, 1H), 1.35 (d, J = 6.4 Hz, 3H), 1.08 (s, 9H). 
13C NMR (125 MHz, CDCl3): δ 143.7, 135.9, 135.7, 134.8, 133.8, 133.7, 130.0, 129.9, 
129.7, 127.9, 127.7, 103.0, 75.0, 74.2, 71.3, 27.0, 26.6, 19.3, 17.1. 
IR (neat): 3464, 2932, 2858, 1644, 1427, 1106, 737 cm-1. 
HRMS (ESI): calculated for C22H28O3Si, 336.1880 [M+H]
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TBDPS S-methyl xanthate 3.105  
 
To a solution of TBDPS hydroxy enol ether 3.104 (2.55 g, 6.92 mmol) in CS2 (60 mL) at 
room temperature, was added NaH (60 % dispersion, 0.42 g, 10.5 mmol) and the resulting 
dispersion was stirred for 30 min. MeI (0.47 mL, 7.55 mmol), was added to the yellow 
dispersion and was stirred at room temperature for 18 h. The mixture was quenched with sat. 
aqueous NH4Cl aqueous solution (40 mL) while cooled on an ice bath. The diluted mixture 
was extracted with diethyl ether (150 mL) and the organic extracts were sequentially washed 
with water (100 mL) and brine (3 × 100 mL). The organic extracts were dried over MgSO4 
and concentrated in vacuo. The residue was purified by flash column chromatography on 
SiO2 (petrol/ethyl acetate, 10:1) to give TBDPS S-methyl xanthate 3.105 as a bright yellow 
oil (3.1 g, 98%). 




 = -16.88 (c 2.79, CHCl3) 
1H NMR (500 MHz, CDCl3): 7.70 (t, J = 7.7 Hz, 2H), δ 7.67 (t, J = 7.7 Hz, 2H), 7.44 – 
7.35 (m, 6H), 6.23 (t, J = 6.2 Hz, 1H), 6.01 (t, J = 5.7 Hz, 1H), 4.49 (dd, J = 5.7 Hz, J = 3.1 
Hz, 1H), 4.37 (m, 1H), 4.18 (q, J = 6.6 Hz, 1H), 2.51 (s, 3H), 1.42 (d, J = 6.6 Hz, 3H), 1.03 
(s, 9H). 
13C NMR (125 MHz, CDCl3): δ 215.3, 143.4, 136.0, 129.8, 129.7, 127.7, 127.6, 102.2, 
82.6, 72.2, 66.5, 36.1, 26.8, 19.2, 19.1, 16.6, 11.4. 
IR (neat): 3070, 2930, 2857, 1645, 1427, 1213, 1060 cm-1. 
HRMS (ESI): calculated for C24H30O3S2Si, 481.1301 [M+Na]
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TBDPS enol ether 3.106  
 
To a solution of TBDPS S-methyl xanthate 3.105 (6.52 g, 14.2 mmol) in toluene (390 mL) 
at 80°C, was added AIBN (0.2 M, 14.2 mL, 2.84 mmol), Bu3SnH (7.7 mL, 28.6 mmol) and 
the reaction mixture was stirred at 80 C for 20 min, before being cooled to room 
temperature. The mixture was concentrated in vacuo and the resultant residue was purified 
by flash column chromatography on neutralised SiO2 (loaded with 2% Et3N in petrol, run 
with petrol/ethyl acetate, 10:1) to give TBDPS enol ether 3.106 as a colourless oil (4.58 g, 
91%). 




 = +9.81 (c 2.1, CHCl3) 
1H NMR (500 MHz, CDCl3): δ 7.69 – 7.66 (m, 4H), 7.44 – 7.36 (m, 6H), 6.26 (d, J = 6.2 
Hz, 1H), 4.64 – 4.63 (m, 1H), 4.46 – 4.43 (m, 1H), 3.92 – 3.86 (m, 1H), 1.89 – 1.85 (m, 1H), 
1.78 – 1.71 (m, 1H), 1.23 (d, J = 6.4 Hz, 3H), 1.06 (s, 9H). 
13C NMR (125 MHz, CDCl3): δ 144.3, 135.8, 135.7, 134.24, 134.15, 129.6, 127.6, 105.7, 
71.0, 64.3, 39.3, 26.9, 20.9, 19.1. 










289 |                                                                                                                 A. W. Markwell-Heys 
TBDPS lactone 3.107 
 
To a solution of TBDPS enol ether 3.106 (4.58 g, 13.0 mmol) in CH2Cl2 (500 mL) at room 
temperature, was added PCC (4.21 g, 19.5 mmol) and the reaction mixture was stirred at 
room temperature for 20 h. The mixture was filtered through a pad of CeliteTM, concentrated 
in vacuo and the residue was purified by flash column chromatography on SiO2 
(petrol/diethyl ether, 3:1) to give TBDPS lactone 3.107 as a colourless oil (2.61 g, 55%). 




 = +6.56 (c 0.61, CHCl3) 
1H NMR (500 MHz, CDCl3): δ 7.65 – 7.63 (m, 4H), 7.47 – 7.38 (m, 6H), 4.14 – 4.07 (m, 
2H), 2.67 (dd, J = 17.2 Hz, J = 5.95 Hz, 1H), 2.48 (dd, J = 17.2 Hz, J = 7.9 Hz, 1H), 2.05 – 
2.00 (m, 1H), 1.68 – 1.57 (m, 1H), 1.33 (d, J = 6.3 Hz, 3H), 1.06 (s, 9H). 
13C NMR (125 MHz, CDCl3): δ 170.1, 135.71, 135.65, 135.64, 133.4, 133.2, 130.1, 130.0, 
127.9, 127.8, 73.3, 65.3, 40.0, 39.6, 26.8, 21.4, 19.0. 
IR (neat): 3071, 2932, 2858, 1736, 1427, 1235, 1104 cm-1. 
HRMS (ESI): calculated for C22H28O4, 391.1706 [M+Na]
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2-(Ethylthio)benzo[d]thiazole 3.113 
 
To a solution of mercapobenzothiazole 3.112 (11.94 g, 71.4 mmol) in DMF (250 mL) at 0 
C, was added NaH (60 % dispersion, 3.7 g, 92.5 mmol) and the reaction mixture was stirred 
at 0 C for 30 min. Bromoethane (5.35 mL, 72.2 mmol) was added dropwise to the cooled 
reaction mixture and was stirred for a further 5 h at 0 C. The reaction was quenched with 
sat. aqueous NH4Cl solution (40 mL) and water (50 mL). The aqueous mixture was extracted 
with 1:1 diethyl ether:CH2Cl2 (2 × 250 mL), and the organic extracts were washed with brine 
(3 × 200 mL), dried over MgSO4 and concentrated in vacuo. The crude residue was purified 
by flash column chromatography on SiO2 (petrol/diethyl ether, 9:1) to give 2-
(ethylthio)benzo[d]thiazole 3.113 as a white crystalline solid (12.79 g, 92%). The 
spectroscopic data was consistent with that reported in the literature.[172]  
Rf = 0.73 (petrol/EtOAc, 1:1) 
1H NMR (500 MHz, CDCl3): δ 7.87 (d, J = 8.1 Hz, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.41 (dd, 
J = 8.1 Hz, J = 7.35 Hz, 1H), 7.29 (dd, J = 8.0 Hz, J = 7.35 Hz, 1H), 3.36 (q, J = 7.4 Hz,  
2H), 1.49 (d, J = 7.4 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ 167.0, 153.4, 135.2, 126.0, 124.1, 121.5, 120.9, 28.0, 14.6. 
IR (neat): 3062, 2969, 2927, 1456, 1426, 992, 773 cm-1. 
HRMS (ESI): calculated for C9H9NS2, 196.0256 [M+H]
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2-(Ethylsulfonyl)benzo[d]thiazole 3.114 
 
To a solution of (NH4)6Mo7O24·4H2O (16.07 g, 13.0 mmol) in 30% H2O2 (221 mL, 2.2 mol) 
at 0 C, was added a solution of 2-(ethylthio)benzo[d]thiazole 3.113 (12.7 g, 65.0 mmol) in 
ethanol (75 mL). The resulting reaction mixture was warmed to room temperature and stirred 
for 48 h, before being quenched with aqueous H2SO4 (10%, 10 mL). The organic solvent 
was removed under reduced pressure and the aqueous mixture was extracted with 1:1 diethyl 
ether:CH2Cl2 (2 × 250 mL) and the organic extracts were washed with brine (200 mL), dried 
over MgSO4 and concentrated in vacuo. The crude residue was purified by flash column 
chromatography on SiO2 (CH2Cl2/petrol, 4:1) to give 2-(ethylsulfonyl)benzo[d]thiazole 
3.114 as a white crystalline solid (12.79 g, 87%). The spectroscopic data was consistent with 
that reported in the literature.[172]  
Rf = 0.1 (CH2Cl2/petrol, 1:1) 
1H NMR (500 MHz, CDCl3): δ 8.23 (d, J = 8.1 Hz, 1H), 8.02 (d, J = 8.1 Hz, 1H), 7.66 – 
7.59 (m, 2H), 3.55 (q, J = 7.45 Hz, 2H), 1.45 (t, J = 7.45 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ 165.4, 152.8, 136.8, 128.0, 127.7, 125.5, 122.3, 49.3, 7.2 
IR (neat): 3065, 2923, 1799, 1554, 1471, 1310, 1140 cm-1. 
HRMS (ESI): calculated for C9H9NO2S2, 249.9965 [M+Na]
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Z/E-Exocyclic enol ethers 3.115:3.116 
 
To a solution of TBDPS lactone 3.107 (140 mg, 0.380 mmol) and 2-
(ethylsulfonyl)benzo[d]thiazole 3.114 (74 mg, 0.326 mmol) in THF (5 mL) at -78 C, was 
added BF3·OEt2 (0.06 ml, 0.5 mmol) followed by LiHMDS (1 M, 0.5 ml, 0.5 mmol) and the 
reaction mixture was stirred at -78 C for 1 h. The reaction mixture warmed to room 
temperature and stirred for a further 30 min. The reaction mixture was again cooled to -78 
C and quenched with AcOH (0.1 ml), followed by warming to room temperature. The 
mixture was concentrated in vacuo and the resultant residue was taken up in THF (5 ml), 
and DBU (0.2 ml, 1.34 mmol) was added to the reaction mixture in one portion, followed 
by stirring at room temperature overnight. The solvent was removed under reduced pressure 
and the resulting residue was purified by flash column chromatography on SiO2 
(petrol/EtOAc, 10:1) to give Z-exocyclic enol ether 3.115 as a colourless oil (34.5 mg, 24%), 
which was found to be a mixture of Z/E isomers 3.115:3.116 in a 1.4:1 ratio respectively. 
Rf = 0.8 (petrol/EtOAc, 2:1) 
1H NMR data for Z-exocyclic enol ether 3.115 
1H NMR (500 MHz, CDCl3): δ 7.71 – 7.66 (m, 4H), 7.44 – 7.37 (m, 6H), 4.38 (qd, J = 6.7 
Hz, J = 1.5 Hz, 1H), 3.78 – 3.70 (m, 1H), 3.37 – 3.31 (m, 1H), 2.25 (ddd, J = 12.8 Hz, J = 5 
Hz, J = 1.9 Hz, 1H), 2.13 – 2.08 (m, 1H), 1.89 – 1.80 (m, 1H), 1.53 – 1.46 (m, 1H), 1.49 (dd, 
J = 6.7 Hz, J = 2.1 Hz, 3H), 1.24 (d, J = 6.2 Hz, 3H), 1.06 (s, 9H). 
1H NMR data for E-exocyclic enol ether 3.116 
1H NMR (500 MHz, CDCl3): δ 7.71 – 7.66 (m, 4H), 7.44 – 7.37 (m, 6H), 4.41 – 4.37 (qd, 
J = 7.0 Hz, J = 1.6 Hz, 1H), 3.78 – 3.70 (m, 1H), 3.37 – 3.31 (m, 1H), 2.53 (ddd, J = 13.3 
Hz, J = 4.8 Hz, J = 1.8 Hz, 1H), 1.89 – 1.80 (m, 2H), 1.53 – 1.46 (m, 1H), 1.29 (dd, J = 7.1 
Hz, J = 1.1 Hz, 3H), 1.20 (d, J = 6.2 Hz, 3H), 1.08 (s, 9H). 
13C NMR for Z/E-exocyclic enol ethers 3.115:3.116 
13C NMR (125 MHz, CDCl3): δ 150.6, 150.2, 135.76, 135.72, 135.70, 134.32, 134.28, 
134.2, 129.71 129.65, 129.64, 129.62, 127.63, 127.59, 127.574, 127.566, 127.53, 127.50, 
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103.95, 103.90, 73.1, 72.6, 69.1, 68.7, 43.1, 42.9, 39.9, 34.0, 26.97, 26.93, 26.91, 21.7, 21.6, 
19.1, 10.9, 9.7. 
IR (neat): 3071, 2932, 2858, 1685, 1590, 1428, 1104 cm-1. 
HRMS (ESI): calculated for C24H32O2Si, 381.2244 [M+H]
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